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ABSTRACT
Until the beginning of this decade the neurohormone, melatonin, had been considered
as little more than a tranquillising hormone, responsible for regulating certain circadian
and circannual rhythms.  In the last eight years, a whole new dimension to melatonin’s
role in biological organisms has emerged.  In 1991 it was discovered [1,2] that melatonin
exhibited antioxidant properties.  Since then, many researchers [3,4] have found
melatonin to be a powerful free radical scavenger and antioxidant.  In the present study,
the ability of melatonin to offer neuroprotection against glutamate, N-methyl-D-aspartate
(NMDA), quinolinic acid (QA) and kainic acid (KA) (collectively referred to as the
glutamate receptor agonists) was investigated.
It was first shown that stress causes an increase in circulating glucocorticoid
concentrations, which resulted in an increase the number of glutamate receptors on
synaptic membranes in rat brain homogenate.  Melatonin acted to reduce the number of
glutamate receptors present on the synaptic membranes, implying that melatonin has
neuroprotective properties, as overstimulation of the glutamate receptors leads to
excitotoxicity and neurodegeneration.
Further investigations showed that  the glutamate receptor agonists induce
neurodegeneration in primary neuronal cell cultures.  Both co-treatment and post-
treatment with melatonin against the glutamate receptor agonists, increased neuronal
cell viability in a dose dependent manner.  Melatonin also appeared to offer protection
against quinolinic acid-induced neurodegeneration following intrahippocampal injections
of quinolinic acid.
The mechanism whereby melatonin offered this protection was investigated.  The
glutamate receptor agonists caused an increase in intracellular calcium concentrations,
which is known [5] to be responsible for initiating the excitotoxic response.  Melatonin had
no effect on regulating intracellular calcium concentrations.
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Additional studies indicated that melatonin was effective at scavenging superoxide
radicals.  Production of superoxide radicals was induced by the glutamate receptor
agonists in primary neuronal cultures.  Superoxide radicals induce lipid peroxidation,
which involves the destruction of lipid membranes by chain reactions.  By acting as an
antioxidant, melatonin was able to reduce quinolinic acid-induced lipid peroxidation in rat
brain homogenate, in a dose dependent manner.  Melatonin was also effective at
reducing lipid peroxidation induced by the glutamate receptor agonists in primary
neuronal cultures.
Melatonin therefore appeared to be offering neuroprotection by removing superoxide
radicals and inhibiting lipid peroxidation.  It had been reported [6] that melatonin inhibits
nitric oxide synthase activity.  This enzyme produces the free radical, nitric oxide, and
can also produce superoxide radicals.  Melatonin was able to reduce nitric oxide
synthase activity in a dose dependent manner.  This is a novel method of
neuroprotection, as melatonin was now acting as an enzyme regulator. 
The results obtained demonstrate that melatonin offers neuroprotection against
glutamate induced excitotoxicity, by removing free radicals and preventing lipid
peroxidation.  The neurohormone offers further protection by decreasing the activity of
enzymes that aid in the neurotoxic cascade.
Melatonin is the most potent naturally occurring free radical scavenger in the body [3]. 
During aging, the serum concentrations of melatonin decrease [7].  During the
senescence of life, free radical damage to the body is at its highest [8], while at the same
time melatonin concentrations are at their lowest.  Melatonin therefore shows potential for
the treatment of diseases and disorders that exhibit an excitotoxic pathology.
-iii-
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CHAPTER 1
LITERATURE REVIEW
1.1. MELATONIN 
1.1.1. Introduction
Herophilos (325 - 280BC) is credited with discovering the human pineal gland.  At the
time of discovery he, and other investigators were examining the brain in an attempt to
find the soul in the body.  For the next 2000 years very little knowledge was accumulated
on the pineal gland, although both doctors and philosophers from Europe and Asia
considered the pineal to be a prime candidate for the seat of the soul. 
By the 19th century, researchers were taking a more scientific and less philosophical
approach to their studies on the pineal gland.  Investigations in lower vertebrates had
revealed that the pineal gland functioned as a photosensory organ.  The gradual loss of
photosensory apparatus in higher vertebrates was interpreted as phylogenetic
regression, and so the pineal glands in higher animals were considered to be little more
than the rudimentary remnants of the non-mammalian pineal gland.
It was not until 1930, that Marburg first suggested a hormonal role for the pineal gland. 
He believed that specific pineal parenchyma cells produced an antigonadotropic
hormone that could retard sexual development in infants.
Following the Second World War, there was a great deal of research conducted on
pineal anatomy, histology, cytology, biochemistry, physiology and pharmacology. 
Melatonin, the principal hormone of the pineal gland, was first isolated in 1958 by Lerner
et al [9].  In the past 50 years, great advances have been made in understanding the role
of the pineal gland in human physiology, the role of melatonin in the regulation of
circadian and circannual rhythms, and the effect of melatonin on endocrine glands.  It
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Figure 1.1: Structure of Melatonin
was only in 1991, that Ianas et al [1,2] first suggested that melatonin may have
antioxidant properties.  Since then a great deal of research has been conducted into this
aspect of melatonin function.  
1.1.2. Structure
Melatonin, 5-methoxy-N-acetyltryptamine (see Figure 1.1) is, evolutionally speaking, a
highly conserved molecule that exists in organisms as different as algae and humans
[8,10].  Although first isolated in 1958, as far back as 1917, McCord and Allen had
reported that pineal extracts contained a substance that lightened the skin of
amphibians.  The molecule was later termed melatonin, because of its ability to cause
aggregation of melanin granules in melanophores.
1.1.3. Biosynthesis
Melatonin is the product of tryptophan metabolism by the pineal gland.  The production of
melatonin is controlled by a visual signal that originates in the retina.  During the hours of
darkness, the retina initiates the production of melatonin, by passing a signal along
unmyelinated fibres [10,11] to the suprachiasmatic nucleus of the hypothalamus [12,13]. 
The suprachiasmatic nucleus is the body’s internal clock which controls circadian
rhythmicity of biological events and behaviour [10,14,15].  Light synchronises this clock
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to the external environment by daily adjustments in the phase of the circadian oscillation
[16].  
A pathway then stretches from the suprachiasmatic nucleus, through the lateral
hypothalamus to the upper thoracic intermedio-lateral cell column.  Impulses are
conveyed via the medial forebrain to the spinal cord by preganglionic cell bodies
synapsing in the superior cervical ganglion [17].  Finally, post ganglionic fibres approach
the pineal together with the pineal blood vessels.  When stimulated during darkness, the
postganglionic sympathetic fibres release noradrenaline which binds to specific
$-adrenergic receptors on the pinealocyte cell membrane [10], so activating melatonin
production in the pineal gland.
The biosynthesis of melatonin in the pineal gland follows a two step process.  Initially,
5-hydroxytryptophan is transformed to 5-hydroxytryptamine (serotonin) by L-amino acid
decarboxylase.  Serotonin is allowed to accumulate in the pineal gland, before it is
converted to N-acetylserotonin, by N-acetyltransferase [18], during the hours of
darkness.  This is because N-acetyltransferase is the rate-limiting enzyme in melatonin
synthesis [10,19], with its function in the pineal gland being regulated by the release of
noradrenaline [20] by the postganglionic synaptic fibres.
The final step in melatonin synthesis, involves the conversion of N-acetylserotonin to
N-acetyl-5-methoxytryptamine (melatonin).  This conversion is achieved by
hydroxyindole-O-methyltransferase using S-adenosylmethionine as a methyl donor
[18,20,21] (see Figure 1.2).
Melatonin is not stored in the pineal gland but is rapidly secreted directly into the
bloodstream [10].  The normal route of melatonin secretion comprises of the pineal
capillaries draining into the surrounding venous sinuses [20].  Melatonin is transported in
the blood non-covalently bound to high-capacity, low-affinity binding sites on plasma
albumin [22], while in cerebrospinal fluid, melatonin is present in its free form [23].  Due
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Figure 1.2: Schematic representation of the actions of light and innervation on
melatonin synthesis in the pineal gland [20]
to its unique lipophilic and hydrophilic nature [24], melatonin is able to easily diffuse into
most tissues and cells in the body.
1.1.4. Metabolism
The half-life of melatonin in rats [25] and sheep [26] is only about 20 minutes.  The major
site of melatonin metabolism is the liver, where melatonin is converted to
6-hydroxymelatonin by the cytochrome P-450-dependent microsomal mixed-function
oxidase enzyme system [27].  Most of the 6-hydroxymelatonin is further conjugated to
sulphate, rendering 6-sulphatoxymelatonin as the major urinary metabolite [10,27,28,29],
although 6-hydroxymelatonin can also be conjugated to glucuronic acid [24,27].
The metabolic pathway of melatonin in the central nervous system is different from that in
 the liver [30].  In the brain, indoleamine-2,3-dioxygenase cleaves the pyrrole ring to form
N-acetyl-5-methoxykenurenamine which is excreted in the urine [18].
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Figure 1.3: Normal Circadian Rhythm of serum melatonin for a male (A) and female
(B).  Each point represents the mean (±SD)  of 10 individuals [20].
1.1.5. The 24-hour Rhythmicity of Melatonin Production
In all species, the daily period of darkness is associated with a rise in the amount of
melatonin produced by the pineal gland [31].  The magnitude of the rise varies among
species, but typically night-time values are 2 - 10 times greater than day-time melatonin
levels [31].  In humans and the rat [32], melatonin production begins to increase at, or
shortly after, the onset of darkness.  The production continues to gradually rise, until a
peak is reached near the middle of the dark phase.  Melatonin levels then begin to drop
to reach day-time values at about the time of lights on (see Figure 1.3) [33].
1.1.6. Effects of Disturbances to the Diurnal Melatonin Cycle
Because the production of melatonin is regulated by the intensity of the light falling on the
retina, the time of the day and even the season of the year [34] affect melatonin
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production.  Any disturbances that throw the melatonin cycle out of phase with the
natural circadian rhythms of the body can harm human well-being [35].  
Seasonal Affective Disorder is characterised by periodically recurring depressive
episodes [36-39], which normally occur during winter. This disorder is especially
prevalent in Scandinavian countries, where it is proposed that a patient’s circadian clock
does not adjust correctly in accordance with the changes in day length, that occur during
the different seasons.  Normally the acrophase of the melatonin cycle is either, phase
advanced of phase delayed with respect to healthy subjects, in patients with this
disorder.  This results in a melatonin cycle out of phase with the patient’s general
environment, and leads to the periods of depression or mania.  Treatment involves
synchronising the melatonin rhythm with the day / night cycle over a period of 4 - 14 days
[40].  This is done by exposing phase advanced patients to 2 500 lux light for 2 hours in
the morning, and phase delayed patients to the same amount of light in the evening. 
Morning appears to be the most beneficial time to give light treatment in most cases,
indicating that circadian rhythms are more likely to be delayed in seasonal affective
disorder patients when compared to controls [36,40].  
Jet-lag results from a similar shift in the melatonin acrophase.  Flying over many time
zones results in a melatonin circadian rhythm that is out of phase with the general
environment [41].  Fortunately most people are able to adjust their circadian rhythms to
suit the new environment within a few days [42].  Taking 5 mg of melatonin [43] at the
local bed time, for the first two days in the new time zone, can be beneficial for helping to
speed up changes in the circadian rhythm.  The use of melatonin as a therapeutic agent
against jet-lag does not appear to have any undesirable endocrine effects [44], with the
only side effect being the promotion of drowsiness [45,46].  
It has also been reported [47] that the depressive effects and feelings of disorientation
that many night workers experience could be caused by a circadian rhythm that is out of
phase with the environment.  In this case however, melatonin treatment would not be
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therapeutic as the work environment is completely out of phase with the signals from the
natural environment that help to regulate the circadian rhythms.
1.1.7. Historic View of the Functions of Melatonin
Up until the discovery of an antioxidant role for melatonin in 1991, researchers had
previously thought that melatonin’s role was restricted to controlling circadian rhythms,
breeding in animals and acting as a tranquillising hormone.
1.1.7.1. Reproduction
The association between the pineal glands and the gonads has been known since the
end of the 19th century, when Heubner published a report of a young boy with early onset
puberty, who was also suffering from a tumour in the brain tissue around the pineal gland
which inhibited melatonin production.  
The association between the pineal and sexual development is related to the production
of melatonin.  Melatonin is able to exert an antigonadal effect [48], and this suggests that
secretion is connected with the estrus and menstrual cycles.  Melatonin and
gonadosteroids appear to function in a feedback loop, as gonadosteroids, estradiols and
testosterone given at physiological doses, significantly increase hydroxyindole-O-
methyltransferase activity, while castration decreases melatonin production [20].
Melatonin has been shown to regulate the seasonal reproductive cycles of Syrian
hamsters by utilising day-length as a primary environmental cue [49].  There are many
hypotheses as to how melatonin regulates seasonal breeding, but the internal
coincidence hypothesis is the one that most evidence supports [18].  This model
proposes that there are two rhythms in the animal body, the melatonin cycle and a
rhythm that is sensitive to melatonin.  It is only when the melatonin peak coincides with
the sensitivity rhythm that gonadal maturation takes place [31] (see Figure 1.4).  This
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would explain why, for many animals, breeding only occurs at certain times of the year,
when the whole breeding population becomes sexually active.
1.1.7.2. Hibernation
Melatonin is also known to play a role in hibernation.  When the ground squirrel
(Spermophilus elegans) is pinealectomised during the summer, hibernation during the
subsequent winter is completely abolished [10].  Pinealectomy of other species does not
completely abolish hibernation, but does appear to upset the hibernation cycle [10]. 
Other mechanisms therefore appear to be involved in the control of hibernation.
1.1.7.3. Temperature
All homeothermic animals, including man, exhibit a diurnal rhythm in body temperature
[34,42].  The temperature rhythm consistently follows the melatonin rhythm with an
inverse amplitude and a delay of about 1.8 hours [50], with melatonin levels starting to
increase as the body temperature of man begins to decline during the evening, and as
the body temperature starts to rise before dawn, so melatonin levels decrease. 
Melatonin therefore appears to play a role in circadian thermoregulatory adjustments in
body temperature, where it adjusts the set point of body temperature to be consistent
with the metabolic rate of the animal.  This is supported by work done by Spencer et al
[51] who observed that pinealectomy drastically reduced the mean core temperature, but
did not alter the rhythmicity of the temperature cycle in female rats.  This relationship
appears to be causal rather than fixed, as some individuals show a temperature rhythm
in the absence of a melatonin rhythm [34].
1.1.7.4 Endocrine Effects
It has been reported that the pineal gland restricts and modulates adrenal
steroidogenesis under normal and stress conditions [52,53].  Kinson et al [54] found, that 
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Figure 1.4: Diagrammatic representation of the internal coincidence model [31].
following pinealectomy, the secretion rates of both aldosterone and corticosterone were
significantly elevated.  The authors therefore concluded that the pineal gland may
normally exert an inhibitory effect on the adrenal cortex.
Many researchers [52,55] also proposed that the principal function of the pineal gland
was to control, coordinate and regulate the physiological adaption of an organism to
stress, where stress was defined as the sum of the biological reactions to any adverse
stimulus, whether physical, mental or emotional, that disturbs an organism’s
homeostasis.  Evidence suggests that the pineal gland exerts a general tranquillising
effect in stress situations [56].  This is supported by the finding that melatonin exhibits an
inhibitory action on the thyroid gland [53].  As the thyroid hormones stimulate general
metabolism in most body tissues, an increase in melatonin production would cause a
general decrease in body metabolism and make an animal more lethargic.
Therefore, until the beginning of this decade, the pineal gland and melatonin were
thought to generally act to synchronise, stabilise and moderate organisms on behalf of
several physiological processes [53].
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1.2. GLUTAMATE
1.2.1. Role of Glutamate in the Mammalian Organism
L-glutamate is the most common free amino acid in the CNS [57,58], existing in
millimolar concentrations in the cytoplasm of most vertebrate neurons [58].  A number of
biological functions, including intermediary metabolism of neuronal tissues, detoxification
of ammonia in the brain and carbohydrate and nitrogen metabolism [57], involve
glutamate.  As an amino acid, glutamate, is also an important building block in the
synthesis of proteins and peptides.  
In 1984, Fonnum [59] showed that glutamate satisfied all the criteria to be called a
neurotransmitter.  Firstly, glutamate is presynaptically localised in distinct neurons and
specifically released by physiological stimuli in concentrations high enough to elicit a
postsynaptic response.  In addition, intracellular Ca2+ is released upon glutamate
stimulation and high affinity uptake mechanisms exist to terminate transmitter action
rapidly.  Finally, cellular and molecular effects of receptor activation are observed, while
synaptic transmission can be blocked by glutamate receptor agonists.  Glutamate was
subsequently classified as one of a number of excitatory amino acids (EAA’s). 
Glutamate and the related EAA’s account for most of the excitatory synaptic activity
[60,61], and they are released by an estimated 40% of all synapses [59,62].  Of the
EAA’s, glutamate is the most dominant and it is said to be the predominant fast excitatory
neurotransmitter in the central nervous system (CNS) [57].
1.2.2. Structure, Biosynthesis and Metabolism
Glutamate is a non-essential amino acid.  In the body there are several precursors for
glutamate synthesis as well as many metabolic pools [58].  Glutamate that is used for
metabolic processes is derived from glucose via the Krebs Cycle [59,63].  In the neuron
the neurotransmitter pool of glutamate is kept separate from metabolic glutamate, and is
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localised in the nerve terminals of glutamatergic neurons [57].  Experiments with cortex
synaptosomes have shown that 80% of released glutamate is derived from glutamine
and less than 20% from glucose [64].  In vivo however it may well be that the transmitter
pool of glutamate will accept any glutamate available, independent of source, and the
synthesis of transmitter itself is not a rate-limiting factor under normal conditions [59].  
1.2.3. Glutamatergic Neuronal Transmission
Glutamate is taken up and stored in synaptic vesicles by an adenosine triphosphate
(ATP) process [65].  The vesicular glutamate transporter is very specific and does not
transport other closely related amino acids, such as aspartate, into the vesicles.  When
glutamatergic nerve terminals are depolarised, vesicular glutamate is released into the
synaptic cleft in a Ca2+-dependent fashion [61,62].  Glutamate exerts its physiologic
actions on several distinct families of glutamate receptors, located principally on
postsynaptic neurons.  The actions of glutamate are terminated when glutamate is
removed from the synaptic cleft by sodium-dependent, high-affinity glutamate uptake
carriers, which are located primarily on glial cells [66,67], but presynaptic terminals also
sequester glutamate directly from the synaptic cleft [60].  Within the glial cells, glutamate
is converted to glutamine via the enzyme glutamine synthetase [63,68].  Glutamine can
then be cycled back to the glutamatergic nerve terminals, where it is converted to
glutamate by the mitochondrial enzyme, phosphate-activated glutaminase [63,69] (see
Figure 1.5).  The rapid removal of glutamate from the synapse is an essential aspect of
neurotransmission [70].  Glutamate concentrations are kept extremely low (2 - 3 µM) in
the synapse [68,71].  This ensures that postsynaptic neurons are only stimulated
following the release of glutamate by the presynaptic neurons. 
1.2.4. Glutamate Receptors
Glutamate is termed a “mixed agonist” because it activates several classes of receptors 
[72].  Each class has a distinct pharmacology and physiology.  The receptors are named 
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Figure 1.5: Schematic representation of a glutamatergic synapse showing a presynaptic
glutamatergic nerve terminal, a postsynaptic neuron, and a glial cell [57].
after the agonist compounds that are specific for eliciting a given pharmacological
response.  Glutamate receptors are divided into the ionotropic receptors, which are
ligand-gated ion channels, and the metabotropic receptors [43], which are linked to G-
proteins [62,74,75] and are associated with changes in the cyclic nucleotides or
phosphoinositol metabolism [57].
1.2.4.1. NMDA Receptors
The NMDA receptor has a very complex structure (see Figure 1.6), containing binding
sites for both glycine and glutamate [76].  Both the glycine and glutamate sites must be
occupied for activation to occur [77,78], and so they are referred to as “co-agonists” of
the NMDA receptor [62].
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Figure 1.6: Diagrammatic representation of the NMDA receptor [86].
Activation of the NMDA receptor is modulated by polyamines, such as spermine and
spermidine [79].  Although the polyamine site need not be occupied for receptor
activation, the presence of polyamines increases the ability of glutamate and glycine to
open the NMDA-receptor ion channel [80].  One of the most important factors of the
NMDA receptor is the voltage-dependent blockade of the receptor ion channel by Mg2+
[57,81-84].  At resting potential (about -70mV), normal extracellular concentrations of
Mg2+ block the NMDA-receptor ion channel and prevent current flow, even when the
glutamate and glycine sites are occupied.  However, because the Mg2+ blockade is
voltage-dependent, the degree of Mg2+ block is reduced as a neuron becomes
depolarised [85] allowing more movement of ions.
The NMDA receptor is ionotropic, permitting an intracellular influx of Ca2+, as well as an
exchange of Na+ and K+ across the cell membrane [58,68,87].   Ca2+permeability of the
NMDA receptor is important as the increase in Ca2+ concentration activates a number of
cellular and second messenger systems, and contributes to the initiation of long-term
potentiation [88-90].
Extracellular Zn2+ appears to act as an inhibitory modulator of channel function at a site
near the “mouth” of the ion channel [58].  A variety of competitive and non-competitive
inhibitors exist for the NMDA receptor.  Among the more common competitive inhibitors
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Figure 1.7: Schematic diagram of the AMPA receptor [86].
are 2-amino-5-phosphonovalerate (AP5) which competes directly with glutamate for the
binding site [58], while the non-competitive inhibitors dibenzocyclohepteneimine
(MK-801), phencyclidine (PCP) and remacemide act within the ion channels to block
current flow [57,58].  High concentrations of the NMDA receptors are found in the
cerebral cortex and CA1 regions of the hippocampus [82].
1.2.4.2. The AMPA Receptor
The "-2-amino-3-hydroxy-5-methylisoxazole-4-proprionate (AMPA) (see Figure 1.7)
receptor is an ionotropic glutamate receptor that appears to be involved in fast excitatory
synaptic transmission [91].  This class of receptor was previously called the “quisqualate
receptor”, but the name has changed following the discovery that quisqualate can
activate several receptor classes [86].  The binding of glutamate to the AMPA receptor is
associated with influx of Na2+ from the extracellular space to the intracellular
compartment.  K+ also passes through the AMPA receptor [58].  Some AMPA [62] and
KA [92] receptors have also been reported to be permeable to Ca2+.
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Several competitive inhibitors compete directly with glutamate for the AMPA binding site. 
Among these antagonists are 6-cyano-7-nitroquinoxaline (CNQX) and
6,7-dinitroquinoxaline-2,3-dione (DNQX).  The AMPA receptor is found in relatively high
concentrations in the cerebral cortex, molecular layer of the cerebellum, CA1 and CA3
regions of the hippocampus, striatum and the nucleus accumbens [58].
1.2.4.3. The Kainic Acid Receptor
The KA receptor is also ionotropic, and although similar to the AMPA receptor, is
differentially sensitive to domoate and KA [93].  As with the AMPA receptor, the KA
receptor is predominantly permeable to Na+ and K+, but some receptor classes also allow
Ca2+ to enter the cell [94].  Elucidation of the pharmacology and function of the KA
receptor has been hampered by lack of a specific antagonist for this receptor type [57]. 
2-Amino-3[-(carboxymethoxy)-5-methylisoxolzol-4-yl]-proprionate (AMOA) and 2-amino-
3-[2-(3-hydroxy)-5-methylisoxazol-4-yl]-proprionate (AMNH) are selective inhibitors of the
KA receptors [58].  KA receptors are found in their highest concentrations in the CA3
region of the hippocampus [58].
1.2.4.4. Metabotropic Receptors
Metabotropic receptors are not linked to ion channels (see Figure 1.8), but are rather
coupled to second messenger systems.  Evidence indicates at least five subtypes of
metabotropic glutamate receptors, which are coupled to G-proteins [85] and cytoplasmic
enzymes.  Depending on the receptor subtype and the cell type, metabotropic receptors
might mediate [95] inositol phosphate metabolism, release of arachidonic acid, or
changes in cyclic adenosine monophosphate levels.  
Agonists for metabotropic receptors include trans-1-aminocyclopentyl-1,3-dicarboylate
(t-ACPD), ibotenic acid, and $-;-methylamino-L-alamine (L-BMAA) [58].  Like KA
receptors, the role of metabotropic receptors within the CNS has not been well defined
because of a lack of good receptor antagonists [57].  Metabotropic receptors may be
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Figure 1.8: Diagrammatic representation of the metabotropic receptor [86].
located on glial cells, as well as neurons.  The highest concentration of metabotropic
receptors is seen in the molecular layer of the cerebellum.
1.2.5. Glutamate Receptor Agonists
Glutamate is the ubiquitous agonist for all of the glutamate receptors.  Among the many
glutamate receptor agonists that have been found are NMDA, L-aspartate, polyamines,
AMPA, quisqualate, KA, domoate, t-ACPD, t-BMAA and iboterate.  For the purposes of
this discussion NMDA, QA and KA will be investigated, as these are the agonists that
were used throughout the study to promote neurotoxicity in the CNS.
Literature Review 17
1.2.5.1. N-Methyl-D-Aspartate
NMDA is a synthetically produced amino-acid that selectively binds to NMDA receptors. 
It is produced by many commercial companies and is neurotoxic if neurons are exposed
to it.
1.2.5.2. Quinolinic Acid
QA is a naturally produced metabolite of tryptophan metabolism [96-98].  QA has been
shown to be present in normal postmortem human brains at levels similar to those of
other species [99], and with concentrations not varying greatly among the different
regions of the brain.  Heyes and Morrison [97] demonstrated that the brain naturally
synthesises QA, and that the rate of QA formation increases in conditions of brain and
systemic immune activation.  QA concentrations have also been shown to increase
during the natural aging process in rats [100].  
Foster et al  [101] showed that there is no active uptake of QA from the extracellular
space, nor is there extracellular metabolism of QA.  It is therefore unlikely that QA is a
neurotransmitter in the classical sense.  QA is however a selective agonist for the NMDA
population of receptors.  Stone and Perkins [102] demonstrated that QA is about one-
quarter as active as NMDA, and approximately as active as glutamate and aspartate at
stimulating NMDA receptors.  It must however be remembered that the latter compounds
have a rapid, high-affinity uptake system for their removal from the synapse, while QA
does not.
Because QA is not removed from the synaptic cleft, QA will continue stimulating the
NMDA receptor.  It is thus a very potent neurotoxin.  QA is known to induce neuronal
lesions after intrastriatatal and intrahippocampal injections in the rat brain [103,104]. 
These lesions closely resemble those observed in the brains of people with Huntington’s
disease [105,106].
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1.2.5.3. Kainic Acid
Kainic acid activates the KA receptors in the brain and is not naturally produced in the
body.  It is however produced by a type of kelp (Digenea simplex) [93].  KA toxicity first
came to the attention of scientists, when they noticed that the inhabitants of Guam and
other Pacific Rim Islands, where uncooked seaweed is eaten regularly, suffered from
neuropathies and dementias [83].  
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1.3. EXCITOTOXICITY
1.3.1. Introduction
Apart from glutamate’s beneficial function as an excitatory neurotransmitter, glutamate
also harbours the potential to be neurotoxic.  The concept of glutamate as an excitotoxin
developed largely due to the work of Olney and his colleagues [107,108] who, in the
1970’s, demonstrated a correlation between the excitatory properties of various
glutamate analogues, and their ability to produce neurotoxic damage at high
concentrations [93].   Excitotoxicity as defined by Olney [109] refers to the paradoxical
property, shown by glutamate and specific EAA analogues, of causing acute neuronal
degeneration by excessive stimulation of postsynaptic EAA ionotropic receptors -
receptors through which glutamate functions as a transmitter.
Agonists acting at the NMDA and KA receptors are among the most potent agonists able
to produce a combination of neuronal excitation and subsequent neurodegeneration.  In
most cases the initiating factor for neurodegeneration is the accumulation of intracellular
Ca2+.  Agonists acting at the NMDA receptor induce increases in Ca2+by activating ionic
channels through which Na+, K+ and Ca2+ can enter the cell [110].  KA receptor agonists
cause an increase in Ca2+ by triggering the release of Ca2+ from intracellular stores.  It is
also possible that under certain pathological conditions such as hypoxia, hypoglycemia,
seizure and epilepsy [111], the transport system can be caused to operate in reverse,
which results in the release of glutamate into the synapse.  High synaptic glutamate
concentrations can prove toxic to neurons, as demonstrated by the Ca2+ c annel blocker
nifedipine,  preventing damage to cultured neurons by QA and other excitotoxins [112].
1.3.2. Mechanism of Excitotoxicity
Normally the release of glutamate acts as a signal between one neuron and another,
triggering the brief opening of receptor-coupled channels, which allows ions to pass
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through the cell’s protective membrane [8].  High concentrations of glutamate, however,
cause these channels to remain open for extended periods of time, permitting an
abnormal, prolonged and finally a lethal influx of ions into the neurons.
There are two principle processes in which EAA induced neurotoxicity can lead to cell
death [93].  These are distinguished by differences in time course and ionic dependence. 
The first process, termed the acute process, involves the rapid swelling of neurons
caused by excessive depolarisation, ion influx and water entry, while the second, slower
or delayed neurotoxic process occurs secondary to Ca2+ influx [58].
1.3.2.1. Acute Toxicity
Acute toxicity occurs because of the rapid influx of mainly Na+ i to the neuron.  This
causes passive Cl- and water entry into the cell via osmotic pressure.  This toxic process
occurs within minutes and depends on the presence of extracellular Na+ and Cl- ions.  It
may be associated with abnormalities in membrane permeability and may be lethal, via
osmotic lysis.  Under some circumstances, the neuron may be able to restore osmotic
pressure and so survive.  This process can be mimicked by depolarising agents like
veratridine [113] or by raising extracellular K+ concentrations.  Activation of non-NMDA
receptors can cause such neurodegeneration, with both KA and AMPA being examples
of potent neurotoxins [114].  The process that takes place may be direct, by over
excitation of the neuron leading to prolonged depolarisation and depletion of energy
reserves, or indirect, for example by excessive Na+ ion influx resulting in Ca2+ build up via
Na+ - Ca2+ exchange.
1.3.2.2. Delayed Toxicity
Delayed neurotoxicity involves Ca2+ influx mediated by the NMDA receptor.  The
increase in intracellular Ca2+ concentration can set off a cascade (see Figure 1.9) of
pathophysiological events that can lead to excitotoxin-mediated neuronal death [5].  In
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Figure 1.9: Schematic representation of the glutamate-receptor mediated processes
that promote oxidative stress [5].
most cases Ca2+ influx does not actively initiate cell death, but rather activates a number
of enzymatic and metabolic processes that set in motion a process that can prove
neurotoxic.  In part, these changes are reversible, as shown by the ability of glutamate
receptor antagonists to confer neuroprotection several hours after an excitotoxic insult
[115].  However, in most cases, once the process has begun, neuronal cell death results.
Among the processes triggered by increased Ca2+ concentrations, is the activation of
proteases such as calpain-1.  These enzymes can degrade major neuronal structural
proteins, and induce cytoskeletal breakdown [116].  Calpain also cleaves xanthine
dehydrogenase to convert it to xanthine oxidase [93,117].  This enzyme converts
hypoxanthine to uric acid while also producing O-2@ [5,118]. 
Ca2+ can also bind to calmodulin to form Ca2+-calmodulin complexes.  The role of this
complex in mammalian cells is to modulate the activity of a large number of enzymes
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[119].  Among the processes activated are Ca2+-calmodulin-linked protein kinases, which
disrupt the cytoskeleton [120], cause mitochondrial dysfunction and activate lipases
[121].  Ca2+-calmodulin complexes can also activate nitric oxide synthase (NOS) [121],
which produces nitric oxide (NO), a toxin that has been implicated in a number of
neurological diseases [122].  Activation of Ca2+-sensitive kinases (proteases) could also
result in over-phosphorylation of cytoskeletal proteins such as tau and ubiquitin,
hyperphosphorylated forms of which are found in neurofibrillary tangles [123].
Phospholipases [93,124] which are capable of breaking down cell membranes and
liberating arachidonic acid may also be activated by Ca2+.  This can lead to the
breakdown of Ca2+ stores within the cell, which can further amplify the excitotoxic
response as there will be even higher intracellular Ca2+ concentrations.   Extracellular
arachidonic acid has been shown to reduce glutamate uptake by astrocytes [125] from
the synapse [126].  This results in greater glutamate receptor activation, and a further
amplification of the neurotoxic process.  Endonucleases responsible for breaking down
genomic DNA may also be activated [93].  Free radical production has been linked to a
loss of cellular Ca2+ homeostasis.  
Dykens [127] reported that isolated cerebral and cerebellar mitochondria produce free
radicals when exposed to elevated Ca2+.  Mitochondria play an important role in the
removal of Ca2+ from cells after a glutamate insult [128,129].  Ca2+ is sequestered to the
mitochondrial matrix [130-132], driven by the proton electron chemical gradient
generated by the electron transport chain [133].  The reduction in the electrochemical
gradient [133] caused by the Ca2+ influx decreases ATP synthesis [134], at a time when
there is great demand for ATP by the plasma membrane Ca2+ pump, and indirectly by the
Na2+ / Ca2+ exchanger [132].  Mitochondrial Ca2+accumulation and the subsequent
permeability transition, may therefore be a critical early event specific to the NMDA
receptor mediated excitotoxic cascade [135,136].
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1.3.3. Free Radicals
1.3.3.1. Structure
All of the processes described in the previous section lead either directly or indirectly to
the elevated production of free radicals.  The production of oxygen free radicals is a
natural consequence of aerobic metabolism, with these molecules being constantly
generated in the body by normal metabolic processes [137,138].  By definition,
oxyradicals are a molecular species capable of independent existence that contain one
or more unpaired  electrons [139-142].  Usually, electrons associated with atoms or
molecules are paired because this makes atoms relatively stable and unreactive.  The
loss of an electron leaves a molecule much more reactive than its paired counterpart.  If
two radicals react, both radicals are eliminated, while if a radical reacts with a non-
radical, another free radical must be produced.  This characteristic allows free radicals to
participate in chain reactions, which may be thousands of events long [143].  Although
there are a variety of free radicals produced by molecules, those that are produced from
molecular oxygen have received the most investigative interest [140].  The oxygen
species that are typically linked to oxidative stress are superoxide anion radical (O-2@), the
hydroxyl radical (@OH) [144], hydrogen peroxide (H2O2) [145], nitric oxide (NO) and
peroxynitrite (ONOO@).  The collective term for these chemicals is “reactive oxygen
species” (ROS), but not all of these species are particularly active in aqueous biological
solutions [146].  
The mammalian brain is especially vulnerable to oxidative stress [147] as it consumes
20% of total body oxygen, contains large amounts of polyunsaturated lipids, is relatively
deficient in protective mechanisms, and readily accumulates iron [146].  Although
estimates vary, it is believed that up to 5% of the oxygen [140,148] taken up by an
organism may eventually end up as damaging oxygen-based radicals.  In the human,
this means that there could be the equivalent of 2 kg of O-2@ produced each year [140].
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1.3.4. Defence Mechanisms against ROS neurotoxicity
The body has many defence mechanisms to deal with oxidative stress [149] (see Table
1.1).  These enzyme systems are normally distributed evenly inside cells [143], and
under normal circumstances these defence mechanisms can deal with the production of
ROS in the neuron.  It is only when there is either an increase in oxyradical production, or
a decrease in cellular ROS defence systems, that neurotoxicity occurs [139].
Table 1.1: Cellular defence / anti-oxidant mechanisms accessible to neurons to protect
against ROS species [146]
Enzymatic Non-Enzymatic
Cu / Zn - Superoxide Dismutase Ascorbic Acid (Vitamin C)
Mn - Superoxide Dismutase "-tocopherol (Vitamin E)
Glutathione Peroxidase Glutathione
Glutathione-S-Transferase
Glutathione Reductase
Catalase
1.3.5. The Superoxide Radical
The free radical O-2@ is generated by multiple enzymatic and non-enzymatic pathways
and is often at the start of the oxidative stress cascade.  Mitochondria are one of the
main producers of other O-2@ [143].  During the production of ATP via the electron
transport chain [146], the oxygen molecule can be reduced to O-2@.  The body protects
against this by kinetically restricting these reactions.  Nevertheless, 1 - 3% of high energy
electrons “leak” in close proximity to oxygen resulting in the formation of O-2@ [5].  As
mentioned earlier, cumulatively this small amount of O-2@ leakage leads to the production
of up to 2 kg of O-2@ during the year.  
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The O-2@ radical can also be generated chemically by auto-oxidative reactions with
catecholamines, tetrahydrofolates and reduced flavins.  This can lead to a free radical
chain reaction as the production of O-2@ leads to the autocatilization of more O
-
2@.
It has also been demonstrated that O-2@ is produced by the metabolism of arachidonic
acid by the cycloxygenases and lipoxygenses [150].  The Ca2+-dependent activation of
phospholipase A2 also yields O
-
2@ through the metabolism or arachidonic acid by the
lipoxygenases and cyclooxygenases to form eiconasoids [151].
Most of the O-2@ generated in a cell is converted to H2O2 by superoxide dismutase
[139,142,152].  The H2O2 is then metabolised by either catalase, or one of the
peroxidases to produce water and oxygen [153].
1.3.6. The Hydroxyl Radical
The @OH radical is probably the most reactive of the ROS species [8,146] as it will react
with almost all molecules in living cells [154].  It is so reactive that no enzyme systems
involving it as a substrate exist [155].  The estimated diffusion distance of 0.3 nm, or one-
hundredth the diameter of a typical protein [156], means that damage will occur where
@OH is formed.  The @OH radical has been implicated in damage to proteins,
carbohydrates, DNA and lipids [140,146,157].
Most of the hydroxyl radicals generated in biological systems are formed when transition
metals [158] or biologically active chelators, such as porphyrins and flavins are present
simultaneously with an oxidant, such as hydrogen peroxide [8].  The breakdown of
hydrogen peroxide is described by the Fenton reaction [5,8] (see Figure 1.10).
Literature Review 26
Figure 1.10: The Fenton reaction [8]
1.3.7. NITRIC OXIDE
1.3.7.1. Introduction
Nitric oxide is a ubiquitous and unique biological messenger molecule that mediates all
of its biological functions through redox-sensitive interactions.  NO’s role in the nervous
system was first recognised when it was shown that glutamate acting at the NMDA
receptor stimulates the formation of NO in cerebral granule cells [85].
1.3.7.2. Physical Properties
At standard temperature and pressure, NO is a gas [159].  However, in most biological
systems NO acts as a dissolved non-electrolyte and not as a gas.  NO tends to be more
soluble in apolar solvents and therefore dissolves selectively in membrane and lipid
phases of cells.  It also has the ability to diffuse very rapidly from 10 µm (less than a cell
size) to several cell diameters [160] in a solution containing proteins and membranes. 
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Neuroscientists regard NO as a highly reactive molecule owing to its short half life (3 -
6 seconds) in comparison to traditional messenger molecules [161].  As NO is a free
radical, it does not remain in it’s native form for very long, before it is oxidised, reduced or
complexed to biomolecules.  It is however relatively less reactive than O-2@ or @OH, and is
a relatively stable carrier of the unpaired electron.  These properties are exploited by
biological systems as a novel class of neurotransmitters.
1.3.7.3. Nitric Oxide Synthase
NO is formed by Nitric oxide synthase [5].  The process involves the conversion of
L-arginine to L-citrulline.  At least 3 different isoforms of the NOS enzyme have been
identified [161].  Neuronal NOS or type I NOS, was first cloned from the rat cerebellum
[162].  The other two isoforms of NOS were isolated from macrophages, where NOS is
used in the immune defence system, and endothelial cells.
Within the nervous system, NO is responsible for relaxing the pyloric sphincter in the
gastrointestinal tract [161], mediating penile erections [163] and vasodilation [164].  NO
is also thought to be involved with the regulation of behaviour.  Studies with mice that
have had the neuronal NOS isoform removed from their genomic make up, exhibit
inappropriate sexual behaviour, fight incessantly and do not respond to appropriate
submissive posturing by wild-type mice [165].  These behavioural abnormalities may be
due to the lack of NOS activity, as there are no detectable differences in brain structure
[166], or testosterone levels [165], between wild type and knock out mice.
The catalytically active form of NOS is a dimer, however dimerisation on its own does not
lead to electron flow.  Neuronal NOS is synthesised as two non-interactive molecules
that bind FMN and FAD [167].  These monomers loosely dimerise upon binding
tetrahydrobiopterin, haem and L-arginine.  Electron transport however, only begins after
an increase in intracellular Ca2+ has led to the formation of a Ca2+-c lmodulin complex. 
This complex is necessary to bind to the dimer.  This causes a conformational change,
which results in activation of the enzyme.
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One of the most important aspects of NO production is that it has been implicated in
neurological damage [167,168].  The glutamate-initiated neurotoxic cascade involves the
increased influx of Ca2+ into the neurons.  This can bind to calmodulin to form the
Ca2+-calmodulin complex.  As this complex regulates NOS activity, NO production will be
initiated [167]. 
In the absence of the L-arginine substrate the neuronal isoform of NOS is able to
produce O-2@ and @OH [169].  This is because the rate of NADPH oxidation for the
neuronal isoform is primarily influenced by the Ca2+-calmodulin isoform, and not by
L-arginine [161].  Therefore under conditions of reduced L-arginine concentrations,
substantial amounts of O-2@ can be produced by NOS.
NO is not a very reactive molecule in its native form, but NO can interact with O-2@ o form
the highly reactive peroxynitrite free radical [5,142,170].  Peroxynitrite is generally
considered to be a more toxic species than either NO or O-2@ alone [171,172].  The
catalytic process triggered by peroxynitrite include initiation of lipid peroxidation, inhibition
of mitochondrial respiration, inhibition of membrane pumps, depletion of glutathione, and
damage to DNA [173].  Gilad et al [173] have demonstrated that melatonin is a
scavenger of peroxynitrite.  Melatonin was able to inhibit the development of DNA single
strand breakages and reduced suppression of mitochondrial respiration in response to
peroxynitrite.
1.3.8. Lipid Peroxidation
Most of our current information concerning biological membranes comes from the fluid
mosaic model, proposed by Singer and Nicholson in 1972 [174].  They proposed that a
membrane consists of a lipid bi-layer, interspersed with proteins and carbohydrates.  The
membrane is a dynamic system, and the composition depends on where in the cell it is
located.  Membranes function to compartmentalise the cell, as well as providing a
surface from which ATP can be produced, receptors can bind, the transport of
Literature Review 29
substances can be controlled.  The structure and integrity of membranes is therefore
essential for the successful functioning of the cell.
Lipid peroxidation is a process whereby membranes are destroyed by oxidative attack
from ROS.  Of all the major classes of biomolecules attacked by ROS, membrane lipids
are probably the most susceptible to oxidative attack, because of the high levels of poly-
unsaturated fatty acids (PUFA) present in these macromolecules.  Lipid peroxidation is
also extremely damaging because self-perpetuating chain reactions are caused by ROS
attack.  Table 1.2 illustrates the three features which characterise the lipid peroxidation
process.  During the initiation step (reaction 1) PUFA’s are attacked by ROS (In@),
resulting in the removal of a hydrogen atom from the PUFA (RH) and the formation of a
lipid-derived radical (R@).  The propagation step (reaction 2) normally begins with the
rapid addition of molecular oxygen to R@, to form the lipid peroxyl radical (ROO@).  This
radical can attack other lipids, to generate a further lipid radical and a lipid hydroperoxide
(ROOH).  A self perpetuating autocatalytic reaction then follows with reactions 2 and 3
undergoing a number of cycles [176].  The final step is a termination step, which results
when two ROO@ radicals react together to form a non-radical product [177].  The removal
of ROS by various antioxidant systems is therefore essential to limit lipid peroxidation
occurring in cells.
Table 1.2: Chain sequence for free radical auto-oxidation [178]
Initiation In@ + RH ---> InH@ + R@ Reaction 1
Reaction R@ + O2 ---> ROO@ Reaction 2
ROO@ + RH ---> R@ + ROOH Reaction 3
Termination 2 ROO@  ---> Non-radical productsReaction 4
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1.4. MELATONIN AS A FREE RADICAL SCAVENGER
1.4.1. Introduction
in 1991, Ianas et al [1,2] gave a completely new dimension to melatonin research, when
the authors claimed that melatonin had both antioxidant and pro-oxidant actions.  In this
first experiment the group used luminol and H2O2 to generate free radicals and used
chemiluminescence to measure free radical production.  Using this system the authors
found that melatonin was able to quench free radical generation at concentrations above
0.25 mM, while below this concentration melatonin was pro-oxidative.
In 1993 these experiments were repeated by Tan et al [3].  This time @OH was generated
by the exposure of H2O2 to ultra violet light, and a spin trap employing
5,5-dimethylpyrroline-N-oxide was used to determine @OH concentrations.  The
scavenging properties of melatonin were compared to glutathione and mannitol, both
well known @OH scavengers.  Under these experimental conditions, melatonin was found
to be a far more efficient @OH radical scavenger, than either glutathione or mannitol. 
Melatonin was also found to lack pro-oxidant activity.
Various studies soon followed with Poeggeler et al [4] showing that melatonin could
remove @OH from a reaction mixture consisting of FeSO4 and H2O2, while Pieri et al [179]
found that melatonin was more effective at scavenging @OH than either trolox (water
soluble vitamin E), ascorbic acid or glutathione.  It has been found that melatonin
scavenges the trichloromethylperoxyl radical [180],   the tert-butoxyl and cumyloxyl
radicals [181], and the peroxynitrite radical [173].
Melatonin scavenges @OH by contributing an electron, thereby rendering the radical non-
reactive, but becoming itself a radical, the indolyl cation radical (see Figure 1.11).  This
product is not very reactive and is therefore non-toxic to the cell [182].  It is believed [7]
that the indolyl cation radical then scavenges the O-2@, thereby becoming N’-acetyl-N
2-5-
methoxykynuramine which is excreted through the urinary system.
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Figure 1.11: The presumed mechanism
whereby melatonin reduces the formation of
the hydroxyl radical [7].
In contrast to other electron donors such as ascorbic acid, melatonin does not transfer
hydrogen to other molecules, nor does it partially reduce oxygen to O-2@ or @OH. 
Additionally, melatonin does not excite oxygen to generate singlet oxygen. This is due to
the great stability of the melatonin molecule, caused by the methyl group which shields
the oxygen in the 5 position, while the acetyl group in the side chain enhances the @OH
scavenging capacity of the molecule [3].  This stability allows melatonin to emit and
absorb photons, quench singlet oxygen and neutralise other excited molecules [8]. 
1.4.2. Effect of melatonin on DNA
Earlier Tan et al [183] had shown that livers of rats treated with the carcinogen safrole,
which damages nuclear DNA by the production of ROS, did not have the same quantity
of DNA adduct formation when co-treated with melatonin.  It was also found that animals
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treated with safrole at night, when physiological levels of melatonin are elevated, had
less DNA damage than rats given safrole during the day, when melatonin levels are
reduced.  This led the authors to conclude that melatonin, even at physiological doses,
was able to provide significant antioxidant protection.  Ikeda et al [184] later
demonstrated, through morphological studies, that nuclear degeneration and DNA
fragmentation are associated with glutamate toxicity in rat cortical neurons.
As glutamate is known to cause neurodegeneration though the production of ROS,
melatonin could offer a neuroprotective role against glutamate induced DNA damage.
1.4.3. Effect of melatonin on lipid peroxidation
Melatonin is the most potent and effective endogenous @OH radical scavenger yet
discovered.  This is due to melatonin’s lipophilic nature which allows melatonin  to
scavenge free radicals inside membrane lipid bi-layers [185].  The indolamine can also
penetrate most cell compartments and provide onsite protection to other
macromolecules [8].
Many studies have been carried out that have demonstrated melatonin to have an
antioxidative action within a lipid-rich medium.  Melchiorri et al [186] demonstrated that
melatonin was able to protect against the paraquat-induced increase in the production of
malondialdehyde (MDA) and 4-hydroalkenals (4-HDA).  These are degraded lipid
products from cell membranes, and are taken to be reliable indicators of lipid
peroxidation [140].  The same group [187] further showed  that paraquat’s 24 hour LD50
was increased from 79 mg / kg in control rats to 251 mg / kg in rats, co-treated with
melatonin. 
Sewerynek et al [188] used rat brain homogenate to investigate melatonin protection
against lipid peroxidation.  This team found that melatonin was able to protect in a dose
dependent manner against the production of MDA and 4-HDA, induced by H2O2.
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Likewise, melatonin was able to protect in a dose dependent manner against carbon
tetrachloride (CCl4)-induced lipid peroxidation [189] in hepatic homogenate.  Under a
number of different experimental protocols [190,191], melatonin has been found to
protect against KA neurotoxicity.  Other studies have also found melatonin to protect
against lipid peroxidation induced by cyanide [192], cysteine [193] and glutamate [194].
1.4.4. Effect of Melatonin on Enzymes
Melatonin has been shown to affect a number of enzymes related to the antioxidative
defence system.  This action is completely different to the antioxidant nature of melatonin
neuroprotection, as in this case melatonin actually affects the activity of enzymes.
1.4.4.1. Glutathione Peroxidase
In 1995, Barlow-Walden et al [195] found that exogenously administered melatonin
stimulated the activity of this enzyme in the brain.  Glutathione peroxidase is involved in
the metabolism of H2O2 and is therefore an essential antioxidant enzyme.  The action of
melatonin may have been via nuclear melatonin receptors [196] showing that melatonin
even acts at the nuclear level. 
1.4.4.2. Glutathione Reductase 
Melatonin can also stimulate glutathione production by stimulating hepatic and cerebral
glucose-6-phosphate dehydrogenase.  This causes an increase in NADPH levels, which
promotes the production of glutathione by glutathione reductase [197].  Glutathione is a
powerful antioxidant and a cofactor for glutathione peroxidase.
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1.4.4.3. Nitric Oxide Synthetase
Benítez-King et al [198] found that melatonin binds with a high affinity to calmodulin.  This
suggests that the hormone is able to modulate cell activity by intracellularly binding to
calmodulin at physiological concentrations.
Pozo et al [6] demonstrated that physiological concentrations of melatonin were able to
inhibite NOS activity.  The inhibition was dose dependent and occurred because of
melatonin binding to calmodulin. This prevented calmodulin binding to the NOS peptide,
thus inhibiting the initiation of NOS activity.  These results suggested a new mechanism
of action for melatonin, where melatonin is able to stop enzymatic activity by inhibiting
receptor substrate interactions.
1.4.5. Melatonin, Free Radicals and Aging
The free radical theory of aging [199] was first introduced in 1956 by Harman.  He
explained that the generation of free radicals and their associated reactions was the
common cause of aging and death in all animals.  This theory is supported by work done
with animals subjected to a calory restricted diet [200-201].  These diets slow the aging
process because there is reduced production of ROS [137] in these animals.  It therefore
seems certain that the production of free radicals is one of the causative processes in
natural aging.
Organisms have a number of antioxidative defence mechanisms which can be use to
neutralise the effect of ROS.  Under ideal circumstances, ROS production is
counterbalanced by the defence system so that cellular damage is kept to a minimum. 
However damage accumulates with age, as some damage is unavoidable.  Also, the rate
at which macromolecules within cells accumulate ROS, appears to increase in
progressively older animals [7].  In a review of age-related alterations in antioxidant
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defence by Matsuo [202] it was found that there was no great deterioration in the
antioxidative system of older animals.  Matsuo therefore theorised that there may be
some, as yet, undiscovered component of the system, that does in fact deteriorate
rapidly.   
Melatonin concentrations decrease with age.  The exogenous administration of
melatonin substantially extends the life span of experimental animals [203].  The decline
in melatonin production could thus result in the increase in aging experienced later in life.
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1.5. GLUCOCORTICOIDS AND THE NEURON
1.5.1. Introduction
When organisms are subjected to circumstances that threaten, or are perceived to
threaten their existence, they initiate a stress response.  The secretion of glucocorticoids
by the adrenal cortex is central to this response [204-206].  In order for the steroid
hormones to be produced, an endocrine cascade first has to be initiated.
The cascade begins with the perception of stress in the brain [207].  Within seconds the
hypothalamus secretes corticotropin releasing factor (CRF) along with a number of other
substances that augment the action of this factor.  These collectively stimulate the
pituitary to release adrenocorticotropic hormone (ACTH) within 15 seconds [208].  This in
turn stimulates the adrenal secretion of glucocorticoids within minutes.
The glucocorticoids divert energy to muscles, promote the breakdown of stored energy
[209], increase blood pressure and suppress anabolic processes, such as growth,
reproduction, and the immune and inflammatory responses [204].  When exposure to
glucocorticoids is prolonged, steroid diabetes, hypertension, impotency and
immunosuppression can occur [208,210].  Another undesirable consequence of
glucocorticoid overexposure is neuronal damage [210,211].  
CNS damage appears to be most pronounced in the hippocampus [212] where neuronal
cell loss occurs.  This is because the glucocorticoids contribute to neuronal degradation
by exacerbating the effects of the EAA’s [213,214].  Moghaddan et al [215]
demonstrated that glucocorticoids cause glutamate accumulation in the hippocampus
and, in part, in the prefrontal cortex.  The same author, in another paper [216],
demonstrated that exposure to physical or pharmacological stress increases the release
of glutamate in the hippocampus and prefrontal cortex.  These results together,
demonstrate that glucocorticoids cause the increased release of glutamate into the
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hippocampus.  This increases extracellular glutamate concentrations, which can cause
overstimulation of glutamate receptors in the neurons.
Neurons consume energy at a high rate and are especially vulnerable to depletion of
energy supplies.  Neurons have a limited ability to store glycogen, and are therefore
heavily dependent on blood glucose as an energy source.  Glucocorticoids also inhibit
glucose uptake [217,218], so hampering ATP production.  Neurons are consequently
less able to remove intracellular Ca2+, and so many neurotoxic processes are initiated
[219].
1.5.2. Corticosterone and Melatonin
Chronic stress increases the adrenal secretion of corticosteroids, which inhibits the
activity of monoamine oxidases to metabolise serotonin.  Consequently, more serotonin
is present to be converted to melatonin [20].  This leads to an increase in the production
of melatonin [220] during times of stress [221].  Conversely pinealectomy enhances
corticosterone production in female rats [222].  Long term stress leads to the sustained
elevation of glucocorticoids, which down-regulates the control mechanisms of the
Hypothalamic-Pituitary-Adrenal (HPA) axis [223], resulting in an inability to terminate the
adrenal responses to stress.  Chronic melatonin treatment has been shown [220] to
affect glucocorticoid receptors in the brain and pituitary.  Melatonin decreased the affinity
of the receptors for their natural ligand, but this effect was only observed in the presence
of corticosterone.  Melatonin could thus protect neurons, by decreasing their receptor
affinity for their natural ligand during times of enhanced corticosterone concentrations. 
Melatonin may also prevent hippocampal receptor loss that usually occurs following long
term exposure to elevated circulating levels of corticosterone.
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1.6. NEUROLOGICAL DISORDERS
1.6.1. Aging
From the day an animal is born it begins to age.  Aging is therefore a natural
phenomenon, and although the process cannot be stopped there are many physiological
factors that can either advance or slow the aging process.
There is much evidence to demonstrate that corticosterone secretion accentuates the
aging process.  Sapolsky et al [212] showed animals that received 3 months of chronic
corticosterone treatment, showed many characteristics of aged rats.  Adrenalectomy at
mid-age has been shown to prevent loss of neurons in the hippocampus, while
prolonged exposure to elevated glutamate titres exacerbates the loss [212,224].
There are two ideas as to how aging and stress are related [225].  The first is that as an
organism ages so it is less able to adapt to stress.  This idea is supported by the many
physiological systems that function normally in younger life, and yet do not adequately
respond to the challenge in old age.  For instance, aged rats compared to young controls
exhibit less efficient HPA axis activity in response to stress [226,227], and are they are
unable to terminate the secretion of glucocorticoids at the end of stress [228].  The
second idea is that stress can accelerate the aging process by impairing hippocampal
functions like learning and memory [229].
The increases in corticosterone concentration need not be large, with Stein-Behrens et al
[230] demonstrating that even slightly elevated corticosterone levels (typical of those in
aged rats) causes greater glutamate accumulation in the hippocampus.  Lowy et al [205]
showed that stress significantly increased extracellular glutamate levels in sham
operated rats, while there was 70% less extracellular glutamate in adrenalectomised rats
that were exposed to the same stress.  A 70% increase in extracellular glutamate is not
as great as the glutamate increase that occurs following ischemia.  A single acute stress
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is therefore not going to produce morphological changes.  Watanabe et al [231] showed
that 3 weeks of stress were needed to cause noticeable damage, demonstrating that
there is however a slow accumulation of damage.
ROS are believed to be responsible for many of the ageing processes.  These molecules
affect the integrity of the macromolecules in the cell.  Although most of the ROS’s
produced are rapidly removed from the cell by the antioxidant defence system, there is a
slow accumulation of damage that occurs during an animal’s life.  It is estimated that
10 000 oxidative hits occur on DNA in the human per day [137].  These damages are
repaired by enzymes that excise the lesion, however there is a steady increase in the 
number of lesions as the animal ages.  Viani et al [232] compared young, adult and old
rat brains.  The group found that old brains were more susceptible to lipid peroxidation,
demonstrating that peroxidation injury can have even more dramatic consequences
when it takes place in the aged brain.  Other @OH mediated oxidative damage also
accumulates exponentially with age [8].
The reason why the aged brain is more susceptible to ROS damage, is that many of the
neuroprotective pathways are no longer as effective as they are in younger animals. 
Melatonin production is also affected with age [233].  In humans, the baby pineal
produces very little melatonin for the first few months, but soon a rhythm is established
with maximum melatonin production at night.  The amplitude of the melatonin peak is at
its greatest in the years before puberty.  After adulthood is reached, the peak melatonin
level reached at night slowly starts to decrease, so that by old age there is very little
variation between night and day time melatonin levels (see Figure 1.12).  The basal day-
time melatonin levels are not affected by age, but rather there is a decrease in the
nocturnal peak, so reducing the amount of melatonin produced in a 24 hour period.
The age related decrease in the ability of the pineal gland to produce melatonin is
probably the result of two factors.  Firstly, the $-adrenergic receptors on the 
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Figure 1.12: Reduction of maximal night time melatonin levels in humans during aging
[7].
pinealocyte membranes, which are responsible for mediating the night time increase in
melatonin production, are reduced in number in advanced age [10], resulting in a weaker
signal being sent to the pinealocyte to produce melatonin.  The second reason, is that
the neuronal message to the pineal gland in old animals may be weakened by the
gradual deterioration in the cells of the hypothalamic suprachiasmatic nuclei, due to the
action of EAA’s on the neurons at this level [7].
The ability of the pineal gland to produce and release melatonin also depends on the
individual.  The amplitude of the night time peak in melatonin production appears to be
genetically controlled [7].  Those individuals with an inherently low circadian production of
melatonin could be more vulnerable to premature aging and other age related diseases
[234], than individuals that produce more melatonin.
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1.6.2. Parkinson’s Disease
Parkinson’s disease is a chronic, progressive disorder of late life, which is characterised
by rigidity, unintentional tremor and bradykinesia [62].  In Parkinson’s disease there is
selective degradation of neuromelanin-containing neurons, especially the nigral
dopaminergic neurons [235].  Glutamate appears to play a pivotal role in the
pathophysiology of Parkinson’s disease, as abnormal patterns of glutamatergic
neurotransmission are important symptoms of Parkinson’s disease [62].
The metabolism of dopamine by monoamine oxidase can yield 6-hydroxydopamine,
which is known to yield ROS [236]. Although proof that ROS stress actively causes the
loss of monoaminergic neurons in Parkinson’s disease is lacking, there is considerable
evidence in animals and humans to support the concept [139].  Post mortem studies
have revealed that the substantia nigra of patients with Parkinson’s disease shows signs
of oxidative stress [237], as well as reduced glutathione peroxidase activity and
glutathione concentrations [238].
Total iron is increased and ferritin is reduced in the substantia nigra pars compacta in
patients with Parkinson’s disease.  This combination suggests that the transition metal is
in a low molecular weight form, capable of catalysing non-enzymatic oxidative reactions,
especially the conversion of H2O2 to @OH [239].  Neuromelanin, a product of dopamine
oxidation, can serve as a reservoir for iron, promoting the generation of oxyradicals.
The drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is often used to model
Parkinson’s disease in animals.  MPTP [240] destroys dopaminergic neurons by the
production of free radicals.   @OH rather than O-2@ [241] appears to be the more neurotoxic
of the two molecules.  Acuña-Castroviejo et al [242] demonstrated that melatonin was
able to protect against many of the adverse effects of MPTP administration.  This
suggests that melatonin may have a role to play in the treatment of Parkinson’s disease.
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1.6.3. Alzheimer’s Disease
Alzheimer’s disease involves selective and progressive degeneration of lower motor
neurons in the spinal cord, and the upper motor neurons in the cerebral cortex. 
Symptoms normally begin to be apparent in mid life [5].  The disease is characterised by
an abundance of senile plaques and neurofibrillary tangles in certain areas of the brain
[85].  The evidence implicating EAA’s in Alzheimer’s disease is circumstantial rather than
direct, but non the less supports the concept that excitotoxicity plays a part in the
pathogenesis of the disease.  EAA metabolism is disturbed in patients with Alzheimer’s
disease [93], with glutamate concentrations inappropriately high in extracellular
compartments [74], suggesting a breakdown in normal uptake mechanisms [115,243]. 
Although excitotoxicity may not be the initiating event in the disease, it may interact with
other factors to fuel continued neurotoxicity and disease progression.
Amyloid $-protein which is derived from the Amyloid Precursor Protein (APP)
accumulates in plaques in Alzheimer’s disease patients [214,244-246].  Amyloid
$-protein has been implicated in neurotoxicity, where it is thought to induce the
production of free radicals [213,247,248] and disrupt calcium homeostasis [123].  Mark et
al [249] showed that amyloid $-peptides induce free radical production, which results in
impairment of ion channels and calcium influx [213].  Bioenergetic defects, or amyloid
$-protein deposition, could be the final common pathway in neuronal death for this
disease. Kirazov et al [250] has shown that glutamate induces the secretion of APP from
cortical slices in a concentration dependent, but biphasic manner, with the highest
release at 50µM L-glutamate and smaller effects at higher glutamate concentrations. 
The APP molecule could thus be cleaved to produce even more amyloid $-protein.  
Melatonin appears as if it could be a neuroprotective agent against Alzheimer’s disease. 
Papolla et al [245] reported that melatonin prevents death of neuroblastoma cells
exposed to amyloid $-protein and amyloid peptide fragment [251].  It has also been
shown that old people and patients with Alzheimer’s Disease [34] appear to suffer from a
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decrease in the amplitude of the melatonin acrophase [252].  Experiments with rodents
have demonstrated that pharmacological treatment with melatonin can increase life
span, prevent premature aging and delay the onset of neurological disease [8].
1.6.4. Huntington’s Disease
Huntington’s disease is an autosomal dominant neurodegenerative disorder that is
caused by a genetic defect localised on chromosome 4 [139,253,254] with an onset at
about 40 years of age [255].
The disease is characterised by disturbances in movement, psychiatric symptoms and a
progressive dementia that leads to severe debilitation and usually death within 15-20
years [139].  The disease also leads to destruction of the brain [256] with the autopsy
brain weight of Huntington’s disease patients normally about 20% less than average
brain weight [254].
The excitotoxic model has been proposed as a possible cause of Huntington’s disease. 
Although there are other factors playing a part in the neurodegeneration that takes place
in this disease, it appears that excitotoxic injury plays an important part in a more
complicated array of neuropathalogical events, but none the less an important function in
the disease process [139].  This is evident by the work of Beal et al [105] who, showed
that the focal injection of QA in the rat striatum very closely reproduces human
Huntington’s Disease post-mortem findings, with a relative increase in somatistatin and
neuropeptide Y content [93].
1.6.5. Cerebral Ischemia
Many different situations can give rise to ischemia, cardiac arrest, thrombotic stroke and
asphyxia.  Although all these conditions involve very different pathophysiologies, they are
all thought to contribute to the neural degradation that occurs following cerebral ischemia
[93]. 
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The ischemic brain damage that occurs can take on several distinct morphological
patterns, depending on the particular conditions of the ischemia.  Cerebral infarction,
which is typically associated with prolonged, focal brain ischemia, is characterised by
irreversible damage to neurons, glia, and other supporting cell types in the brain.  In
contrast, transient global ischemia, such as that accompanying cardiac arrest and
resuscitation, principally injures specific populations of neurons known to be highly
vulnerable to ischemia [257].  The pyramidal cells in the CA1 zone of the hippocampus,
small and medium sized neurons in the striatum, non-cortical neurons in layers 3, 5 and
6, and the cerebellar Punkinje cells are among those neurons most susceptible to
ischemic injury [204].
Within three minutes of disruption to cerebral circulation, the extracellular K+
concentration around neurons rises from ±3 mM to as high as 80 mM [258].  At the same
time, astrocytes and neurons can become swollen.  The swelling is reversible if the
period of ischemia is brief.  The reversibility depends on the CNS region and the age of
the animal.  If the period of ischemia lasts longer than three minutes, necrosis of the
neurons may occur.  However, neurons that are restored to normal function after a
period of ischemia, also succumb to delayed neuronal degradation.  This only occurs a
few hours [93] to several days [259] after the insult.
Following transient global ischemia, glucocorticoid levels rise.  Therefore what is viewed
as “expected” neuronal damage in response to focal or global ischemia, may in fact,
represent ischemic damage worsened by the acute hypersecretion of glucocorticoids
[204].  Reducing glucocorticoid release following ischemia could therefore offer
therapeutic value.
The extracellular glutamate concentration is known to rise greatly during ischemia
[75,257,260] or anoxia.  This is because ATP levels fall [261], and based on
thermodynamic grounds, the glutamate uptake carrier is expected to operate backwards,
releasing glutamate into the extracellular space [262,263].  Phillis et al [264] found that
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while ischemia causes an increase in glutamate release into the extracellular space
during ischemia, glutamate levels tend to undergo a further, unexpected rise during the
initial 30 - 40 minutes reperfusion.  This could have resulted from the formation of toxic
free radicals, including @OH.  Blockade of NMDA receptors by MK-801, following fluid
percussion injury, attenuated some of the neuropathological events that normally follow
this injury [265], demonstrating that glutamate must be involved in neurodegeneration. 
Following reperfusion there is also a burst of ROS production as xanthine oxidase
metabolises hypoxanthine that has accumulated during the ischemia [143].
Melatonin has been found to protect against ischemia induced neurotoxicity.  Cho et al
[266] have demonstrated that melatonin protects CA1 hippocampal neurons when
administered during, or at least 2 hours following transient forebrain ischemia in rats. 
Greater neurodegeneration has also been shown [267] to occur in pinealectomised rats
following middle artery occlusion and glutamate receptor mediated, epilepsy-like
seizures. 
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1.7. OBJECTIVES
The objectives of this study were firstly to determine whether melatonin could act as a
neuroprotective agent under a number of neuropathological conditions, and secondly to
attempt to elucidate the mechanism of neuroprotection, should it be occurring.
The potential neuroprotective properties of melatonin were investigated under the
following circumstances:
a. Under conditions of stress, when glucocorticoid concentrations increase,
b. During excitatory amino acid insult, under in vitro conditions,
c. And against excitatory amino acid insult, under in vivo conditions.
Studies involving the EAA’s were limited to four different glutamate receptor agonists. 
Glutamate was used as it is the “mixed-agonist” that acts on all glutamatergic receptors. 
NMDA was used as it is the main agonist of the NMDA class of receptor, while QA (which
also acts at the NMDA receptor) was chosen because it is an endogenous compound
that is extremely neurotoxic, and is thought to play a role in the pathology of Huntington’s
disease.  The KA and AMPA receptors, together with the NMDA receptor make up the
three classes of ionic glutamate receptors.  The KA and AMPA receptors have similar
structures and modes of action [268].  KA was therefore used as the agonist of choice for
investigations on these classes of receptors.
It was hoped that following this investigation, the potential neuroprotective properties of
melatonin would be better understood, and that knowledge gained could ultimately be
used by future researchers in the treatment of a number of neurodegenerative diseases.
CHAPTER 2
EFFECT OF CORTICOSTERONE AND MELATONIN ON
GLUTAMATE RECEPTORS
2.1. INTRODUCTION
Exposure to acute or chronic stress may be associated with neurological and
physiological disorders [269,270].  These could result from the neurotoxic effects of
stress on hippocampal neurons.  Chronic exposure to stress has been shown to cause
hippocampal neuronal loss [271-273], as well as atrophy of dendrites in hippocampal
CA3 neurons [231].
Among the many neurochemical changes that occur as a result of stress, the secretion
of adrenal steroids [274], and especially corticosterone in rats [275], is thought to play an
important role in stress induced neurotoxicity.  Glucocorticoids cause glutamate
accumulation in the synaptic cleft of the CNS [215], which causes continuous stimulation
of the postsynaptic glutamate receptors.  This allows excessive movements of Ca2+, Na+
and K+ into the neurons, which can lead to neuronal death. 
In this experiment the effect of melatonin on glutamate receptors was investigated, to
determine whether melatonin could give any protection against corticosterone-induced
neurotoxicity.
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2.2. EFFECT OF CHRONIC CORTICOSTERONE TREATMENT
AND MELATONIN ON 3H-GLUTAMATE RECEPTOR
BINDING
2.2.1. Introduction
Corticosterone is the main adrenal steroid secreted during stress in rats.  Corticosterone
increases glutamate release [216], with the result that higher than normal concentrations
of the EAA’s exist in the synaptic cleft [276].  This can cause overstimulation of the
receptor on the post-synaptic neuron, leading to excessive Ca2+ influx and
neurodegeneration.  High circulating levels of corticosterone therefore have the potential
to cause severe damage to neurons.
Corticosterone does not cause neurodegeneration directly, but it is known to affect
glutamate re-uptake and increase glutamate receptor numbers on neurons [22]. 
Increasing receptor numbers has the potential to upset the homeostasis of a neuron. 
This is because an increase in receptor number, results in a greater number of potential
binding sites for synaptic glutamate to bind.  With more receptors stimulated, there is a
greater inflow of ions into the neuron, and the ionic potential is greatly affected.  The
neuron would have to work harder to extrude the ions that flowed into the neuron.  As
mentioned earlier, corticosterone is known to increase synaptic glutamate
concentrations, and so an increase in receptor numbers would be doubly problematic to
the neuron.  Firstly, there would be more glutamate to bind to receptors, so a greater
stimulus would be received by the postsynaptic neuron.  Secondly, there would be more
receptors available for glutamate to bind to.  As each receptor can allow ions to pass into
the cell, more receptors could result in more ions passing into the neuron.  This could
cause Ca2+ levels to rise markedly, which would initiate a number of neurotoxic
processes.  
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Chronic corticosterone treatment should mimic the effects of stress on rat neurons, and
so the following experiment was carried out to determine the effect of corticosterone and
melatonin treatment on synaptic glutamate receptors.
2.2.2. Materials and Methods
2.2.2.1. Chemicals and Reagents
Corticosterone, melatonin and bovine serum albumin (fraction V powder) (BSA) were
purchased from the Sigma Chemical Company (USA).  L-[G-3H]-glutamate (1 mCi / ml)
was purchased from Amersham International plc (England).  Emulsifier Scintillator PlusTM
scintillation cocktail and scintillation vials were obtained from the Packard Company
(USA).  Ethylenediaminetetraacetic acid (EDTA),  tris(hydroxymethyl)-aminomethane
(Tris) and Triton X-100 were obtained from Unilab (South Africa).  All other chemicals
were of the highest quality available and were purchased from commercial distributors.
2.2.2.2. Animals
Adult male Wistar rats, purchased from the South African Institute for Medial Research
(Johannesburg, South Africa) were used throughout the study.  The animals were
housed under artificial illumination with a daily photoperiod of 12 hours (lights on at
06h00).  The animal-house temperature was maintained at a constant 20oC to 24oC,
while an extractor fan ensured the constant removal of stale air.  The rats were housed
four per cage with food and water provided ad libitum. 
2.2.2.3. Corticosterone and Melatonin Treatment Schedule
Rats were divided into 4 groups and treated as shown in Table 2.1.  Corticosterone was
administered to the animals for 7 days at 12 pm.  
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Table 2.1: Administration of melatonin and corticosterone to rats.
Group Melatonin Corticosterone
Control 0 0
Melatonin 1 mg / kg 0
Corticosterone 0 5 mg / kg
Corticosterone and Melatonin1 mg / kg 5 mg / kg
The melatonin and corticosterone were suspended in sweet oil and administered
separately, so that each animal effectively received two subcutaneous injections each
day.  Control animals received an equivalent volume of vehicle in each case.
2.2.2.4. Brain Removal
Rats were sacrificed by neck fracture and decapitated.  The brain was exposed by
making an incision through the bone on either side of the parietal structure, from the
foramen magnum to near the orbit.  The calvarium was removed, exposing the brain
which was easily removed for use in experiments.
2.2.2.5. Preparation of Synaptic Membranes
Each brain was homogenised in 40 volumes of 5mM Tris acetate buffer (pH 7.4)
containing 1 mM EDTA.  The homogenate was centrifuged at 50 000 x g at 4oC for 20
minutes.  The pellets were resuspended and washed a further 3 times with 40 volumes of
50 mM Tris acetate buffer (pH 7.4).  The pellets were then resuspended in 20 ml of
0.32 M sucrose and rapidly frozen in liquid nitrogen and stored at -70oC until use.
2.2.2.6. Protein Assay
Protein concentrations were determined using a modified method of Lowry et al [277]. 
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The absorbance values obtained were converted to mg / ml from a standard curve
(Appendix 1) generated from BSA.
2.2.2.7. Glutamate Binding Assay Procedure
Binding studies were performed using a method similar to that described by Yoneda et al
[80].  On the day of the binding study, the frozen synaptic membranes were thawed,
diluted up to 40 volumes with buffer and centrifuged at 50 000 x g at 4oC for 20 minutes. 
The pellets were resuspended and treated with 0.08% Triton X-100 [278] for 10 minutes. 
This was followed by centrifugation at 50 000 x g at 4oC for 20 minutes.  The pellets were
resuspended in 50mM Tris acetate buffer.  Protein concentration was determined as in
2.2.2.6.  The samples were diluted to a final working protein concentration of 1mg / ml
using 50 mM Tris-acetate buffer (pH 7.2).  Incubation mixtures consisted of 250 µl
membrane preparation, 170 µl of 50 mM Tris-acetate buffer (pH 7.4), 50 µl glutamate
ranging from 0 - 400 nM final concentration and 30 µl of 3H-glutamate to give a final
concentration of 10 nM.  The tubes were incubated for 40 minutes at 24oC and the
reaction was terminated by the addition of 4 ml of ice cold Tris-acetate buffer (pH
7.2).  This was followed immediately by rapid filtration through Whatman GF/C filters
in a 12 place Millipore sampling manifold under negative pressure.  The filters were
washed a further 3 times with 4 ml of ice cold Tris-acetate buffer, before being dried
by negative pressure and placed in scintillation vials containing 3 ml of scintillation
cocktail.  After 24 hours, the radioactivity in the vials was measured using a
Beckman (Model LS 2800) Liquid Scintillation Counter.  All results were expressed
as fmol 3H-glutamate bound per milligram protein.
2.2.2.8. Statistical Analysis
The results were analysed using a one-way analysis of variance (ANOVA).  If the F
values were significant, the Student-Newman-Keuls test was used to compare the
treated and control groups.  The level of significance was accepted at P<0.05.
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2.2.3. Results
The specific binding expressed as fmoles 3H-glutamate bound / mg protein, was
calculated.  Saturation curves and Scatchard plots [279] were derived from the data for
each of the 4 groups.  The Kd and Bmax values for the plots (Figures 2.1 - 2.8) are
shown in Table 2.2.
Table 2.2: Kd and Bmax values derived from the data. (n=4) 
(a P<0.05 vs Control; b P<0.001 vs Control)
Test Bmax (pmoles / mg protein) Kd (nM)
Control 161 ±2.37 327
Melatonin 153 ±2.83a 323
Corticosterone 235 ±3.02b 462
Corticosterone and Melatonin216 ±1.43b 455
Corticosterone caused an up-regulation in the number of binding sites when compared
to control animals, with Bmax values more than doubled.  Melatonin reduced the Bmax
values for both control and corticosterone treated animals.
Although melatonin did not appear to be able to bring receptor numbers down to the
levels of control animals, it did cause a significant reduction in the number of receptors in
those animals treated with corticosterone.
Chronic administration of corticosterone also caused an increase in the dissociation
constant for glutamate receptors.  Co-treatment with melatonin did not cause a
significant change in the dissociation constant, for either control or corticosterone treated
animals.
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Figure 2.1: Saturation Curve of 3H-Glutamate binding to synaptic membranes from
control rats.  (n=4)
Figure 2.2: Scatchard Plot of  3H-Glutamate binding to synaptic membranes from control
rats. 
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Figure 2.3: Saturation Curve of 3H-Glutamate binding to synaptic membranes from
melatonin treated rats.  (n=4)
Figure 2.4: Scatchard Plot of  3H-Glutamate binding to synaptic membranes from
melatonin treated rats. 
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Figure 2.5: Saturation Curve of 3H-Glutamate binding to synaptic membranes from
corticosterone treated rats.  (n=4)
Figure 2.6: Scatchard Plot of  3H-Glutamate binding to synaptic membranes from
corticosterone treated rats. 
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Figure 2.7: Saturation Curve of 3H-Glutamate binding to synaptic membranes from
corticosterone and melatonin co-treated rats.  (n=4)
Figure 2.8: Scatchard Plot of  3H-Glutamate binding to synaptic membranes from
corticosterone and melatonin co-treated rats. 
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2.2.4. Discussion
These results demonstrate that melatonin is able to reduce the number of glutamate
receptors (Bmax).  This appeared to be a general occurrence, as melatonin had the
same effect on both control and corticosterone treated animals.  The effect of melatonin
also appeared to be concerned exclusively with the reduction in receptor numbers, as
there was no effect on binding affinity (Kd).
Chronic treatment of rats with corticosterone caused a marked increase in receptor
numbers while reducing the affinity of the receptor for its substrate.  Co-treatment with
melatonin however, appeared to reduce receptor numbers, without affecting the binding
affinity of the receptors for glutamate.
Corticosterone appears to cause an upregulation in the number of glutamate receptors
on neurons.  These receptors do not however show the same affinity for glutamate as do
receptors from neurons not treated with corticosterone.  Some of the negative effects of
greater glutamate receptor numbers on the neurons may therefore be negated by the
decrease in affinity of the receptor for its substrate.
Melatonin may be doubly effective at reducing the effects of increased glutamate
receptor numbers.  First melatonin reduces the number of glutamate receptors on the
neurons, and secondly it does not change the affinity of the glutamate receptors for their
agonist.  Therefore, while reducing receptor numbers, melatonin does not enhance
affinity for glutamate by the receptors. 
The results imply that melatonin may be able to protect neurons from the increased risk
of glutamate receptor overstimulation, by inhibiting the increase in glutamate receptor
numbers brought about by chronic corticosterone treatment.
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2.3. THE MEASUREMENT OF GLUTAMATE BINDING TO RAT
CEREBRAL MEMBRANES FOLLOWING EXPOSURE TO
PHYSICAL STRESS
2.3.1. Introduction
The previous experiment had measured the effect of chronic treatment of rats with
exogenous sources of melatonin and corticosterone.  The following experiment was
conducted to investigate whether application of physical stresses to animals, in place of
exogenous corticosterone treatment, would give similar results.  Pharmacological doses
of melatonin were used.
2.3.2. Materials and Methods
2.3.2.1 Chemicals and Reagents
All reagents used were as per experiment 2.2.2.1.
2.3.2.2. Experimental Procedure
Animals were divided into 3 groups of 5 animals each.  The animals in the control group
did not receive any stress.  In addition they were not injected with sweet oil vehicle, as it
was thought that the daily handling of the animals may induce a physical stress.  The
remaining two groups of animals were stressed as shown in Table 2.3.  Of the two
stressed groups, one group received a dose of 1 mg / kg melatonin immediately prior to
the onset of the stress, while the other group received a similar volume of sweet oil
vehicle.  All stresses were started at 11 am.  The temperature in the cold room was 4oC. 
The loud music consisted of heavy metal music, with lots of high pitched sounds, played
at a high volume from speakers directly above the cages.  Physical distress was
Corticosterone 59
observed in the animals while the music was being played.  Different stresses were used
so animals would not become conditioned to any one stress.
Table 2.3: Stresses applied to rats each day
Day Stress Duration
1 Cold Room 2 hours
2 Cold Room 2 hours
3 Loud Music 2 hours
4 20oC Swim Test Till Exhaustion
5 Cold Room + Loud Music 2 hours
6 Loud Music 2 hours
On day 7, the animals were killed and their brains rapidly removed as described in
2.2.2.4.  Synaptic membranes were prepared and glutamate binding studies were carried
out as described in 2.2.2.5 and 2.2.2.7 respectively.
2.3.2.3. Statistical Analysis
Results were analysed as explained in section 2.2.2.8.
2.3.3. Results
The specific binding expressed as fmoles 3H-glutamate bound / mg protein was
calculated.  Saturation curves and Scatchard plots were derived for each of the groups. 
The equilibrium dissociation constant (Kd) and maximum number of binding sites (Bmax)
values for the plots (Figures 2.9 - 2.14) are shown in Table 2.4.
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Table 2.4: Bmax and Kd values derived from the data. (n=4) 
(a P<0.001 vs Control; b P<0.01 vs Control)
Group Bmax (pmoles / mg protein) Kd (nM)
Control 121 ±3.64 219
Stress - No Melatonin 171 ±3.85a 233
Stress and Melatonin 142 ±4.5b 190
The stress caused a significant increase (P<0.01) in the number of glutamate receptors
(Bmax) on the synaptic membranes.  Animals treated with the same stress, but injected
with melatonin, had a lesser increase in the number of glutamate receptors.
The effect of physical stress on the affinity of the glutamate receptors (Kd) for their ligand
varied for those treated with melatonin and those that were not treated.  Those animals
that did not receive melatonin had a lower affinity for the ligand than control animals,
while animals that received melatonin, had a higher affinity.  
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Figure 2.9: Saturation Curve of 3H-Glutamate binding to synaptic membranes from
control, unstressed rats.  (n=4)
Figure 2.10: Scatchard Plot of 3H-Glutamate binding to synaptic membranes from control,
unstressed rats. 
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Figure 2.11: Saturation Curve of 3H-Glutamate binding to synaptic membranes from
stressed, untreated with melatonin rats.  (n=4)
Figure 2.12: Scatchard Plot of 3H-Glutamate binding to synaptic membranes from
stressed, untreated with melatonin rats. 
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Figure 2.13: Saturation Curve of 3H-Glutamate binding to synaptic membranes from
stressed, and melatonin co-treated rats.  (n=4)
Figure 2.14: Scatchard Plot of 3H-Glutamate binding to synaptic membranes from
stressed, and melatonin co-treated rats. 
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2.3.4. Discussion
The results demonstrate that physical stress was able to cause much the same effects
as the injection of corticosterone to the animal.  This is shown by the fact that both
techniques caused an increase in the number of glutamate receptors.  As in the
corticosterone treated animals, melatonin was able to lower the number of receptors in
stressed animals, but not to control levels.
One difference between the animals injected with corticosterone, and those that were
treated with the physical stresses, was that the glutamate receptors from the animals that
had received melatonin in the stressed experiment, had a greater affinity for their agonist
than either of the groups of animals that did not receive melatonin.
Previously it had been found that melatonin had no effect on glutamate receptor affinity. 
No explanation for this difference could be found, other than that an in vivo system was
being used, and the physical stress would have affected more than just the production of
corticosterone.  One of the other hormones or steroids produced during stress may have
interacted with melatonin to cause this effect.
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2.4. Conclusions
It has been demonstrated that corticosterone causes an increase in the number of
glutamate receptors.  This can be brought on by the chronic treatment of animals with
corticosterone, or by exposing the animals to physical stresses.  The chronic treatment
with corticosterone caused a greater increase in receptor numbers than the physical
stress.  The reason for this is that physical stress may not have raised circulating
corticosterone levels to the same highs as the 5 mg / kg injections.  The increased
number of receptors also led to a decrease in binding affinity of glutamate receptors for
their substrate.
Melatonin appears to cause a decrease in the number of receptors.  When melatonin
treated animals were compared to control, corticosterone treated, and stressed animals,
there was a decrease in the Bmax values in all cases.  This demonstrates that melatonin
must have a general effect of decreasing neuronal glutamate receptor numbers.  In the
rats treated with corticosterone, melatonin did not affect binding affinity.  However in the
animals treated with physical stresses, binding affinity was increased, when compared to
both control and stressed animals that had not been treated with melatonin.  The results
from the corticosterone treated animals strengthen the argument that melatonin causes
a direct reduction in receptor numbers without affecting the binding affinity of the
receptor.  The physical stresses that the rats were subjected to in experiment 2.3., would
have increased corticosterone levels as well as the concentration of other adrenal
steroids.  These steroids, together with other hormones that are secreted during stress,
may have increased the affinity of the glutamate receptors for their ligands, in melatonin
treated,  stressed animals.
Corticosterone is a glucocorticoid, and the glucocorticoids like other steroid hormones
react with proteins in the cytoplasm of sensitive cells [280] to form a steroid-receptor
complex.  This complex moves to the nucleus where it stimulates the transcription and
translation of specific proteins.   It is therefore likely that corticosterone brings about the
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increase in the number of glutamate binding sites by inducing an increase in the rate of
synthesis of glutamate receptor proteins.  How melatonin reduces this process is not
known, although it is speculated that melatonin interferes with the transcription and
translation of receptor proteins, either by inhibiting the formation of the steroid-receptor
complex, or by preventing the steroid-receptor complex from initiating transcription in the
nucleus.
An alternative hypothesis is that melatonin may be competing for binding to the
glutamate receptors.  This would cause a decrease in the amount of 3H-glutamate bound
to the synaptic membranes and would indicate that there was a reduction in glutamate
receptors.  There is however no literature to support this theory that melatonin
competitively binds to glutamate receptors.  
Glucocorticoids are also known to cause increases in synaptic glutamate, by inhibiting
the uptake of the amino acid by glial cells [217].  This leads to higher glutamate levels in
the synapse, which can cause overstimulation of the glutamate receptors.  Over
stimulation of neuronal cells can result in a cascade of neurotoxic events.  An increase in
glutamate receptor numbers, and an increase in synaptic glutamate concentrations could
result in neurons being considerably overstimulated.  This could cause changes in
neuronal function, or even neuronal death.   Glutamate has been implicated in numerous
neurodegenerative diseases [75,115,139], and protection against excessive stimulation
of the receptors would be vital in protecting neurons.
CHAPTER 3
THE EFFECT OF GLUTAMATE, N-METHYL-D-ASPARTATE
QUINOLINIC ACID, AND KAINIC ACID ON NEURONAL CELL
VIABILITY
3.1 INTRODUCTION
Excitotoxicity is the term conceived by Olney to denote the group of excitatory amino
acids which selectively kill neurons and cell bodies by their depolarising actions [5].  The
process is receptor mediated, as it has been demonstrated [281] that EAA antagonists
prevent both excitation and toxicity in neurons.
The mechanism by which excessive EAA receptor activation leads to neuronal death
involves increased membrane permeability and abnormal Na+, Cl- and Ca2+ influx into the
neuron [282].  The first two ions disrupt the osmotic pressure of the neuron which can
lead to lysis of the neuron, while elevated intracellular Ca2+ concentrations can lead to
the activation of a number of intracellular enzymes and regulator proteins [5,283].
In the brain there are a number of  different glutamate receptors that have very distinct
pharmacological and physiological properties [72].  EAA receptors have been
characterised according to their effect on ionic balance (ionotropic) or secondary
messenger systems (metabotropic).  The ionotropic receptors [284] are characterised as
NMDA, AMPA and KA.  Each of these receptors [57] are coupled to ligand-gated ion
channels which are permeable to both Na+ and K+, and in the case of NMDA receptors,
Ca2+ as well. 
For these experiments it was decided to work with glutamate and the glutamate agonists;
KA, NMDA and QA.  NMDA is the agonist for the NMDA receptors which are the most
populous of the glutamate receptors.  KA is the neurotoxic analog of glutamate that
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interacts with the KA receptor [285].  When injected into animals, KA typically induces
seizures and causes extensive neuronal damage.  QA acts at the NMDA receptor [286],
but the toxicity that occurs is similar to that observed during KA toxicity.  QA is thought to
be involved in Huntington’s disease, and concentrations of this EAA are known to
increase in the brain [100] with age.  
In order to test whether melatonin offers any neuroprotection, the neurotoxicity of the
EAA’s first had to be investigated.  This series of experiments was performed to
determine the concentrations at which the various agonists prove toxic to neurons, and
to determine LD50 values for the various agonists.
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3.2. EFFECT OF GLUTAMATE ON NEURONAL CELL
VIABILITY
3.2.1. Introduction
L-Glutamate is the most abundant free amino acid in the central nervous system [57]. 
The role of glutamate as a neurotransmitter was only widely accepted in 1974, when
Fronnum  [59] reviewed the data known at that time and showed that glutamate met all
the criteria of a neurotransmitter.  In the past decade glutamate has also been shown to
be a very potent neurotoxin.  The concept of glutamate as an excitotoxin is largely thanks
to the work of Olney and colleagues [109], who demonstrated a correlation between the
excitatory properties of various glutamate analogues and their ability to produce
neurotoxic damage.
In the present study primary neuronal cultures were treated with varying concentrations
of glutamate.  Trypan blue staining was used to assess the extent of glutamate-induced
neuronal cell death.  Trypan blue is a dye that is used to measure cell viability.  Only
dead cells are permeable to the dye, as they have damaged cell membranes.  This
results in dead cells staining blue, while living cells remain unstained [287].
3.2.2. Materials and Methods
3.2.2.1. Chemicals and Reagents
Glutamate, Eagle’s Minimum Essential Medium (MEM), Hanks’ Balanced Salts (modified
form) (HBSS), Trypan Blue and Cytosine-$-D-arabinofuranoside were purchased from
Sigma Chemical Company (USA).  Trypsin and trypsin inhibitor were purchased from
Boehringer Mannheim (Germany).  Foetal Calf Serum (FCS) was obtained from Delta
Bioproducts (South Africa).  Sodium Benzylpenicillin (Novopen) and Streptomycin
Sulphate (Novo-Strep) were supplied by Novo Nordisk (Pty) Ltd (South Africa).  Sterile
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Figure 3.1: Positive pressure filtration system [288]
disposable tissue culture flasks (25 cm2) were purchased from Corning Costar (USA).  All
other chemicals were of the highest grade obtainable from commercial sources.
Minimal Essential Media was prepared in Milli-Q water from powder and supplemented
with; 10 mM sodium hydrogen carbonate (NaHCO3), 1 mM pyruvate, 20 mM potassium
chloride (KCl), Streptomycin (100 mg / L) and Penicillin (100 000 U / L).  This solution
was later supplemented with foetal calf serum (10% v / v).
Hank’s balanced salt solution was prepared from powder in milli-Q water, supplemented
with 10 mM NaHCO3 and Streptomycin (100 mg / L) and Penicillin (100 000 U / L).
3.2.2.2. Preparation of Culture Reagents
MEM and HBSS were prepared in batches of multiples of one litre.  Both reagents were
sterilised by positive filtration (Figure 3.1) through a Millipore filtration unit using the
following filters: prefilter, type SM42 “membrane filter” 50K (size 130); a 0.45 µm,
142 mm type NA filter; and a 0.22 µm, 142 mm type GS filter.  
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The reagents  were aseptically dispensed into sterile cell culture bottles.  Sterilisation of
cell culture bottles was carried out by autoclaving for 45 minutes in an Everlight vertical
type autoclave.  After filtration the reagents were  incubated at 37oC for 48 hours to test
that no contamination had occurred.
Foetal calf serum was added to the MEM on the third day after filtration through a
0.45 µM Millipore filter using a Swinex-25 holder (Millipore Corporation, USA).  The MEM
was further incubated at 37oC for 48 hours to check that no contamination had occurred.  
3.2.2.3. Establishment of Primary Neuronal Cell Cultures
Primary neuronal cultures were established from the brains of day old rats.  The rats
were overdosed with ether and then placed in a sterile 250 ml beaker containing cold
0.15 M saline.  The heads were removed with scissors and the brains dissected out and
transferred to a 50 ml beaker containing cold HBSS.  All subsequent steps took place
under the laminar flow hood.
The brains were pooled and minced into approximately 1 mm3 pieces before being 
transferred to sterile 15 ml tubes containing 5 ml, 0.2% trypsin in HBSS.  After 20 -
30 minutes of incubation at 37oC in a shaking water bath, the tissue pieces were
collected by centrifugation at 3500 x g for 5 minutes at 4oC, rinsed with fresh HBSS, and
incubated for a further 5 minutes at 37oC in 0.1% soybean trypsin inhibitor.  After another
wash in HBSS, the cells were dissociated by titrating the tissue through the narrow bore
of a fire-polished pasteur pipette.   Tissue was titrated until most pieces of visible size
had been disrupted.  Using a sterile pasteur pipette, a suspension of cells was placed
onto a haemacytometer and counted.  Counts obtained were used to calculate the
volume of cell suspension required to seed approximately 1 000 000 cells per 3 ml of
MEM containing 10% FCS in a 25 cm2 culture flasks.  Neurons were allowed to attach to
the surface of the culture flask for 2½ hours, after which the media was discarded and
replaced with 5 ml MEM containing 10% FCS and 10 µM cytosine-$-D-
arabinofuranoside.
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3.2.2.4. Routine Cell Culture Procedure
All cell culture procedures were conducted on a laminar flow bench which had previously
been sterilised by regular swabbing with 70% ethanol and exposure to ultraviolet light.  In
addition to this, all equipment used under the laminar bench was either purchased
sterile, autoclaved or swabbed with 70% ethanol prior to use.  When not required for
experimental purposes, neuronal cells were incubated at 37oC in 25 cm2 flasks
containing 5 ml of 10% (v/v) foetal calf serum supplemented media containing 10 µM
cytosine-$-D-arabinofuranoside.  Media was changed when the nutrients had been
exhausted, indicated by a change in the pH of the media.
3.2.2.5. Agonist Exposure
All experiments were conducted in 7 - 10 day old cultures.  The MEM was discarded from
each flask and the neurons were washed with 4 ml of HBSS.  Thereafter the cultures,
into which 3ml of fresh MEM containing glutamate had been added, were incubated at
37oC for 20 minutes.  Following incubation, the cultures were washed twice with 3 ml
HBSS, before 3ml fresh MEM containing 10% FCS and 10 µM cytosine-$-D-
arabinofuranoside was added.  The neurons were incubated for a further 18 hours at
37oC.
3.2.2.6. Assessment of Neuron Viability
Trypan Blue staining was used to assess neuronal viability.  Cultures were incubated in
0.04% trypan blue solution for 5 minutes.  Percent viability was assessed by counting the
number of dead neurons which stained blue as well as the total number of neurons in
five randomly chosen fields per plate using an inverted microscope.  Counting was done
by an observer unaware of the experimental conditions.
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3.2.2.7. Statistical Analysis
Results were analysed as described in section 2.2.2.8.
3.2.3. Results
The effect of glutamate treatment on primary neuronal cell cultures is shown in Figure
3.2.  Increasing concentrations of glutamate resulted in a decrease in percent viability. 
The LD50 value was calculated to be 275.5 µM.
3.2.4. Discussion
Glutamate was shown to be a powerful neurotoxin that killed the primary neurons in a
dose dependent manner.
Glutamate Agonists and Neuronal Viability 74
Figure 3.2: The effect of various concentrations of glutamate on cell viability.  Values
represent the mean ± SEM (n=3-5) (nsP>0.05; **P<0.01; ***P<0.001 in comparison to zero
controls).
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3.3. EFFECT OF N-METHYL-D-ASPARTATE ON NEURONAL
CELL VIABILITY
3.3.1. Introduction
NMDA is an agonist of the NMDA class of glutamate receptor.  NMDA receptors are the
most common of the glutamate receptors and are widely distributed in the brain.  Much
interest has focussed on the NMDA receptor, because in animal experiments blockade
of the receptor by aminophosphonocarboxylates (AP5 and AP7) or by the non-
competitive antagonists (MK-801, phencyclidine, ketamine), resulted in the symptoms of
many neurological disorders caused by hypoxia, ischemia and traumatic brain injury
[289] being dramatically reduced.
In the present study effect of various doses of NMDA on neuronal viability was
investigated using trypan blue staining.
3.3.2. Materials and Methods
NMDA purchased from Research Biochemicals International (USA) was used in place of
glutamate.  Otherwise the method used was exactly the same as that in experiment 3.2.
3.3.3. Results
The effect of NMDA treatment on primary neuronal cell cultures is shown in Figure 3.3. 
Increasing concentrations of NMDA resulted in a decrease in percentage viability. 
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3.3.4. Discussion
The neurotoxic properties of NMDA were able to cause a concentration dependent
decrease in neuronal cell viability.  The LD50 value for NMDA could not be calculated,
because a 50% decrease in cell viability was never achieved with the concentrations of
agonist used.
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Figure 3.3: The effect of various concentrations of NMDA on cell viability.  Values
represent the mean ± SEM (n=3-5) (nsP>0.05; *P<0.05; ***P<0.001 in comparison to zero
controls).
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3.4. EFFECT OF QUINOLINIC ACID ON NEURONAL CELL
VIABILITY
3.4.1. Introduction
Quinolinic acid is a neurotoxic metabolite of the tryptophan-kynurenine pathway [97,98]. 
It is usually present in the brain in nanomolar concentrations [110].  Substantial increases
occur in a broad spectrum of infections and inflammatory neurological diseases, e.g.
ischemia brought on by strokes [110].  Heyes et al [97] recently reported that microglia
and macrophages may be an important source of this neurotoxin.  QA acts at the NMDA
receptor [290], but the toxicity that occurs is similar to that produced by KA toxicity.  This
agent has been shown to induce neuronal lesions after intrastriatal and intrahippocampal
injections in the rat brain [103].  These lesions closely resemble those observed in the
brains of individuals with Huntington’s Disease.
In this study, the effect of increasing doses of QA on primary neuronal cultures was
investigated.
3.4.2. Materials and Methods
QA which was purchased from the Sigma Chemical Company (USA) was used in place
of glutamate.  Otherwise the method was the same as in experiment 3.2.
3.4.3. Results
The effect of QA treatment on primary neuronal cell cultures is shown in Figure 3.4. 
Increasing concentrations of QA greatly decreased the percent viability of the neuronal
cultures.  The LD50 value was calculated to be 218.4 µM.
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3.4.4. Discussion
QA is a very potent neurotoxin.  The viability of the neuronal culture was greatly reduced
by treatment with increasing doses of quinolinic acid.
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Figure 3.4: The effect of various concentrations of QA on cell viability.  Values represent
the mean ± SEM (n=3-5) (nsP>0.05; ***P<0.001 in comparison to zero controls).
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3.5. EFFECT OF KAINIC ACID ON NEURONAL CELL
VIABILITY
3.5.1. Introduction
Kainic acid is an agonist for a subtype of non-NMDA glutamate receptors [291].  The
neurotoxic action of KA was discovered by Olney et al [292] while they were investigating
the neurotoxic effects of glutamate.  In addition to inducing lesions directly, KA also
triggers epileptiform activity and secondary brain injury that can be reduced by
anticonvulsent drugs [293].
In the present study we wished to investigate whether KA too, could prove toxic to
primary neuronal cultures.  
3.5.2. Materials and Methods
KA which was purchased from Research Biochemicals International (USA) was used in
place of glutamate, otherwise the method was as in experiment 3.2.
3.5.3. Results
The effect of various concentrations of KA on primary neuronal cell cultures is shown in
Figure 3.5.  Increasing concentrations of KA resulted in a decrease in cell viability when
compared to control cultures.  The LD50 value was calculated to be 359.6 µM.
3.5.4. Discussion
The glutamate agonist KA was found to be a very effective neurotoxic agent.  Cell
viability was decreased as the concentration of KA was increased.
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Figure 3.5: The effect of various concentrations of KA on cell viability.  Values represent
the mean ± SEM (n=3-5) (nsP>0.05; **P<0.01; ***P<0.001 in comparison to zero controls).
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3.6. Conclusions
The neurotoxic effects of glutamate and the glutamate agonists; NMDA, QA and KA was
investigated.  The results obtained confirm other reports that glutamate [72,294-297],
NMDA [294,295,341,342], QA [289] and KA [295,297] are toxic to neurons when present
in high concentrations.  In all cases treatment resulted in death to a number of neurons,
which was expressed as a decrease in cell viability compared to untreated control
neurons.
Of the various agonists tested, QA was found to be the most neurotoxic.  This is
demonstrated by the fact that only 29.22% of neurons survived in flasks treated with
500 µM of QA.  Similar doses of glutamate, KA and NMDA yielded survival rates of
38.72%, 44.18% and 54.31% respectively when compared to control cultures.
The results obtained demonstrate that all of the agonists tested are toxic to neurons. 
This provides a basis in order to test the hypothesis that melatonin is able to protect
against the neurotoxicity induced by the different agonists.  The experiments in Chapter
4 are therefore concerned with investigating whether melatonin is able to protect against
neurotoxicity caused by the different agonists. 
CHAPTER 4
EFFECT OF TREATMENT ON PRIMARY NEURONAL CELL
CULTURES WITH MELATONIN AND GLUTAMATE RECEPTOR
AGONISTS
4.1. INTRODUCTION
The neurohormone melatonin, 5-methoxy-N-acetyl-tryptamine, is primarily synthesised in
the pineal gland and released into the bloodstream in a diurnal rhythm, peaking at night
[31].  Melatonin has many important physiological functions, including the regulation of
seasonal reproduction and circadian rhythms [24].  Recently, much work has focussed
on the antioxidant properties of melatonin [180,234].  Melatonin has been reported to
rapidly scavenge hydroxyl- [3] and peroxyl radicals [299], and it has been reported to be
a more potent free radical scavenger than either glutathione, mannitol, or vitamin E
[299].  Among the properties attributed to melatonin are the suppression of the
development of cataracts in newborn rats treated with the glutathione depleting agent,
buthionine sulfoximin [300] the protective effect of melatonin against cyanide-induced
seizures and lipid peroxidation in mice [192], as well as a decrease in DNA damage in
rats treated with the carcinogen safrole [183].
Much of the toxicity associated with glutamate receptor activation is the result of
excessive elevation of intracellular neuronal Ca2+ evels [58].  There are many possible
ways in which Ca2+ overload may kill cells, including activation of intracellular proteases
and lipases, impaired mitochondrial functions, and the generation of free radicals [301]. 
Free radicals, and products of free radical reactions, can cause damage to
macromolecular targets such as DNA, proteins, and cellular membranes [302,303].  A
particularly important consequence of free radical damage in cells, is the peroxidation of
polyunsaturated fatty acids, which results in the formation of lipid peroxides and
aldehydes [304].  These products can cause extensive damage to membrane structure
and integrity, and it is this damage that can result in death to neurons.  
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Melatonin has unique physiological properties which distinguish it from other
antioxidants.  In contrast to all other known low molecular weight antioxidants, the
melatonin molecule, once oxidised, cannot be reduced or regenerated. This built in
safety mechanism protects against auto-oxidative free radical generation and toxic redox
cycling [8].
It has been proposed that glutamate neurotoxicity enhances free-radical production,
thereby causing neuronal death in a variety of age-related diseases.  It was therefore
decided to investigate the neuroprotective properties of melatonin against glutamate and
the three neurotoxic glutamate agonists; NMDA, QA and KA, that had been found to be
neurotoxic in Chapter 3.  
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4.2. INVESTIGATION OF THE POTENTIAL NEUROTOXIC
ACTIONS OF MELATONIN SUPPLEMENTATION
4.2.1. Introduction
Before an investigation could be made into whether melatonin was able to protect
against glutamate receptor induced neurotoxicity, it was necessary to investigate the
effect of melatonin on primary neuronal cell cultures.
4.2.2. Materials and Methods
4.2.2.1. Chemicals and Reagents
Melatonin was purchased from Sigma Chemical Company (USA) and dissolved in
ethanol.  The final ethanol concentration in the culture flasks was 1.5%.  The same
concentrations of ethanol were added to all control incubations.
4.2.2.2. Cell Culture Technique
Cell culture reagents and primary neuronal cells were prepared as described in section
3.2.2.2. and 3.2.2.3.
4.2.2.3. Procedure for Melatonin Treatment
Ten day old cultures were used in this experiment.  The MEM was discarded and the
cells washed with 4 ml HBSS.  Thereafter, 5 ml fresh MEM was placed in the culture
flasks.  Appropriate aliquots of melatonin stock and 50% ethanol stock solutions were
added to the flasks so as to give final melatonin concentrations of 0 - 1000 µM, while
keeping ethanol concentrations constant.  Final ethanol concentrations did not exceed
1.5%.  Cultures were returned to the 37oC  incubator for 20 minutes.  These were then
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washed twice with 3 ml HBSS before the addition of 3 ml of fresh MEM.  The neurons
were incubated at 37oC for a further 18 hours.  Trypan blue staining, as described in
section 3.2.2.6. was carried out in order to assess the neuronal viability of the cultures. 
Each experiment was carried out in duplicate.
4.2.2.4. Statistical Analysis
The results were analysed as described in section 2.2.2.8.
4.2.3. Results
The effect of melatonin treatment on primary neuronal cell cultures is shown in Table 4.1. 
Increasing concentrations of melatonin had no significant (P=0.5165) effect on neuronal
viability.
Table 4.1: The effect of various concentrations of melatonin on
Neuronal Cell Viability (n=5)
Melatonin Concentration (µM) % Viability SEM
0 99.39 0.60
10 98.75 1.25
150 99.01 0.61
500 99 1.02
1000 100.07 0.52
4.2.4. Discussion
The exposure of primary neuronal cultures to melatonin, at  concentrations as high as
1 mM, did not significantly alter the viability of the neuronal cultures.  The use of ethanol
as a vehicle also did not appear to have any neurotoxic effects.
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Since melatonin did not have any effect on the neurons, it was decided to determine
whether the hormone could protect neuronal cell cultures from neurotoxicity induced by
the glutamate receptor agonists tested in Chapter 3.
Melatonin and Neuronal Viability 89
4.3. EFFECTS OF MELATONIN CO-TREATMENT WITH
GLUTAMATE, N-METHYL-D-ASPARTATE, QUINOLINIC
ACID AND KAINIC ACID ON NEURONAL VIABILITY
4.3.1. Introduction
In Chapter 3, it had been demonstrated that glutamate, and the glutamate receptor
agonists; NMDA, QA and KA, were very strong neurotoxins.  Previous experiments
[57,190] had demonstrated that melatonin was able to protect against KA induced
neurotoxicity.  However Giusti et al [295] also found that melatonin was not able to
protect against NMDA induced neurotoxicity.
In this experiment, an investigation was carried out to determine whether melatonin is
able to protect neurons against the above mentioned neurotoxins.  Cultures were co-
treated with varying concentrations of melatonin and a fixed concentration of agonist. 
The percent neuronal viability was assessed by trypan blue staining.
4.3.2. Materials and Methods
4.3.2.1. Chemicals and Reagents
Melatonin was prepared in ethanol as described in section 4.2.2.1.  The ethanol
concentration was kept the same in all culture flasks.  Glutamate, NMDA, QA and KA
were dissolved in Milli-Q water.  All other reagents and chemicals were prepared as
described in 3.2.2.1.
4.3.2.2. Experimental Procedure
Primary neuronal cultures were prepared as described in section 3.2.2.3.  Agonists
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(420 µM) were applied as described in section 3.2.2.5, except that melatonin (0 - 
500 µM) was added to the culture medium at the same time. 
The percentage viability of cultures was determined using the trypan blue assay as
described in section 3.2.2.6.
Results were analysed as described in 2.2.2.8.
4.3.3. Results
The addition of melatonin to neuronal cultures treated with glutamate receptor agonists
caused an increase in the survival rate of neurons with all the agents tested (see Figures
4.1 - 4.4).  In the absence of melatonin, viability of neuronal cultures ranged from as low
as 48.8% for QA treated cultures, to as high as 67.4% for NMDA treated cultures.
Melatonin was able to protect the neurons in a dose dependent manner.  Maximum
protection was offered in all cases when 500 µM of melatonin was applied to the culture
medium.  Melatonin was able to offer significant protection from 100 µM of KA and QA,
while concentrations as low as 10 µM offered significant protection in the NMDA treated
cultures.  
Glutamate treated cultures required 250µM of melatonin before significant protection was
achieved.
In no case did the survival rates of the cultures reach 100% after melatonin treatment.
4.3.4. Discussion
The results show direct evidence of a dose-dependent neuroprotective effect of
melatonin against the four agonists investigated.  Melatonin was able to offer maximum
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protection at 500µM concentration.  Melatonin may have offered greater protection at a
higher dose, however the aim of this experiment was not to determine melatonin dosage
regimes, but rather to investigate whether melatonin did indeed increase survival rates of
primary neuronal cultures.
The doses of agonist used, led to a significant reduction (P>0.05) in viable cells when
compared to untreated control cultures.  As Giutsi had demonstrated [295], melatonin
was indeed able to protect neurons against KA induced neurotoxicity.   It was however
also found that melatonin afforded protection against glutamate, NMDA, KA and QA-
induced neurotoxicity.  This was significant in that Giutsi et al [295] had not found
melatonin to be neuroprotective against NMDA induced neurotoxicity.  There were
however differences in the techniques used between this experiment and those used by
Giutsi et al.  These differences in technique may have resulted in melatonin proving
protective in these results, while it was not protective when Giutsi performed a similar
experiment.
It has thus been shown that melatonin is able to increase neuronal viability following
neurotoxic insults initiated by glutamate, NMDA, KA and QA. 
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Figure 4.1: Effect of melatonin on neuronal viability when co-treated with 420 µM
Glutamate.  Values represent the mean ± SEM (n = 6 - 9) (nsP>0.05; *P<0.05; **P<0.01 in
comparison to zero controls)
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Figure 4.2: Effect of melatonin on neuronal viability when co-treated with 420 µM
NMDA.  Values represent the mean ± SEM (n = 6) (nsP>0.05; **P<0.01; ***P<0.001 in
comparison to zero controls)
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Figure 4.3: Effect of melatonin on neuronal viability when co-treated with 420 µM QA. 
Values represent the mean ± SEM (n = 6) (nsP>0.05; *P<0.05; **P<0.01; ***P<0.001 in
comparison to zero controls)
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Figure 4.4: Effect of melatonin on neuronal viability when co-treated with 420 µM KA. 
Values represent the mean ± SEM (n = 7) (nsP>0.05; *P<0.05; ***P<0.001 in comparison to
zero controls)
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4.4. INVESTIGATION TO DETERMINE WHEN TO ADD
MELATONIN TO ACHIEVE MAXIMUM
NEUROPROTECTION
4.4.1. Introduction
Melatonin has been suggested as a neuroprotective agent against a number of
neurological disorders.  Among the disorders mentioned are Alzheimer’s disease
[245,251] and Cerebral Ischemia [266].  Each of these disorders involves different
mechanisms that lead to neurotoxicity.  It was hoped that by investigating when, in
relation to the agonist insult, melatonin was able to offer protection, an idea of the
mechanism of the neuroprotective action could be determined.
It had been demonstrated (in section 4.3.) that melatonin was able to protect against
neurotoxicity induced by glutamate, NMDA, QA and KA.  However it was not known
when it was best to administer melatonin to achieve maximum protection.
This experiment was aimed at determining whether melatonin should be administered
prior to the onset of excitotoxicity as a preventative measure, or whether co-
administration of melatonin during glutamate excitotoxicity offered greater protection.  In
addition, the effect of melatonin as a means of treating neuronal damage, after glutamate
toxicity had occurred, was also investigated.
4.4.2. Materials and Methods
4.4.2.1. Chemical Reagents
Chemicals used were prepared as in 4.3.2.1, except that a lower dose of agonist
(100µM) was used, as this was the lowest dose of agonist that gave significant
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decreases in cell viability in Chapter 3.  A low dose of melatonin (150µM) was also used
so that subtle changes in neuronal survival could be better observed.
4.4.2.2. Experimental Procedure
Primary neuronal cultures were prepared as described in section 3.2.2.3.  Agonists were
applied as described in section 3.2.2.5, except that neurons were either pre-treated, co-
treated of post-treated with melatonin (see Table 4.2).  Neurons pre-treated with
melatonin had sufficient melatonin added to the existing growth media  to make up to the
correct melatonin concentration 20 minutes before the addition of the media containing
the agonist.  Cultures co-treated with melatonin during the agonist insult, had melatonin
added to the incubation media, together with the agonist.  Finally, in cultures post-treated
with melatonin, the  cultures were treated with agonist as per normal, and melatonin was
added to the fresh medium that was put into the flasks following the insult.  Neurons were
then incubated for 18 hours in the presence of melatonin.
The percentage viability was assayed as described in section 3.2.2.6, and the results
were analysed as explained in 2.2.2.8.
Table 4.2: Experimental parameters used to determine when best to
administer melatonin to achieve maximum neuroprotection
Time of Treatment Melatonin (150µM)
Pre-Treatment Added 20 minutes prior to addition of agonist
Co-Treatment Added during 20 minute exposure to agonist
Post-Treatment Added 20 minutes after inducing agonist toxicity (18 hours)
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4.4.3. Results
The results (see Figures 4.5 - 4.8) demonstrated that no protection was offered to
neurons that were pre-treated 20 minutes prior to the insult.  In those flasks where
cultures were co-treated with agonist and melatonin, there was significant protection
offered, except in the case of the flasks treated with glutamate, where no significant
increase in cell viability was recorded in comparison to control cultures.  Neurons post-
treated for 18 hours with melatonin,  following the 20 minute agonist insult, all showed
significant increases in cell viability.
4.4.4. Discussion
Melatonin given 20 minutes prior to the agonist insult was not effective at protecting
neurons against agonist-induced neurotoxicity.  The melatonin was removed from the
culture medium before the addition of the agonist, so that only melatonin that had been
taken up by the neurons would have remained in the culture.  These results suggest that
melatonin must act as an antioxidant, as melatonin given before the insult, and
production of ROS, is not able to offer protection.
Apart from the neuronal cultures co-treated with glutamate, all the other cultures co-
treated or post-treated with melatonin had their viability increased.  This would suggest
that melatonin is protecting the neurons from the post insult production of ROS.
Co-treatment with glutamate and melatonin caused an increase in cell viability, although
it was not statistically significant.  Experiment 4.3. had demonstrated that at high
melatonin and glutamate concentrations, co-treatment could result in a significant
increase in neuronal viability.  It was therefore decided that all future experiments would
use co-administration of the agonist and melatonin, as the method of preference. 
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Figure 4.5: Effect of time of melatonin administration on the neuroprotection against
glutamate toxicity.  Values represent the mean ± SEM (n= 4 - 5) (nsP>0.05; *P<0.05 in
comparison to zero controls)
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Figure 4.6: Effect of time of melatonin administration on the neuroprotection against
NMDA toxicity.  Values represent the mean ± SEM (n= 3 - 5) (nsP>0.05; *P<0.05;
**P<0.01 in comparison to zero controls)
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Figure 4.7: Effect of time of melatonin administration on the neuroprotection against QA
toxicity.  Values represent the mean ± SEM (n = 5) (nsP>0.0 ;**P<0.01 in comparison to
zero controls)
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Figure 4.8: Effect of time of melatonin administration on the neuroprotection against KA
toxicity.  Values represent the mean ± SEM (n = 5) (nsP>0.0 ;**P<0.01; ***P<0.001 in
comparison to zero controls)
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4.5. MOVEMENT OF 3H-MELATONIN INTO NEURONS
4.5.1. Introduction
The previous experiments demonstrated that melatonin is effective at reducing neuronal
cell death induced by the various glutamate agonists.  It is not known how melatonin
protects the neurons, but it is proposed that melatonin acts as a neuroprotector  by
removing free radicals within the cell.  In order to do this, melatonin would first have to
enter the neurons, as neurons cannot naturally produce melatonin.
In this experiment the accumulation of melatonin within neuronal cells was investigated.
4.5.2. Materials and Methods
4.5.2.1. Chemical Reagents
[O-methyl-3H]melatonin  (1 mCi  / ml) was purchased from Amersham International plc
(England).  Triton X-100 was purchased from Unilab (South Africa).
Melatonin was prepared in absolute ethanol and diluted with Milli-Q water to obtain the
correct stock concentration.  Final ethanol concentrations in the flasks did not exceed
1.5%.
3H-melatonin was diluted in MEM, and a working stock was prepared so that it would give
a final concentration of 0.1 µCi / ml media, once present in the incubation flask.
4.5.2.2. Preparation of Primary Neuronal Cultures
Primary neuronal cultures were established as explained in section 3.2.2.3.
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4.5.2.3. Experimental Procedure
A modified method of Sorg et al [125] was used to measure melatonin uptake.  Seven to
ten day old primary neuronal cell cultures were washed with 4 ml of HBSS, after which
3 ml of MEM was added.  To this was added 100 µl of melatonin to give a final
concentration of 500 µM, and 100 µl of 3H-melatonin in MEM to give a final concentration
of 0.1 µCi / ml.  The flasks were then returned to a 37oC incubator.
Samples were removed at 0, 10 , 20 and 30 minutes after the addition of melatonin to
the flasks, to measure 3H-melatonin uptake into the cells.
To assay for 3H-melatonin, the MEM containing the radiolabelled melatonin was
immediately poured out of the flasks, and the flasks were washed with 4 ml of ice-cold
50 mM Tris-HCl Buffer (pH 7.4) containing 5 mM melatonin.  This was poured off and
2 ml of 10 mM NaOH containing 0.1% Triton X-100 was added to the flasks.  The flasks
were left at room temperature for 10 minutes, before being gently agitated and the
contents being poured into new reaction tubes.  A 500 µl aliquot of the solution in the
reaction tube was added to 3ml of scintillation cocktail.  After 24 hours, the radioactivity in
the scintillation vials was measured using a Beckman (Model LS 2800) Liquid
Scintillation Counter.  All radioactivity was expressed as fmol 3H-glutamate / mg protein. 
An aliquot of the solution left in the reaction  tube was used to determine the protein
concentration using the modified method of Lowry et al as explained in section 2.2.2.6. 
All results were analysed as described in section 2.2.2.8.
4.5.3. Results
3H-melatonin uptake increased significantly as the incubation time increased (see Figure
4.9).  After a 30 minute incubation in the presence of melatonin, there was a 32.1%
increase in intracellular melatonin concentration compared to controls (25.7 fmol / mg
protein).
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4.5.4. Discussion
Melatonin accumulates in the interior of the neuron.  Being a lipid soluble molecule [305],
melatonin could simply diffuse into the interior structure of the neuron through the cell
membrane, or there may be transport proteins to allow melatonin to enter the neurons.
The aim of this experiment was not to determine the mechanism by which melatonin
enters the neuron, but rather to determine whether melatonin accumulates within the
neuron.  The neurons that were used had been in a melatonin free environment for 7 -
10 days, and so there should have been no intracellular melatonin present in the
neurons prior to the application of the melatonin in the MEM.
The fact that melatonin can be found intracellularly, shows that melatonin is present,
should it be needed to perform a neuroprotectant role.
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Figure 4.9: 3H-Melatonin uptake over time.  Values represent the percent increase (±
SEM) compared to zero controls.  (n=4) (ns P>0.05; ***P<0.001 in comparison to zero
control)
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4.6. CONCLUSIONS
Chapter 3 had demonstrated the neurotoxic effects of glutamate, NMDA, QA and KA on
primary neurons.  In this chapter melatonin was investigated to see if it afforded any
neuroprotection against the agonist induced neurotoxicity.
It was first demonstrated that melatonin dissolved in an ethanol vehicle was not
neurotoxic to neuronal cultures.  No significant changes in neuronal viability occurred
even at melatonin concentrations of 1 mM.
When primary neuronal cultures were co-treated with both melatonin (0 - 500 µM) and an
agonist (420 µM), the melatonin was able to protect in a dose dependent manner. 
Melatonin was also found to only be neuroprotective when administered either during or
after the agonist insult on the neurons.  This would indicate that melatonin is offering
protection by inhibiting neurotoxic processes that occur after the agonist insult.
The excitotoxic model of neurotoxicity proposes that when the NMDA or KA receptors
are stimulated, Ca2+ moves into the neuron.  Over stimulation of these receptors would
thus lead to excessive Ca2+ influx [118].  Ca2+ stimulates a number of pathways that can
give rise to the production of free radicals.  Mitochondria attempt to accumulate the Ca2+,
but this affects the membrane potential and decreases the efficiency of the mitochondria. 
This can increase ROS production.
Melatonin could well be acting, either to inhibit Ca2+ nflux into the neurons, or as an ROS
scavenger.  Chapters 6 - 9 will investigate these possible neuroprotective pathways.
CHAPTER 5
EFFECT OF QUINOLINIC ACID AND MELATONIN ON 
HIPPOCAMPAL NEURONS
5.1. INTRODUCTION
In the previous two chapters it had been demonstrated that glutamate and the glutamate
agonists, NMDA, QA, and KA, induce neuronal cell death in primary neuronal cell
cultures.  It had also been shown that melatonin was able to protect neurons to a certain
degree from EAA-induced neurotoxicity.  In this experiment, an investigation was made
to determine whether melatonin was able to protect neurons in an in vivo situation.
Quinolinic acid is an agonist of the neuronal NMDA receptor [102,306], which has been
detected in both the human and rat brain [79].  Intrastriatal and intrahippocamal
injections of QA into the rat brain have been shown to induce neuronal lessions
[103,104].  These lesions closely resemble those observed in the brains of individuals
with Huntington’s Disease [105,106].
Previous experiments had demonstrated QA to be the most potent of the glutamate
agonists tested.  At high concentrations melatonin had been shown to partially protect
cultured primary neurons.  An investigation was thus made to investigate whether
melatonin could protect hippocampal neurons against insults induced by QA.  The
hippocampus was selected as it is very densely populated with glutamate receptors, and
is also known to be susceptible to QA attack. 
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5.2. HISTOLOGICAL INVESTIGATION
5.2.1. Introduction
Histology is derived from the Greek word for web or tissue, and involves the examination
of preserved, sectioned and stained tissues.  Most of our knowledge of internal tissue
structure has come from this branch of science [307].
In this experiment it was decided to investigate whether melatonin offered
neuroprotection against QA-induced intrahippocampal lesions in the rat brain.  After
treatment, the hippocampus of the rats was sectioned and examined microscopically for
evidence of any morphological changes.
5.2.2. Materials and Methods
5.2.2.1. Chemicals and Reagents
Quinolinic acid and melatonin were purchased from Sigma Chemical Company (USA). 
Paraffin wax was obtained from Lasec (South Africa).  Cresyl violet stain was purchased
from BDH Chemicals Ltd (England), while DPX was purchased from Philip Harris Ltd
(England).  Haupt’s adhesive consisted of the following; 1 g gelatine, 100 ml water, 2 g
phenol and 15 ml glycerol.  Sodium Pentobarbitone was purchased from Merck
(Germany) and was made to a working concentration of 60 mg / kg , by diluting in water. 
All other chemicals were of the highest quality available and were purchased from
commercial distributors.
5.2.2.2. Animals
Adult, male Wistar rats were cared for as described in section 2.2.2.2.
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5.2.2.3. Surgical Procedures 
i. Bilateral Intrahippocampal Injections of Quinolinic Acid
Male rats were anaesthetized with sodium pentobarbital (60 mg / kg i.p.) and placed in a
stereotaxic frame.  The rat skull was orientated according to the König and Klippel
stereotaxic atlas [308].  After a sagittal cut in the skin of the skull, the bregma suture was
located and holes were drilled with an electrical trepan drill at the following co-ordinates;
4.4 mm anterior, 2 mm lateral of the sagittal suture.  Care was taken not to lesion the
meninges.  A Hamilton syringe, with a cannula of diameter 0.3 mm, was used to inject
1 µmol of quinolinic acid in 2 µl of PBS, 3 mm ventral of the dura.  The injection was
administered at a rate of 1 µl per minute and the cannula was left in sutu for a further
3 minutes following the drug injection, to allow for passive diffusion away from the canulla
tip and to minimise spread into the injection tract.  The cannula was then slowly removed
and the scalp was closed with sutures.  Animals were kept in an incubator (37oC) until
they recovered from the anaesthesia.
ii. Sham Lesioned Rats
Rats to be used as controls were subjected to the surgical procedures outlined in section
5.2.2.3.(i).  However, stereotaxic injections into the hippocampus were free of QA, and
comprised only of PBS.
5.2.2.4. Treatment Regimes
Animals were divided into three groups as shown in Table 5.1.
Sweet Oil was administered sub-cutaneously at the same dosage as that given to the
mel (+) rats.  QA was dissolved in PBS made up to pH7.4.
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Table 5.1: Treatment regime for each group of animals
Group Received 20 mins prior
to operation (s.c.)
Intrahippocampal
injection consisted of:
Received daily doses
for 5 day after
operation
Control Sweet Oil PBS Sweet Oil
Mel (-) Melatonin in Sweet Oil
(10 mg / kg)
1µmol QA in PBS Melatonin in Sweet Oil
(10 mg / kg)
Mel (+) Sweet Oil 1µmol QA in PBS Sweet Oil
Animals were treated for 5 days following surgery.  Injections of sweet oil or melatonin
were administered at the same time (14h00) each day, so as to increase circulating
melatonin concentration, when levels should have been physiologically at their lowest.
5.2.2.5. Brain Removal
Rats were sacrificed and their brains were removed as described in section 2.2.2.4.
5.2.2.6. Histological Techniques
i. Fixing the brain
Immediately after death, animal tissues begin to break down as a result of autolysis and
bacterial attack.  Fixation functions to chemically stabilise proteins, and thus preserve
structures. 
Brains were removed from the skull as in section 2.2.2.5, and rapidly fixed in a mixture of
formol (30%), glacial acetic acid, and ethanol (2:1:7 v/v) for 2 hours.  After fixation, the
brains were stored in 70% ethanol.
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ii. Specimen Preparation and Embedding
In order to be cut, the slices need to be supported.  Imbedding involves the infiltration
and orientation of tissue in the paraffin wax support medium.
The tissue was dehydrated (using increasing concentrations of ethanol), followed by the
removal of the ethanol using xylene.  Finally the tissue was immersed in molten paraffin
wax, which removed the xylene, while infiltrating the tissue without encountering water. 
The method used is shown in Table 5.2.
Table 5.2: Procedure for embedding brains in paraffin wax
Step Processing Agent Time
1 70% Ethanol 1 hour
2 90% Ethanol 1 hour
3 Absolute Ethanol I 1 hour
4 Absolute Ethanol II 1 hour
5 Xylene I 1 hour
6 Xylene II 1 hour
7 Melted Paraffin Wax I (57oC) 1 hour
8 Melted Paraffin Wax II (57oC) 1 hour
  
iii. Blocking Out
The brain material was fixed into a block so that it could be cut with a microtome.  A
mould was formed from two L-shaped metal bars.  These were coated with ethanol-
glycine to prevent the block sticking to the mould.  A little molten wax was added to the
mould and allowed to harden.  The brain was removed from the final molten wax stage
(previous section) and placed into the mould with warmed forceps.  The brain was then
completely covered in molten wax.  Air was gently blown over the surface of the wax until
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Figure 5.1: Diagram of wax block ready for
sectioning with brain embedded in the centre
the top solidified.  The whole mould was then immersed in a large dish of cold water. 
This was to enable the wax to solidify quickly, and prevent the formation of crystals that
might have disrupted the tissue.  The blocks were left overnight in cold water to ensure
that the wax had completely solidified.
iv. Sectioning
The wax block was trimmed with a razor blade so that two of the sides were parallel,
while the other two converged slightly (see Figure 5.1).  The sides were cut so as to
leave about 2 mm of wax around the tissue.  The wax block was attached to a small
wooden block with a small amount of molten wax.
Sectioning was done using a rotary microtome.  The microtome was set to cut sections of
10 µm thickness.  As sections were cut they would stick to one another, so as to form
long ribbons.  When the part of the brain containing the hippocampus was reached,
every second section was removed and placed in a water bath (40oC) using a paint
brush.
v. Transferring Sections to Slides
Three sections at a time were removed from the water bath and placed onto microscope
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slides containing a thin layer of Haupt’s adhesive.  The slides were left overnight in an
oven at 40oC.
vi. Staining
The sections were Nissl stained using cresyl violet.  This stains Nissl substances intense
purple, the nuclei purple, and leaves the background clear [309].
Before the section could be stained, it first had to be dewaxed and rehydrated as the
stain is water soluble.  This was done as per Table 5.3.
Table 5.3: Procedure for dewaxing and rehydrating brain sections
Step Processing Agent Time
1 Xylene I (dewaxing) 5 minutes
2 Xylene II 5 minutes
3 Xylene / Absolute Ethanol (1:1) 3 minutes
4 Absolute Ethanol 5 minutes
5 Absolute Ethanol Overnight at 30oC
Sections were stained by placing in a 0.1% cresyl violet solution for 2 hours.  The slides
were differentiated rapidly in 95% ethanol by rinsing in a flat dish until the background
was clear.  Sections were then dehydrated again as shown in Table 5.4.
Table 5.4: Procedure for dehydrating brain sections after staining
Step Processing Agent Time
1 Absolute Ethanol I 5 minutes
2 Absolute Ethanol II 5 minutes
3 Xylene I 5 minutes
4 Xylene II 5 minutes
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vii. Mounting of the Slides
While the slides were kept moist with xylene, enough DPX was added to just cover the
tissue.  A cover slip was placed over the tissue.  The slides were allowed to dry on a flat
surface for 48 hours.
5.2.2.7 Photo-microscopy
The slides were photographed using a combination Olympus camera and light
microscope.
5.2.3. Results
Neurons were investigated in an area adjacent to the site of the quinolinic acid injection. 
Care was taken not to select samples that may have been physically damaged by the
cannula.  All damage that resulted was therefore of a neurochemical nature and not a
result of physical damage caused by the cannula.  Neurons in the CA1 and CA3 regions
of the hippocampus were examined.  Neurons in the control group from both the CA1
region (Figure 5.2) and those in the CA3 region (Figure 5.5) appeared to be undamaged. 
The neurons in  the CA1 region (Figure 5.4) and those in the CA3 region (Figure 5.7)
of those animals treated with melatonin, also appeared to be undamaged.  Neurons
from the QA treated animals showed signs of degeneration by virtue of their
roundness and swelling in the CA1 region (Figure 5.3), while the CA3 region (Figure
5.6) showed signs of degeneration.
5.2.4. Discussion
These results demonstrate that melatonin appears to protect against QA-induced
neurotoxicity.  QA acts at the NMDA receptors, allowing Ca2+, Na+ and K+ to enter the
neurons.  The influx of these ions can upset the ionic balance of the neurons, leading to
swelling and lysis [5,103].  This phenomenon appears to be occurring in Figure 5.3.
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The influx of Ca2+ into the cell can also activate many free radical producing  pathways,
which can prove toxic to the neurons [310].  A combination of changes in osmotic
pressure and free radical damage could have resulted in the neurodegeneration
observed in Figure 5.6.
Melatonin appeared to protect neurons from the neurotoxic effects of QA as neurons co-
treated with melatonin did not appear to swell (Figure 5.4), nor was there the
neurodegeneration observed in the Mel (-) cultures in the CA3 region (Figure 5.6) when
melatonin was administered (Figure 5.7).
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Figure 5.2: Micrograph of cells in the CA1 region of the hippocampus from a
control animal. (Bar = 10µm)
Figure 5.4: Micrograph of cells in the CA1 region of the hippocampus from an
animal treated with quinolinic acid and melatonin. (Bar = 10µm)
Figure 5.3: Micrograph of cells in the CA1 region of the hippocampus from an
animal treated with quinolinic acid only.  (Bar = 10µm)
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Figure 5.5: Micrograph of cells in the CA3 region of the hippocampus from a
control animal (Bar = 10µm)
Figure 5.7: Micrograph of cells in the CA3 region of the hippocampus from an
animal treated with quinolinic acid and melatonin. (Bar = 10µm)
Figure 5.6: Micrograph of cells in the CA3 region of the hippocampus from an
animal treated with quinolinic acid only. (Bar = 10µm)
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5.3. EFFECT OF INTRAHIPPOCAMPAL ADMINISTRATION OF
QUINOLINIC ACID ON 3H-GLUTAMATE RECEPTOR
BINDING
5.3.1. Introduction
In the previous experiment it was determined that melatonin appeared to offer protection
against QA induced neurotoxicity in the hippocampus.  Neurons of rats treated with
melatonin, both before and after the intrahippocampal administration of QA, did not
appear to swell in the CA1 region, nor undergo neurodegeneration in the CA3 region. 
The previous studies were however not able to quantify the protection offered by
melatonin.
It was therefore decided to conduct receptor binding assays on hippocampal neurons of
animals treated as in experiment 5.2.  Glutamate receptors are known [175] to be the
most abundant neuroreceptor found in the hippocampus, and it was therefore decided to
determine whether there was a reduction in the number of glutamate receptors.  If there
was a reduction, it would demonstrate that there could possibly be a reduction in the
number of viable neurons in the hippocampus.  If receptor numbers remained constant,
this would demonstrate that the number of viable neurons had remained the same after
the QA injection.
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5.3.2. Materials and Methods
5.3.2.1 Chemicals and Reagents
All chemicals used in the intrahippocampal injections were as described in section
5.2.2.1., while chemicals used for the glutamate binding studies were the same as those
used in section 2.2.2.1.
5.3.2.2. Preparation of Synaptic Membranes
Rats were treated as described in section 5.2.2.4.  On the fifth day following the
operation, the rats were sacrificed and the brains removed as described in section
2.2.2.4.
The hippocampi were dissected from the brains according to the method of Glowinski
and Iversen [311].   Synaptic membranes were prepared from the individual hippocampi
using the method described in section 2.2.2.5.
5.3.2.3. Glutamate Binding Assay Procedure
The Glutamate binding assay was performed as described in section 2.2.2.7.
5.3.2.4. Statistical Analysis
The results were analysed as per the method in section 2.2.2.8. 
5.3.3. Results
Saturation isotherms were plotted for control (Figure 5.8), Mel (-) (Figure 5.10), and Mel
(+) (Figure 5.12) glutamatergic receptors on hippocampal synaptic membranes.  The
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data was converted to Scatchard plots so as to determine the Bmax for each of the
treated groups (see Figures; 5.9, 5.11 and 5.13).
The Bmax values obtained in each case are shown in Table 5.5.  QA caused a
significant (P<0.001) decrease in the number of glutamate binding sites, while those
animals which received a combination of QA and melatonin (mel (+)) showed a less
dramatic decrease in binding sites compared to control animals. 
At the same time, the receptors of animals that received melatonin in conjunction with
QA injections had very similar Kd values to those of control animals.  The receptors of
QA treated animals that did not receive melatonin had a much higher glutamate binding
affinity than either control or melatonin treated animals.
Table 5.5:Comparison of Bmax values obtained from glutamate receptor binding
studies.  (n=3) (a P<0.001 vs Control; b P<0.01 vs Control)
Test Treatment Bmax (fmol 3H-glutamate /mg protein) Kd
1 PBS (Control) 97 ± 1.86 116
2 Quinolinic Acid 29 ± 2.63a 86
3 Quinolinic Acid and Melatonin 80 ± 2.52b 119
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Figure 5.8: Saturation isotherm of 3H-glutamate binding to hippocampal synaptic
membranes from control rats.  (n=4)
Figure 5.9: Scatchard plot of  3H-glutamate binding to hippocampal synaptic membranes
from control rats.
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Figure 5.11: Scatchard plot of  3H-glutamate binding to hippocampal synaptic membranes
from quinolinic acid treated rats (mel (-)).
Figure 5.10: Saturation isotherm of 3H-glutamate binding to hippocampal synaptic
membranes from quinolinic acid treated rats (mel (-)).  (n=4)
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Figure 5.12: Saturation isotherm of 3H-glutamate binding to hippocampal synaptic
membranes from quinolinic acid and melatonin treated rats (mel (+)).  (n=4)
Figure 5.13: Scatchard plot of  3H-glutamate binding to hippocampal synaptic membranes
from quinolinic acid and melatonin treated rats (mel (+)).
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5.3.4. Discussion
The results showed that QA treated animals that did not receive melatonin, had a very
significant reduction in receptor numbers, while animals treated with melatonin did not
exhibit the same sharp reduction in receptor numbers.  QA treatment had also changed
the nature of those receptors that were present on the neurons, in that they had a higher
affinity for glutamate than did the control neurons.  The receptors of animals that had
been treated with both melatonin and glutamate had similar Kd values to control animals,
and did not appear to have been affected by the QA treatment.  These results
demonstrate that melatonin treatment partially prevents the QA-induced reduction in
glutamate receptor numbers.  This could indicate that there are more functional neurons
present in both control, and melatonin and QA co-treated animals, than in animals that
only received QA.  Melatonin thus appears to have protected the neurons.
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5.4. CONCLUSION
The histological analysis of the hippocampus of animals treated with QA, showed that
there was a very definite swelling of neurons in the CA1 region and degradation of
neurons in the CA3 region.  Neurons obtained from animals treated with 5 mg / kg
melatonin, both before and for 5 days following the QA injection, did not appear to have
been affected by the QA. These results appeared to show that melatonin offered
neuroprotection against intrahippocampal injections of QA.  However, these studies did
not explain the method by which melatonin offers  protection, nor the level of protection
offered. 
The binding studies attempted to quantify any neurodegeneration that may be induced
by the QA.  Results showed that there was a significant reduction in the Bmax values for
both animals that did and those that did not receive melatonin prior to and following the
QA injection.  The reduction in the Bmax value was however considerably greater in
those animals that did not receive melatonin.
In the QA treated animals that did not receive melatonin, the reduction in receptor
numbers could be the result of a loss of neurons.  For those animals that received both
melatonin and quinolinic acid, melatonin treatment was not able to maintain receptor
numbers at the same level as control animals.  This could be because there was still
some damage to the neurons, and melatonin was not able to completely protect them. 
However, the results obtained in section 2.2 show that melatonin clearly causes a down
regulation in glutamate receptor numbers, while not affecting Kd values.  The results
obtained in this experiment could therefore indicate the natural decrease in glutamate
receptor numbers that occurs from the administration of pharmacological doses of
melatonin to rats.
The results from the in vivo studies thus show that melatonin appears to protect
hippocampal neurons from degeneration caused by intrahippocampal injections of QA. 
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Together with the results obtained from the cell culture studies in Chapter 4, it could be
argued that melatonin appears to be a very effective agent at protecting neurons from
the glutamate receptor agents.  It was therefore decided to investigate further the mode
by which melatonin brings about this neuroprotection.
CHAPTER 6
EFFECT OF GLUTAMATE, N-METHYL-D-ASPARTATE,
QUINOLINIC ACID, KAINIC ACID AND MELATONIN ON
INTRACELLULAR CALCIUM LEVELS
6.1. INTRODUCTION
Calcium ions are the most abundant cations found in vertebrates, where they are used
largely in a structural role in bones [312].  Ca2+ is also used widely in processes such as
muscular contraction, stimulus secretion coupling, transduction of hormonal information
and neuronal conduction [153,313].  More recently the discovery of calcium-dependent
regulatory proteins [119] has suggested a role for Ca2+ in the modulation of various
metabolic processes within the cell.  The ability of Ca2+ to regulate metabolic processes
within the cell, is believed to be due to the “sticky” nature of Ca2+ ions, which allows them
to bind to a variety of ligands such as proteins and phosphate groups [314].  Ca2+
appears to damage cellular proteins and membranes by activating proteases such as the
calpains [315], and by promoting free radical production via the activation of lipases [316]
or nitric oxide synthetase [317].  Any changes in the regulation of Ca2+ will therefore
cause a loss of control to many other intracellular processes.
EAA stimulated Ca2+ influx promotes free radical accumulation in neurons by several
means. These include the activation of phospholipases that induce phospholipid
hydrolysis, accumulation of arachidonic acid, and the subsequent oxidation by cyclo-
oxygenase and lipoxygenase [316], conversion of xanthine-dehydrogenase to xanthine-
oxidase which catalyses the oxidation of hypoxanthine to xanthine and generates the
superoxide radical [143]; and activation of nitric oxide synthase [318] which generates
nitric oxide, which reacts with O-2@ to form the highly destructive peroxynitrite radical [317].
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An investigation was made into the effect of agonist stimulation on intracellular calcium
levels and whether melatonin had any effect on Ca2+ accumulation in neurons.  Atomic
absorption spectroscopy was used to determine the intracellular Ca2+ concentration in
the primary neuronal cultures.
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6.2. EFFECT OF THE GLUTAMATE RECEPTOR AGONISTS ON
INTRACELLULAR CALCIUM ACCUMULATION
6.2.1. Introduction
The glutamate receptors allow the influx of Ca2+ into neurons.  Under normal conditions
this leads to a change in the cell membrane polarity, which allows neurons to transfer
impulses from one to another.  Excess stimulation by the EAA’s can lead to intracellular
Ca2+ levels rising.  The normal mechanisms that remove Ca2+ from the neurons are not
able to cope with this sudden influx.  As Ca2+ is ble to regulate many enzymatic
reactions, the higher intracellular Ca2+concentrations in neurons can initiate many
neurotoxic reactions.
Both the NMDA and KA receptors [87,191] are reported to allow Ca2+ influx into cells. 
This investigation was conducted to determine changes in intracellular Ca2+
concentrations following neuronal stimulation by the various glutamate receptor agonists
used in the previous experiments. 
6.2.2. Materials and Methods
6.2.2.1. Chemical Reagents
Calcium Chloride (CaCl2) standard was purchased from Unilab (South Africa).  Glass
Culture Tubes (10 x 75 mm)  were purchased from Kimble (USA).
6.2.2.2. Glassware Preparation
All glassware was treated by the modified method of Kelly et al  [319].  The procedure
involved soaking the glassware in 25% (v / v) HNO3 for 48 hours followed by another
48 hour soak in Milli-Q water containing 5 g / l of the chelating resin iminodiacetic acid.
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6.2.2.3. Cell Culture Procedure
The neurons were treated with agonists as described in section 3.2.2.5.
The reactions were stopped at specific times to determine the intracellular Ca2+
concentration.  The various groups are shown in Table 6.1.
Table 6.1: Experimental Groups
Group Test
Control Poured off MEM.  No Agonist.  Assayed immediately
0 min Agonist Added.  Immediately removed and assayed cells
20 min Cells treated with agonist for 20 minutes.  Cells assayed at the end of this
time
60 min Cells treated with agonist for 20 minutes, then allowed to recover in fresh
MEM.  Assayed 60 minutes after initiation of insult
18 hours Cells treated exactly as in section 3.2.2.5.  18 hours after the insult, the cells
were assayed
6.2.2.4. Calcium Assay Procedure
The existing media was poured out of the incubation flasks.  A 2 ml aliquot of 50 mM Tris-
HCl buffer (pH 7.4) was added to each incubation flask.  The cells were scraped off the
surface of the flasks with a cell scraper and the cell suspensions were poured into new
glass culture tubes.  The inside of the flask was rinsed with an additional 2 ml of Tris-HCl
buffer to remove any cells, and this too was poured into culture tubes to give a final
volume of 4 ml.  The tubes were centrifuged at 3 500 x g for 10 minutes at 4oC, before
the supernatant was poured off.  The pellets were resuspended in 1 ml of Tris-HCl buffer. 
A 100 µl fraction of the suspension was kept for cell enumeration using a
haemacytometer.  The tubes were then centrifuged at 4oC at 3 500 x g for a further
10 minutes, before the supernatant was discarded.  The pellets were resuspended in
0.2 ml of 68% nitric acid, before being boiled at 100oC for ± 10 minutes, or until all the
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solid material had been digested.  An 800 µl aliquot of Milli-Q water was added to each
tube to give a final volume of 1 ml.  Ca2+ levels of the solution were determined by flame
atomic absorption spectroscopy, using a GBC 909 Atomic Absorption
Spectrophotometer.  The fuel source was nitric oxide; acetylene; slit width was 0.5 nm;
wavelengh set at 422.7 nm; and current 3 mA.  The absorbance values were converted
to µM Ca2+ concentrations for a standard curve (Appendix 2) generated from a standard
CaCl2 solution.
The data was expressed as µg calcium / 106 cells, and were analysed as described in
section 2.2.2.8.
6.2.3. Results
The results are shown in Figures 6.1 - 6.4.  Glutamate and QA caused a significant
increase in intracellular Ca2+ levels at 0 minutes and 20 minutes, while KA and NMDA
caused significant increases at 0, 20, and 60 minutes.  None of the agonists caused a
significant increase in intracellular Ca2+when readings were taken 18 hours after the
insult.
In all cases, the intracellular Ca2+ levels were highest at 0 minutes.  KA caused the
largest increase in intracellular Ca2+ concentration at 0 minutes, with a five fold increase,
while glutamate caused the least with only a 3.4 fold increase.
6.2.4. Discussion
Application of the glutamate agonists caused a rapid increase in intracellular Ca2+ as
measured by atomic absorption spectroscopy.  All agonists caused at least a 3.4 fold
increase in intracellular Ca2+ lmost immediately.  Ca2+ is known [72] to rapidly move into
neurons following the opening of the Ca2+ channels by the glutamate receptor agonists. 
These results would indicate that this is indeed the case.
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The agonists were applied for 20 minutes.  At the end of this time, neurons were assayed
and intracellular Ca2+ concentrations determined.  Twenty minutes following the agonist
insult, there was a significant increase in Ca2+ levels compared to controls.  However
Ca2+ levels were lower in all cases to those at 0 minutes.  It therefore appeared that there
was a general trend to remove Ca2+ from the neurons, even though the agonists would
still have been stimulating the receptors.  Active processes to remove Ca2+ from the
neurons would have been in operation.  These processes require ATP, which could
result in the leakage of O-2@ form the electron transport chain.
After 60 minutes Ca2+ levels were lower than the earlier two readings in all cases.  Ca2+
levels were significantly higher than control cultures for KA and NMDA, while QA and
glutamate treated neurons appeared to have already brought Ca2+ levels close to those
of controls, just 1 hour following the insult.  The agonists were no longer present in the
incubation medium and the cells should have had time to reduce intracellular Ca2+ evels.
Eighteen hours following the agonist insult, all cultures had reduced Ca2+ levels so that
they were no longer significantly different to control cultures.  Intracellular processes had
therefore been able to remove the excessive Ca2+ from the neurons, or neurons had
died and so Ca2+ and other ions could move freely into and out of the dead cells, with
their disrupted cell membranes.
This experiment has demonstrated that following an agonist insult, intracellular Ca2+
levels are significantly increased for at least one hour in the case of NMDA and KA. 
Levels for all agonists were significantly increased for the first 20 minutes.  This increase
in intracellular Ca2+ initiates a number of intracellular processes, that could be potentially
neurotoxic to neurons.
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Figure 6.1: Effect of glutamate insult on intracellular calcium over time.  Values represent
the mean ± SEM (n=3) (nsP>0.05; **P<0.01; ***P<0.001 in comparison to zero controls)
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Figure 6.2: Effect of NMDA insult on intracellular calcium over time.  Values represent
the mean ± SEM (n=3) (nsP>0.05; **P<0.01; ***P<0.001 in comparison to zero controls)
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Figure 6.3: Effect of QA insult on intracellular calcium over time.  Values represent the
mean ± SEM (n=3) (nsP>0.05; *P<0.05; ***P<0.001 in comparison to zero controls)
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Figure 6.4: Effect of KA insult on intracellular calcium over time.  Values represent the
mean ± SEM (n=3) (nsP>0.05; *P<0.05; ***P<0.001 in comparison to zero controls)
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6.3. EFFECT OF MELATONIN ON INTRACELLULAR CALCIUM
ACCUMULATION
6.3.1. Introduction
In Chapters 4 and 5 it had been demonstrated that melatonin was able to protect
neurons from glutamate receptor agonist induced neurotoxicity.  The method by which
melatonin brought on this protection was however not known.
Intracellular Ca2+ is known to initiate a number of cellular processes that can prove
neurotoxic to neurons.  It was therefore decided to investigate whether the presence of
melatonin during the 20 minute agonist incubation, and for 40 minutes after the
application of the agonist, had any effect on intracellular Ca2+ evels.
6.3.2. Materials and Methods
6.3.2.1. Chemical Reagents
Melatonin (500 µM) was prepared as in 4.2.2.1.  All other reagents were prepared as in
6.2.2.1.
6.3.2.2. Experimental Procedure
Glassware was prepared as per 6.2.2.2, while neuronal cultures were prepared as
described in section 3.2.2.3.
Neurons were treated as in section 4.3.2.2, the sole difference being that melatonin
(500 µM) was added to the MEM both during, and after, the agonist insult.
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6.3.2.3. Calcium Assay Procedure
The method described in 6.2.2.5. was employed.  Cultures were compared using a
student t test to check for significance.
6.3.3. Results
Intracellular Ca2+ concentrations were compared between cultures that had received
melatonin, and those that had not, one hour after the initiation of the agonist insult.  In all
cases the presence of melatonin did not cause a significant difference in intracellular
Ca2+ levels compared to samples that had not received melatonin.  Table 6.2. lists the
results obtained.
Table 6.2: Effect of melatonin on Intracellular Ca2+concentrations following treatment
with glutamate receptor agonists (n = 5)
Agonist Melatonin (µM) Ca2+ (µg / 106 cells) SEM P value
Glutamate 0 14.36 1.418
0.3161
Glutamate 500 16.127 0.6095
NMDA 0 21.289 1.807
0.5093
NMDA 500 17.856 4.387
QA 0 19.511 0.2867
0.2607
QA 500 15.681 2.918
KA 0 20.455 3.496
0.2634
KA 500 26.649 3.245
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6.3.4. Discussion
These results demonstrate that melatonin has no effect on intracellular Ca2+
accumulation within neurons.  The effect of melatonin as a protective agent must be at
some other level in neurons.
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6.4. CONCLUSIONS
It has been demonstrated that application of the glutamate receptor agonists causes an
increase in intracellular Ca2+ [59].  The increase occurs almost instantaneously as the
increase in intracellular Ca2+ is used during neurotransmission under normal conditions. 
When neurons are overstimulated, rapid increases in intracellular Ca2+ concentrations
result [320].  Neurons attempt to reduce the higher than normal intracellular Ca2+
concentrations but it can take hours before intracellular Ca2+ levels are retuned to levels
that are no longer significantly higher than untreated cultures.  Mitochondria are actually
involved in the removal of Ca2+ from cells [128,129,321].
Ca2+ initiates a number of potentially neurotoxic processes within the neuron [322].  Many
of these processes involve the production of O-2@ ions.  Another major area of O
-
2@
production is the mitochondrion.  Electron “leakage” occurs during the electron transport
chain because the gradient has been disrupted by the Ca2+ accumulation within the
mitochondria.  This results in the production of O-2@.  The large influx of Ca
2+ into the cell
also  requires active transport to remove the ions out of the neuron [323], which
necessitates the production of ATP in the mitochondria.  While the electron gradient is
disrupted on the mitochondrial membrane, ATP cannot be produced very effectively
[324].  This results in a drop in ATP levels and the further generation of O-2@ by the
mitochondria.
In Chapters 4 and 5, melatonin had been shown to protect neurons against neurotoxicity
induced by certain glutamate receptor agonists.   Melatonin does not act at the glutamate
receptors, so an intracellular mode of action is envisaged.  Ca2+ being the first neurotoxic
step following excessive agonist stimulation has been investigated, but melatonin does
not act at this level.  An increase in intracellular Ca2+ concentrations is one of the first
undesirable events that occur in a neuron following excessive stimulation by the EAA’s
[325].  Any method that could inhibit the rapid rise in intracellular Ca2+ accumulation
would therefore be potentially protective to neurons.  Melatonin does not appear to have
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any influence on Ca2+ accumulation, so any neuroprotection afforded by melatonin must
be at a further stage along the EAA-induced neurotoxic cascade.  It was therefore
decided to investigate whether melatonin was able to scavenge the potentially neurotoxic
O-2@ produced following Ca
2+ stimulation.
CHAPTER 7
ROLE OF MELATONIN AS A SUPEROXIDE ANION
SCAVENGER
7.1. INTRODUCTION
Reactive oxygen species are continually generated intracellularly in aerobic organisms. 
If allowed to react uncontrollably these are capable of causing extensive damage to
DNA, carbohydrates, proteins and lipids within the cell [326].
Cells possess highly effective antioxidant defence mechanisms to protect neurons
against free radical species [327].  These protective mechanisms can be classified into
two main categories [146], namely the enzymatic defence mechanisms, which include
superoxide dismutase, and the non-enzymatic cellular antioxidants, which include
Vitamins A and E.  Under normal conditions these defence mechanisms are quite
capable of protecting neurons, but under conditions of excessive ROS production, these
mechanisms may not be able to cope and neurotoxicity may result [139].
ROS are generated by the addition of a single electron to O2.  The radical is usually
generated as a result of electron “leakage” from the electron transport chain located in
the mitochondria [143], and by activation of certain enzymes.
Overstimulation of EAA receptors results in the influx of Ca2+, Na+, and K+ into neuron [8]. 
As these ions cause a change in the osmotic pressure, the neuron attempts to pump the
ions out of the cell.  The transport of ions is an active process that requires energy. 
Mitochondria are forced to produce more ATP, and so there is a chance of greater
electron leakage.  Enzymes such as xanthine dehydrogenase [324] and nitric oxide
synthetase [167] are also activated by Ca2+, so the influx of Ca2+ into the neurons results
in greater activity of these enzymes.  One of the by-products of the activities of these
enzymes is the production of O-2@.
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Superoxide anions can be very reactive and can lead to neurodegeneration [328].  It has
been proposed [310] that the EAA’s are neurotoxic because they lead to increased
production of O-2@.  Melatonin has been shown to reduce neurodegeneration under a
number of different conditions that involve the production of O-2@ [234].  As melatonin did
not affect intracellular Ca2+ ccumulation in neurons following an EAA insult, it was
decided to investigate whether melatonin could affect the production of the potentially
neurotoxic O-2@ ions in neurons.
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7.2. EFFECTS OF GLUTAMATE, N-METHYL-D-ASPARTATE,
QUINOLINIC ACID AND KAINIC ACID ON SUPEROXIDE
ANION FORMATION IN RAT FOREBRAIN HOMOGENATE
7.2.1. Introduction
Previous experiments (see Chapter 3)  had demonstrated that the glutamate receptor
agonists were able to cause neurodegeneration.  One mechanism that had been
proposed for these neurotoxic effects was the production of O-2@. It was therefore
decided to investigate whether incubating homogenised rat forebrain with increasing
concentrations of the glutamate receptor agonists caused an increase in O-2@ production.
The nitro-blue tetrazolium (NBT) assay, which is generally accepted [304] to be a reliable
method for assaying for superoxide anions, was used.  The assay involves the reduction
of the NBT ion to the insoluble diformazan form, which can be extracted with glacial
acetic acid.
7.2.2. Materials and Methods
7.2.2.1. Chemical Reagents
Nitro-blue tetrazolium and Nitro-blue diformazan (NBD) were purchased from the Sigma
Chemical Company (USA).  Glacial acetic acid was purchased from Holpro Chemical
Company (South Africa).  All other chemicals used were of the highest quality available
from commercial sources.
A 0.1% NBT solution was made by dissolving the NBT in ethanol before making up to the
required volume with Milli-Q water.  The final ethanol concentration in the incubation
flasks was less than 1.5%.
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7.2.2.2. Preparation of Standards
NBD was used as a standard.  A series of reaction tubes, each containing appropriate
aliquots of NBD dissolved in acetic acid were prepared.  A standard curve (Appendix 3)
was determined by measuring the absorbance at 20µM intervals.  The absorbance was
read at 560 nm using a Shimadzu UV-160A UV-visible recording spectrophotometer.
7.2.2.3. Preparation of Rat Forebrain Homogenate
Adult, male Wistar rats were used for the experiment.  These were cared for as
explained in section 2.2.2.2.
On the morning of the experiment, the brains were removed as described in section
2.2.2.4. The forebrains were weighed before being homogenised in ice cold 50 mM Tris-
HCl buffer (pH 7.4) in a glass homogeniser to produce a 10% (w / v) homogenate.
7.2.2.4. The Nitro-Blue Tetrazolium Assay
A modified method of Ottino and Duncan [304] was used for this assay.  To 1 ml samples
of brain homogenate, 0.4 ml of a 0.1% NBT solution and 100 µl of the relevant agonist
being tested was added and allowed to incubate for 90 minutes at 37oC. On termination
of the incubation, the suspensions were centrifuged at 3000 x g for 10 minutes.  The
supernatant was poured off and the pellet was dissolved in 2.5 ml glacial acetic acid.
The relative absorbance values were measured at 560 nm.  The amount of NBD formed
was determined from the standard curve in Appendix 3.  Final results were expressed as
µM diformazan produced / mg protein.
Protein assays were carried out as described in section 2.2.2.6, and all results were
analysed as described in section 2.2.2.8.
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7.2.2.5. Exposure of Brain Homogenate to the Different Agonists
Stock solutions were prepared so that on addition of 100 µl of agonist dissolved in Milli-Q
water, the stock solution would be diluted down to the correct incubation concentration. 
The following agonists were tested; glutamate, NMDA, QA, and KA.  Agonists were
tested at the following concentrations; 0, 0.25, 0.5, 0.75 and 1 mM.
7.2.3. Results
The results are shown in Table 7.1.  In all cases the addition of agonists to the brain
homogenate was not able to cause significant changes (P>0.05) in the production of O-2@.
7.2.4. Discussion
The production of O-2@ in rat forebrain homogenate was not significantly changed by
exposure of any of the agonists.
Although it would have been expected that the production of O-2@ w uld increase in
response to the agonist insult, this did not occur.  The most probable reason for this is
that rat forebrain homogenate was used.  If glutamate, or any of the other agonists, were
to cause an increase in O-2@ production, the process would be initiated by an increase in
intracellular Ca2+ levels.  By using homogenate, any Ca2+ control was effectively
destroyed, and so the binding of the agonists to the receptors would have had no
regulating effects.  This would explain why similar results were obtained for all of the
different concentrations of agonists used.
Because Ca2+ would have been present to initiate many of the O-2@ producing pathways,
there would still have been production of superoxide anions.  It would therefore still be
possible to investigate whether melatonin removes superoxide anions from rat forebrain
homogenate.
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Table 7.1: Diformazan produced at different agonist concentration (n = 5)
Agonist Concentration (mM) Diformazan (µM/mg Protein) SEM
Glutamate 0 75.748 1.455
Glutamate 0.25 82.534 3.511
Glutamate 0.5 84.916 4.097
Glutamate 0.75 83.756 3.669
Glutamate 1 81.636 1.956
NMDA 0 87.624 6.024
NMDA 0.25 89 6.529
NMDA 0.5 87.644 6.366
NMDA 0.75 85.996 6.507
NMDA 1 86.108 6.307
QA 0 91.778 6.788
QA 0.25 85.478 5.623
QA 0.5 83.618 6.891
QA 0.75 85.602 4.257
QA 1 83.938 3.11
KA 0 79.418 2.957
KA 0.25 75.9 4.737
KA 0.5 77.534 5.964
KA 0.75 80.674 3.806
KA 1 78.816 2.606
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7.3. MELATONIN AS A SUPEROXIDE ANION SCAVENGER IN
RAT FOREBRAIN HOMOGENATE 
7.3.1. Introduction
In the previous experiment it had been demonstrated that although the glutamate
receptor agonists did not appear to have any effect on O-2@  production, the production of
O-2@ never the less took place in the bain homogenate.
Mitochondrial dysfunction and free radical-induced oxidative damage have been
implicated in the pathogenesis of several neurodegenerative diseases, such as
Alzheimer’s Disease and Huntington’s Disease [234].  Melatonin has been suggested to
be a very powerful anti-oxidant that could protect against neurotoxicity.  It was thus
decided to investigate whether melatonin was able to act as an O-2@ cavenger in rat
forebrain homogenate.
7.3.2. Materials and Methods
7.3.2.1. Chemical Reagents
Melatonin was purchased from Sigma Chemical Company (USA).  It was dissolved in
absolute ethanol and then made up with water so that the final solution was a 50%
ethanol solution.
7.3.2.2. Experimental Protocol
Rat forebrain homogenate was prepared as in section 7.2.2.3, while the NBT assay was
performed as in section 7.2.2.4.  The only alteration was that melatonin was added
instead of 100 µl agonist.  The homogenate was treated with two different concentrations
of melatonin, viz. 100 µM and 500 µM.
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7.3.3. Results
The results are shown in Figure 7.1.  Melatonin at 100 µM was unable to cause a
significant reduction in O-2@ concentration as measured by the NBT assay.  Treatment of
the homogenate with 500 µM melatonin caused a significant reduction in the amount of
NBD produced.
7.3.4. Discussion
These results demonstrate that at high concentrations, melatonin was able to act as a
superoxide anion scavenger. The fact that melatonin was only able to protect when used
at high concentrations, demonstrates that melatonin was not a potent O-2@ scavenger. 
Melatonin (500 µM) was only able to reduce the amount of diformazan produced by
13.2% when compared to untreated controls.
These results show that although melatonin is able to act as an antioxidant in forebrain
homogenate, is has only limited neuroprotective effects, and must be present in high
concentrations.
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Figure 7.1: Effect of melatonin on production of superoxide anions in rat brain
homogenate.  Values represent the mean ± SEM (n = 5) (ns P>0.05 , ** P<0.01 in
comparison to zero control)
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7.4. SUPEROXIDE ANION SCAVENGING PROPERTIES OF
MELATONIN IN NEURONAL CELL CULTURES
7.4.1. Introduction
Previous experiments using rat forebrain homogenate had demonstrated that melatonin
was able to scavenge O-2@ when applied in high doses, and that the glutamate receptor
agonists had no effect on O-2@  production.  It was thought that the reason that the
agonists had no effect was because the integrity of the neurons had been disrupted by
homogenisation.
It was therefore decided to investigate the effects of co-treatment of neuronal cell
cultures with the same glutamate receptor agonists and melatonin.  It was hoped that this
method would give an indication of the degree to which O-2@ production was affected by
the various agonists, and also demonstrate whether melatonin had any O-2@ scavenging
properties.
7.4.2. Methods and Materials
7.4.2.1. Chemical Reagents
Cell culture media preparation was carried out as explained in section 3.2.2.2.  The
agonists were prepared in sterile Milli-Q water as described in 7.2.2.5, and melatonin was
prepared as described in 7.3.2.1.
7.4.2.2. Preparation of Neuronal Cultures
Primary neuronal cultures were established as explained in section 3.2.2.3.
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7.4.2.3. Experimental Procedure
A modified method of Ottino and Duncan [304] was used to measure O-2@ production. 
Ten day old cultures were washed with 3 ml of HBSS, after which 3 ml of fresh MEM was
placed in each culture flask.  A 1.2 ml aliquot of NBT was added to each flask, after
which the cultures were treated as shown in Table 7.2.
After a 3 hour incubation at 37oC, the cells were scraped off the surface of the culture
flasks using a cell scraper.  The media containing the suspended cells was poured into
centrifugation tubes.  Five hundred microlitres of the cell suspension was kept for
enumeration using a haemacytometer, while the rest was centrifuged for 10 minutes at
4000 x g.  The pellets were resuspended in 1ml of glacial acetic acid.
The absorbance of the extracts was measured at 560 nm, and converted to µM
diformazan using the NBD standard curve (Appendix 3).  Final results were expressed
as µM diformazan / 104 cells.  All results were analysed as described in section 2.2.2.8.
7.4.3. Results
The effect of various glutamate receptor agonists on superoxide anion production was
first investigated.  All of the neuronal cultures incubated with the agonists showed
significant increases in the production of O-2@ (see Figure 7.2).  QA caused the greatest
increase, with O-2@ production being increased 14.6 fold.  Glutamate caused the least
increase in O-2@ production, but it still increased production 8.1 fold.
The effectiveness of melatonin as a O-2@ scavenger varied depending on the agonist
used.  Melatonin was able to protect against glutamate (Figure 7.3) and NMDA (Figure
7.4) induced O-2@ production when used at 500 µM.  Low doses of melatonin offered no
significant protection against O-2@.  Melatonin was able to offer significant protection
against QA (Figure 7.5) at both high and low concentrations.   Melatonin did not appear
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to offer any reduction in KA (Figure 7.6) induced O-2@ production with either of the doses
used.
Table 7.2: Experimental groups used to measure superoxide
anion production in primary neuronal cell cultures.
Group Agonist (350 µM) Melatonin Concentration (µM)
1 Control (Zero) 0
2 Glutamate 0
3 Glutamate 100
4 Glutamate 500
5 NMDA 0
6 NMDA 100
7 NMDA 500
8 QA 0
9 QA 100
10 QA 500
11 KA 0
12 KA 100
13 KA 500
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Figure 7.2: Effect of various glutamate receptor agonists on superoxide anion production
in primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3) (*** P<0.001
in comparison to zero control)
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Figure 7.3: Effect of various concentrations of melatonin on glutamate-induced superoxide
anion production in primary neuronal cell cultures.  Values represent the mean ± SEM. (n
= 3) (ns P> 0.05; * P< 0.05 in comparison to zero control)
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Figure 7.4: Effect of various concentrations of melatonin on NMDA-induced superoxide
anion production in primary neuronal cell cultures.  Values represent the mean ± SEM. (n
= 3) (** P< 0.01 in comparison to zero control)
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Figure 7.5: Effect of various concentrations of melatonin on QA-induced superoxide anion
production in primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3)
(*** P< 0.001 in comparison to zero control)
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Figure 7.6: Effect of various concentrations of melatonin on KA-induced superoxide anion
production in primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3)
(ns P> 0.05 in comparison to zero control)
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7.4.4. Discussion
All of the agonists increased O-2@ production in neuronal cells.  The increase in O
-
2@
production could be caused by the increased intracellular Ca2-   brought on by
overstimulation of the glutamate receptors.  O-2@ is toxic to neurons [310] and could lead
to neuronal death.
Melatonin has been reported [234] to be an effective O-2@ scavenger.  This experiment
investigated the O-2@ scavenging properties of melatonin brought about by the application
of agonists.  Melatonin was able to significantly scavenge O-2@ when applied at 500 µM to
neurons treated with glutamate.  Low doses (100 µM) of melatonin caused no significant
reduction in O-2@ levels.  Melatonin was also able to significantly reduce the amount of O
-
2@
able to react with NBT in neurons treated with NMDA and QA.  Both of these agonists act
at the NMDA receptor.  Melatonin was particularly effective at scavenging O-2@ from
neurons treated with QA.  This is significant as QA caused the greatest increase in O-2@
levels when compared to controls.  Melatonin did not appear to offer protection against
KA-induced O-2@ production.
In no case did melatonin bring O-2@ levels down to those of control cultures that did not
receive treatment.  The fact that melatonin was able to reduce O-2@ lev ls in neurons
treated with three of the agonists, and not in cultures treated with KA, is also of interest. 
More studies  would need to be carried out to investigate the exact mechanism that was
occurring.
Superoxide Anions 161
7.5. CONCLUSION
These results demonstrated that melatonin was able to reduce O-2@ levels in rat brain
homogenate.  High doses of melatonin (500 µM) were able to significantly reduce O-2@
levels, although the effect appeared to be rather limited.
Because the neurons had been disrupted when working with rat brain homogenate, it
was found that addition of the agonist had no effect on O-2@ production.  It was therefore
decided to investigate the effect of the agonists and melatonin on primary neuronal
cultures.
The agonists tested, all caused a significant increase in O-2@ production.  QA caused the
largest increase in O-2@ production.  As O
-
2@ is a very neurotoxic agent, this could explain
the reason why QA was also the most neurotoxic agonist in the tests carried out in
Chapter 3.
Melatonin was able to offer some protection against O-2@ production by scavenging the 
O-2@ in most cultures.  High doses (500 µM) of melatonin were much more effective than
the low (100 µM) doses at scavenging O-2@.  With glutamate treated neurons,  500 µM
melatonin was able to more than halve the amount of O-2@ able to interact with NBT, while
in the QA treated neurons, 500 µM melatonin cut the amount of O-2@ that reacted with
NBT down to a third.  Melatonin was however not able to offer any significant O-2@
scavenging activity with KA treated neurons.  The reasons for this are not clear, and
more investigations are necessary to determine why melatonin was ineffective against
one agonist, but effective against the others.
In conclusion, it was shown that the glutamate receptor agonists cause a large increase
in O-2@ production.  Melatonin was able to scavenge O
-
2@ and was able to significantly
lower O-2@ concentrations in rat brain homogenate.  In primary neuronal cultures, 500 µM
melatonin was able to significantly reduce the amount of free O-2@ abl  to react with NBT
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in cultures treated with glutamate, NMDA and QA.  Unfortunately, melatonin did not
appear to be able to reduce the amount of O-2@ that was able to interact with NBT in KA
treated cultures.
CHAPTER 8
EFFECT OF GLUTAMATE RECEPTOR AGONISTS AND
MELATONIN ON LIPID PEROXIDATION
8.1. INTRODUCTION
In all living cells, the cell membrane separates the cell interior from the external
environment, and also functions to compartmentalise the internal structures of the cell. 
Membranes are not static boundaries that segregate regions, but are dynamic systems
responsible for among other things; the production of ATP, the selective transport of
substances into and out of the cells, the binding of regulatory agents (such as hormones
and growth factors), and the binding of neurotransmitters that mediate the transmission
of nerve impulses [329].
Membranes are composed primarily of protein and lipid molecules.  The fluid mosaic
model of membrane structure proposed by Singer and Nicholson [174], is the accepted
model of membrane structure.  Membranes are believed to consist of a lipid bi-layer
containing a mixture of proteins and carbohydrates.
Changes in membrane fluidity through physical and chemical disturbances, e.g. 
oxidative stress, can cause changes to neuronal characteristics, and the activities of the
transport proteins.  Neuronal membranes are especially vulnerable to free radical
mediated oxidative stress, since the brain consumes 20% of the total body oxygen, is
relatively deficient in protection mechanisms such as glutathione and vitamin E, and
contains large amounts of polyunsaturated lipids [330].  In Chapter 7, the glutamate
receptor agonists were shown to greatly increase O-2@ production. The oxidative
destruction of polyunsaturated fatty acids is known as lipid peroxidation, and is extremely
damaging as a result of the self-perpetuating chain reactions they cause [310].  Since
some free radical production is inevitable in cells, several enzymatic and non-enzymatic
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defence mechanisms have evolved to protect cells.  Any alterations though, in either the
defence mechanisms or the production of free radicals, could upset this balance and
lead to neurotoxicity.
This series of experiments were conducted to investigate the effect of the glutamate
receptor agonists; glutamate, NMDA, QA and KA, on lipid peroxidation levels.  The use
of melatonin as a free radical scavenger was also investigated.  The thiobarbaturic acid
(TBA) assay was used to determine lipid peroxidation.  The principal of the experiment
involves the reaction of malondialdehyde (MDA) and 4-hydroxyalkenals (4-HDA) with
TBA to yield a pink complex which can be extracted with butanol and read at 532 nm. 
MDA and 4-HDA are degraded lipid products from cell membranes, and are taken as
reliable indicators of oxidative stress [140,331].
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8.2. EFFECT OF GLUTAMATE, NMDA, QA AND KA ON LIPID
PEROXIDATION IN RAT FOREBRAIN HOMOGENATE
8.2.1. Introduction
The O-2@ can react with membranes to set off membrane destroying reactions [8].  As
membranes are vital for proper cell function, any damage to membranes could be toxic
to neurons.   Among the products of the membrane destroying reactions are MDA and 
4-HDA [140].
The following experiment was conducted to investigate the effects of the various
glutamate receptor agonists on lipid peroxidation in rat forebrain homogenate.
8.2.2. Materials and Methods
8.2.2.1. Chemical Reagents
Butylated Hydroxytoluene (BHT) and 2-Thiobarbaturic acid (TBA) were purchased from
the Sigma Chemical Company (USA).  1,1,3,3-Tetramethoxypropane was obtained from
Fluka AG (Switzerland).  Trichloroacetic Acid (TCA) was obtained from Saarchem (Pty)
Ltd (South Africa), while butanol was supplied by Holpro Chemical Company (South
Africa).
BHT was dissolved in absolute ethanol, while all the other chemicals were dissolved in
Milli-Q water.
All agonists were prepared as described in 7.2.2.5.
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8.2.2.2. Preparation of Standard Curve
1,1,3,3-Tetramethoxypropane was used as a standard.  A series of reaction tubes, each
containing appropriate aliquots of water and standard solution were prepared with Milli-Q
water to a final volume of 1 ml.  A calibration curve was generated by measuring the
absorbance at 5 nmole intervals.  The absorbance was read at 532 nm using a
Shimadzu UV-160A UV-visible recording spectrophotometer and plotted against the
molar equivalent weight of MDA in the complex assayed (see Appendix 4).
8.2.2.3. Incubation of Rat Brain Homogenate with the Glutamate Receptor
Agonists
Rat forebrain homogenate was prepared as explained in section 7.2.2.3.  The
homogenate was frozen in liquid nitrogen and stored at -70oC until used in the assay.  All
samples were used within 14 days of the homogenate preparation.  Test samples
revealed that storage of the homogenate did not alter lipid peroxidation levels compared
to fresh brains.
A modified method of the TBA assay as described by Ottino [288] was used to determine
lipid peroxidation.
Rat brain homogenate (1 ml) contained varying concentrations of the glutamate agonists
(0 - 1 mM) was incubated in a shaking water bath for 1 hour at 37oC.  At the end of the
incubation, 0.5ml BHT (0.5g / l in absolute ethanol) and 1 ml 25% TCA were added to the
mixture.  The samples were centrifuged at 2000 x g for 20 minutes at 4oC to remove
insoluble proteins.  Following centrifugation, 2 ml of protein free supernatant was
removed from each tube, and a 0.5 ml aliquot of 0.33% TBA was added to this fraction. 
All tubes were heated for an hour at 95oC in a water bath.  After cooling, the TBA-MDA
complexes were extracted with 2 ml butanol.  The absorbance was read at 532 nm and
MDA levels were determined from the standard curve generated from 1,1,3,3-
tetramethoxypropane.  Final results were expressed as nmoles MDA / mg protein.
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Protein estimation was performed as described in section 2.2.2.6, and all results were
analysed as described in section 2.2.2.8.
8.2.3. Results
The results obtained are shown in Table 8.1.  QA was the only agonist that caused a
significant increase (P<0.001) in lipid peroxidation, when compared to controls. 
8.2.4. Discussion
Increasing concentrations of glutamate, KA, and NMDA up to 1 mM had no significant
effect on MDA production.  QA was the only one of the agonists that caused a significant
increase in MDA production.
As in Chapter 7, where increasing concentrations of the agonists had no effect on the
production of O-2@ in rat brain homogenate, most of the agonists had no effect on MDA
production.  This could be because the experiment used disrupted cells, where receptor
mediated control of intracellular processes would no longer have been active.   An
increase in lipid peroxidation would have been expected from the agonists, because the
previous experiment had demonstrated that the glutamate agonist caused an increase in
O-2@ production.
These results are similar to those of Rios and Santamaria [332] who found that
glutamate and KA were not able to cause significant increases in lipid peroxidation using
rat brain homogenate but, QA was found to be a potent lipid peroxidant in rat brain
homogenate.  Melchiorri et al [191] were able to get KA to induce lipid peroxidation in rat
brain homogenate.  They were however, using far higher KA concentrations than were
used in either the present experiment, or by Rios and Santamaria [332].
QA caused lipid peroxidation in a dose dependent manner.  The reason for this is not
clear, but it is possible that QA was acting as a pro-oxidant, thus initiating lipid
Lipid Peroxidation 168
peroxidation.  Štipek et al [333] have however shown that the effect of QA on lipid
peroxidation in the rat brain depends on iron.  QA is able to chelate ferrous (but not
ferric) ions to form a complex, and it is this complex that stimulates lipid peroxidation. 
The results suggest that QA does not have a direct peroxidative effect, but that it
modulates lipid peroxidation via its interaction with Fe2+.  This would explain why only QA
was able to stimulate lipid peroxidation when using brain homogenate.
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Table 8.1: Amount of MDA Produced At Various Agonist Concentrations
Agonist Concentration (mM) MDA Produced (nmoles / mg Protein) SEM
Glutamate 0 1.285 0.031
Glutamate 0.25 1.293 0.078
Glutamate 0.5 1.226 0.066
Glutamate 0.75 1.034 0.038
Glutamate 1.0 1.263 0.053
NMDA 0 0.92 0.002
NMDA 0.25 1.039 0.017
NMDA 0.5 0.856 0.051
NMDA 0.75 0.964 0.043
NMDA 1.0 0.882 0.08
QA 0 1.176 0.037
QA 0.25 2.15 0.049
QA 0.5 3.147 0.113
QA 0.75 3.514 0.11
QA 1.0 4.245 0.047
KA 0 0.851 0.027
KA 0.25 0.911 0.045
KA 0.5 0.938 0.036
KA 0.75 0.948 0.035
KA 1.0 1.027 0.031
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8.3. EFFECT OF MELATONIN ON QUINOLINIC ACID INDUCED
LIPID PEROXIDATION IN RAT BRAIN HOMOGENATE
8.3.1. Introduction
Experiment 8.2. demonstrated that QA was the only one of the agonists tested that
induced lipid peroxidation in rat homogenate.  Although neither the exact mechanism,
nor why QA exclusively caused an increase in lipid peroxidation was known, it was
speculated that the induction of lipid peroxidation must involve free radicals.
Melatonin is a very effective free radical scavenger, and so it was decided to investigate
whether melatonin could reduce QA induced lipid peroxidation in rat brain homogenate.
8.3.2. Materials and Methods
Experiments were conducted exactly as in experiment 8.2, except that only QA was
used.  In addition, melatonin was added at various concentrations (0 - 1mM) at each QA
concentration.  Melatonin was prepared by dissolving it in absolute ethanol, and
subsequently diluting it with Milli-Q water so that the final ethanol concentration in the
brain homogenate was 0.5%.
8.3.3. Results
Co-treatment of brain homogenate with QA and increasing melatonin concentrations
resulted in an overall decline in MDA production.  Melatonin at a concentration of 1 mM
reduced the MDA formed to ±2.25 nmoles / mg protein, irrespective of how high the MDA
concentration had reached in the absence of melatonin in each of the QA treated
samples.  These results suggest that melatonin significantly decreases the basal level of
lipid peroxidation compared, to controls in a concentration dependent manner (see
Figure 8.1).
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8.3.4. Discussion
The results demonstrate that QA-lipid peroxidation of rat whole brain homogenate is
markedly inhibited by melatonin in a concentration dependent manner.
Melatonin was not however able to decrease MDA production to levels attained in
samples without QA.  Thus, although melatonin is effective at lowering lipid peroxidation,
it is not able to protect completely against QA induced neurotoxicity. 
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Figure 8.1:  Effect of melatonin on quinolinic acid (0-1mM)-induced increase in
MDA concentration in homogenate of whole rat brain.  Values represent the
mean ±SEM (n=6) (nsP>0.05; *P<0.05; **P<0.01; ***P<0.001 in comparison to
0 melatonin control)
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8.4. EFFECT OF MELATONIN ON GLUTAMATE AGONIST
INDUCED LIPID PEROXIDATION IN NEURONAL CELL
CULTURES
8.4.1. Introduction
In the previous two experiments, rat forebrain homogenate had been used to test the
effect of melatonin and the various agonists on lipid peroxidation.  As in Chapter 7, it was
found that rat forebrain homogenate was not the most effective medium to investigate
the effect of agonists.  The neurons had been disrupted, and so any effect caused by the
agonist binding to membrane receptors would not cause physiological changes in the
cell.
It was therefore decided to investigate the effect of the various glutamate agonists on
neuronal cell cultures.  Neuronal cultures offer an opportunity to work with uniform whole
cells.  Any intracellular changes that result from the binding of the agonist to the
receptors could therefore be investigated.  The effect of melatonin on lipid peroxidation
was also investigated.
8.4.2. Materials and Methods
8.4.2.1. Chemical Reagents
Cell culture reagents were prepared as explained in section 3.2.2.2. The glutamate
agonists were prepared in Milli-Q water, and melatonin was prepared as described in
7.3.2.1. 
Chemicals used for the TBA assay were prepared as described in 8.2.2.1.
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8.4.2.2. Preparation of Primary Neuronal Cultures
Primary neuronal cultures were established as explained in section 3.2.2.3.
8.4.2.3. Experimental Procedure
A modified method of Ottino [288] was used to measure lipid peroxidation.  Seven to ten
day old cultures were washed with 4 ml of HBSS, after which 3 ml of fresh MEM
containing the agonists and melatonin (see Table 8.2) was placed in each culture flask.
Cultures were returned to the 37oC incubator for 20 minutes.  These were then washed
twice with HBSS before the addition of 3 ml of fresh MEM.  The neurons were incubated
at 37oC for a further 18 hours.  At the end of this time, the neurons were scraped off the
surface of the culture flasks using a cell scraper.  The media containing the suspended
cells was poured into centrifugation tubes and centrifuged at 4000 x g for 10 minutes. 
The cells were then resuspended in 1.1 ml of 50mM Tris HCl (pH 7.4).  A 100 µl aliquot
was removed for later enumeration using a haemacytometer.  To the 1 ml of sample that
remained, 0.5 ml BHT and 1 ml of 0.25% TCA were added.  The suspension was
vortexed and then centrifuged at 2000 x g for 20 minutes at 4oC.  A 2 ml aliquot of the
protein free supernatant was removed, and 0.5 ml of 0.33% TBA was added.  The
solution was heated for 1 hour at 95oC.  After cooling, the TBA-MDA complexes were
extracted with 2 ml butanol.  The absorbance was read at 532 nm, and the MDA levels
were determined from the standard curve generated from 1,1,3,3,-tetramethoxypropane. 
Final results were expressed as nmoles MDA / 106 cells.  All results were analysed as
described in section 2.2.2.8.
Lipid Peroxidation 175
Table 8.2: Experimental groups used to measure lipid peroxidation in cell culture.
Group Agonist (500 µM) Melatonin Concentration (µM)
1 Control (Zero) 0
2 Glutamate 0
3 Glutamate 100
4 Glutamate 1000
5 NMDA 0
6 NMDA 100
7 NMDA 1000
8 QA 0
9 QA 100
10 QA 1000
11 KA 0
12 KA 100
13 KA 1000
8.4.3. Results
The results demonstrate that all the agonists except glutamate caused a significant
increase in lipid peroxidation (see Figure 8.2) when compared to untreated cultures.  QA
and NMDA caused the most significant increases in lipid peroxidation, with MDA
production increasing more than 3.5 fold in QA treated cultures when compared to
controls.  KA also caused a significant increase in lipid peroxidation, with just less than a
2 fold increase occurring.
In all cases, melatonin was able to significantly reduce lipid peroxidation (see Figures
8.3 - 8.6).  Co-treatment with 1 mM melatonin at the same time as 500 mM glutamate or
KA resulted in MDA concentrations even lower than those for control cultures.  NMDA
and QA, which caused the largest increase in lipid peroxidation, were not able to induce
lipid peroxidation to the same levels in the presence of melatonin.  A 1 mM dose of
melatonin reduced MDA levels to slightly above those of untreated control cultures.
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8.4.4. Discussion
Each of the agonists investigated was able to increase MDA levels in neuronal cell
cultures, although glutamate did not cause a significant increase.  KA was able to almost
double the production of MDA, while NMDA and QA caused the most significant
increases in lipid peroxidation.  Both of these agonists act at the NMDA receptor.  The
fact that both of these agonists act at the same receptor demonstrates, that
overstimulation of the NMDA receptor in particular could make neurons more susceptible
to neuronal degeneration caused by lipid peroxidation.
Melatonin is a powerful free radical scavenger.  Lipid peroxidation results from the
destruction of cell membranes by free radicals.  By removing free radicals, melatonin
could offer protection to the neurons.  In this set of experiments, it has been clearly
shown that the presence of melatonin in the culture flasks, while the neurons were being
subjected to the agonist attack, significantly reduces the amount of lipid peroxidation that
occurs.  In all cases, except for KA, doses as low as 100 µM melatonin significantly
reduced MDA levels when compared to cultures untreated with melatonin.  At a dose of
1 mM melatonin, lipid peroxidation had been brought down to levels below that of control
cultures for glutamate and KA treated cultures, while MDA levels were only slightly higher
than control values for NMDA and QA treated cultures.
The glutamate agonists caused a significant increase in MDA production in all cultures
tested for lipid peroxidation.  The presence of melatonin in the culture flasks, together
with the agonists, during the incubation, was able to cause a significant reduction in lipid
peroxidation.  Melatonin is therefore a very potent inhibitor of neuronal lipid peroxidation.
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Figure 8.2: Effect of various glutamate receptor agonists (500nM) on MDA production in
primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3) (nsP>0.05;*
P<0.05; *** P<0.001 in comparison to zero control)
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Figure 8.3: Effect of various concentrations of melatonin on glutamate-induced MDA
production in primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3) 
(* P< 0.05 in comparison to zero control)
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Figure 8.4: Effect of various concentrations of melatonin on NMDA-induced MDA
production in primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3) 
(* P< 0.05; ** P< 0.01 in comparison to zero control)
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Figure 8.5: Effect of various concentrations of melatonin on QA-induced MDA production
in primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3)(** P< 0.01
in comparison to zero control)
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Figure 8.6: Effect of various concentrations of melatonin on KA-induced MDA production
in primary neuronal cell cultures.  Values represent the mean ± SEM. (n = 3) (ns P> 0 05;
** P< 0.01 in comparison to zero control)
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8.5. CONCLUSION
These results demonstrate that QA was the only agonist able to induce lipid peroxidation
in rat forebrain homogenate.  The reason that lipid peroxidation may not have been
induced by the other agonists, is that disrupted cells were used.  Lipid peroxidation
occurs as a result of a free radical attack on a lipid membrane.  By disrupting the
neurons there may not have been receptor based control over free radical production. 
Another reason why there may not have been an increase in lipid peroxidation is that
agonists were only used up to a concentration of 1 mM.  Melchiorri et al [191] have
demonstrated that melatonin is able to protect against KA-induced lipid peroxidation in a
concentration dependent manner.  These workers used a KA concentration of 12 mM. 
QA is a more potent excitotoxin than KA, and is thus able to produce marked increases
in lipid peroxidation at concentrations as low as 100 µM.
Even in the presence of the potent excitotoxin, QA, melatonin was able to protect against
lipid peroxidation.  This was demonstrated by the significant reduction in the production
of MDA in QA treated brain homogenate.  Melatonin was however not able to decrease
MDA production to levels attained in samples without QA.
It was also demonstrated that all of the agonists except glutamate caused a significant
increase in lipid peroxidation in primary neuronal cell cultures.  When incubated in the
presence of 500 µM agonist and 1 mM melatonin, the agonists had little to no effect on
lipid peroxidation levels.  In fact, lipid peroxidation was lower in glutamate and
KA-induced samples that were co-treated with 1 mM melatonin, than in untreated
controls.
Melatonin has been shown to be a very potent free radical scavenger in previous
experiments.  Tan et al [3] showed that melatonin is a more efficient hydroxyl radical
scavenger than either glutathione or mannitol, within an artificial hydroxyl radical
generating system.  Pieri et al [299] showed that melatonin was the most effective agent
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at detoxifying the peroxyl radical when compared to trolox (water soluble vitamin E),
ascorbic acid and glutathione.  Subsequently, Tan et al [183] demonstrated that
melatonin is able to protect against the DNA damage in vivo caused by the carcinogen
safrole.  
Melatonin has been shown to be protective against a number of other toxins including;
the prooxidative agent carbon tetrachloride [189], the excitatory amino acid glutamate
[295], the apoptosis promoting agent dexamethasone [334], and nitric oxide synthase [6]. 
This data demonstrates that there is a definite role for melatonin in the antioxidative
defence system of an organism.
It is therefore proposed that melatonin reduces lipid peroxidation in both primary
neuronal cultures and forebrain homogenate by removing free radicals from the solution. 
By removing free radicals, melatonin would be protecting the neuronal membranes,
which are very susceptible to free radical attack. 
CHAPTER 9
EFFECT OF MELATONIN AND VARIOUS GLUTAMATE
RECEPTOR AGONISTS ON NITRIC OXIDE SYNTHASE
ACTIVITY
9.1. INTRODUCTION
Nitric oxide is a unique molecule that is involved in many biological processes.  NO is
able to interact with the epithelium of blood vessels to mediate blood flow [164], is used
by macrophages as an immune defence mechanism, and is a neurotransmitter of central
and peripheral nervous systems [161].  Neuroscientists regard NO as a highly reactive
molecule, owing to its short half-life (3 - 6 seconds) [161].
NO influences neurotransmitter release [335], by augmenting the phosphorylation of
synaptic vesicle proteins associated with neurotransmitter release.  This is thought to
occur through cGMP activation of cGMP-dependent-protein kinases.  NO is known to
play a role in NMDA-receptor mediated neurotransmitter release, as NOS inhibitors block
NMDA-receptor mediated neurotransmitter release [336].  After activation of the NMDA
receptor [92], L-arginine is converted to NO by nitric oxide synthase.  This enzyme has to
interact with a number of co-factors to be effective.  NOS must first bind to calmodulin,
while FAD, Ca2+, NADP+ and tetrahydrobiopterin must also be present for the enzyme to
be active in neuronal cells [167].
NOS can induce neurotoxicity in one of two ways.  When NO is present in large
concentrations, it can initiate a neurotoxic cascade.  NO mainly kills neurons via its
conversion to peroxynitrite [5,142].  NO interacts with the superoxide ion to form the
peroxynitrite radical, which is highly toxic to neurons.
Apart from this, in the absence of the L-arginine substrate, NOS is able to produce O-2@
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and hydrogen peroxide in substantial quantities [161].  This is especially relevant to
neuronal cells as the rate of NADPH oxidation in the neuronal isoform is primarily
influenced by the binding of a Ca2+-c lmodulin complex to the NOS, and not by
L-arginine concentrations.  An increase in intracellular Ca2+ would allow more 
Ca2+-calmodulin complexes to form, and so more NOS would be induced into action. 
This could result in greater NO and O-2@ production, both of which are highly toxic
compounds to neurons.
Melatonin has been shown to be highly effective in removing O-2@ from brain
homogenate, and so could offer neuroprotection.  Melatonin has also been shown to be
a peroxynitrite scavenger [173].  Recently, Pozo et al [6] demonstrated that melatonin
was able to inhibit NOS activity.  It was therefore decided to investigate this on rat
forebrain homogenate.  
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9.2. EFFECT OF MELATONIN ON NITRIC OXIDE SYNTHASE
ACTIVITY
9.2.1. Introduction
The enzyme NOS converts L-arginine to L-citrulline.  NO is the main product of the
reaction, although O-2@ and other free radicals may also be produced.  The rate of the
reaction is controlled by a Ca2+ / calmodulin complex that interacts with NOS to cause a
conformational change that results in NOS becoming active.
The experiment was conducted to determine whether the presence of melatonin in rat
forebrain homogenate had any effect on NOS activity.
9.2.2. Materials and Methods
9.2.2.1. Chemical Reagents
L-citrulline, DL-dithiothreitol, (6R)-5,6,7,8-tetrahydrobiopterin dihydrochloride,
hypoxanthine-9-$-D-arabinofuranoside, BSA, Dowex -50W (50X8-100) and L-arginine
were purchased from Sigma Chemical Company (USA).  L-[U-14C] Arginine
monochloride (50 µCi / ml) was purchased from Amersham International (England). 
Flavin adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide phosphate
(NADP) were purchased from Boehringer Mannheim (Germany).  N-[2-hydroxyethyl]
piperazine-N’-2-hydroxypropanesulfonic acid (HEPES), EDTA and Tris were obtained
from Unilab (South Africa).  All other chemicals were purchased from normal commercial
sources and, were of the highest quality available.
Homogenisation buffer consisted of 25 mM Tris-HCl buffer (pH 7.4) containing 1 mM DL-
dithiothreitol.
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Incubation buffer (pH 7.6) consisted of the following (concentration is final once added to
homogenate and NADP); 25 mM Tris-HCl Buffer, 1 mM DL-dithiothreitol, 30 µM (6R)-
5,6,7,8-tetrahydrobiopterin dihydrochloride, 10 µM FAD, 0.5 mM hypoxanthine-9-$-D-
arabinofuranoside, 0.5 mg / ml BSA, 0.1 mM CaCl2, 10 µM L-arginine and 40 nM
3H-arginine.
HEPES buffer consisted of 0.1 M HEPES, 10 mM EDTA, and 0.175 mg / ml L-citruline.
9.2.2.2. Preparation of Brain Homogenate
Adult, male Wistar Rats that had been housed as described in section 2.2.2.2. were
used in this study.  On the day of the experiment, the animals were sacrificed and their
brains were removed using the method described in section 2.2.2.4.
The brains were placed in ice-cold homogenisation buffer.  All subsequent procedures
were carried out at 0 - 4oC.  The forebrain was separated from the cerebellum, and
placed in a vial.  Each forebrain was finely chopped and 2 ml of homogenisation buffer
was added, before the homogenate was sonicated (6 x 10 seconds) using a VibracellTM
sonicator.  The crude homogenate was centrifuged for 5 minutes at 1000 x g, and the
aliquots of supernatant were either stored at -20oC for protein determination (see section
2.2.2.6), or used immediately to measure NOS activity.
9.2.2.3. NOS Activity Assay
Total NOS activity (soluble and membrane bound isoforms) was measured using a
modified method of Bredt and Snyder [337].  The final incubation volume was 100 µl, and
consisted of 10 µl crude homogenate, 80 µl of pre-warmed incubation buffer and 10 µl of
(1 mM final) NADP to initiate the reaction.  The reaction vial was incubated at 37oC for
30 minutes.  Control incubations were performed by the omission of NADP from the
solution.  The reaction was terminated by the addition of 400µl of ice-cold HEPES buffer. 
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The reaction mixture was poured into a disposable beaker containing 1.5 ml of Dowex -
50W ion exchange resin at pH 7.0.  To this was added 1 ml of Milli-Q water.  The cocktail
was mixed together and the Dowex was allowed to settle at the bottom of the beaker.  An
850 µl aliquot of solution, containing no Dowex, was removed and added to 3 ml of liquid
scintillation cocktail.  After 24 hours the radioactivity in the vial was measured using a
Beckman Liquid Scintillation Counter.  All radioactivity was expressed as pmoles
L-14C-citrulline produced / mg protein / minute.
Where melatonin or the glutamate receptor agonists were used, these were mixed into
the incubation buffer at the required concentrations.
Results were analysed as explained in section 2.2.2.8.
9.2.3. Results
The results obtained (see Figure 9.1) demonstrate that melatonin causes a significant
reduction in NOS activity.  A 100 µM dose of melatonin caused a 13.3 % decrease in
NOS activity.
In experiments conducted to see if the presence of 350 µM of each of the glutamate
agonists caused (see Table 9.1) any increase in NOS activity, no significant difference 
(P = 0.2226) was found.  There was also no significant difference in NOS activity
between the different agonists. 
Table 9.1: Effect of the various glutamate receptor agonists on L-14C-citrulline production
Agonist L-14C-Citrulline produced (pmol / mg protein / min ) SEM
Control 5.214 0.1336
Glutamate 5.005 0.1772
NMDA 5.396 0.2612
QA 5.204 0.1332
KA 5.548 0.3682
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Figure 9.1: Rate of L-14C-Citrulline production by NOS while being treated with various
concentrations of melatonin in rat forebrain homogenate.  Values represent the mean (±
SEM) (n=5) (*** P< 0.001 in comparison to zero control)
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9.2.4. Discussion
These results demonstrate that melatonin reduces NOS activity in a dose dependent
manner.  This would be beneficial to the neuron, because increased NOS activity
brought on by excessive NMDA stimulation can produce NO and O-2@, both of which are
neurotoxic.
The glutamate agonists did not cause an increase in NOS activity.  It is accepted in the
literature [161,167] that NMDA, and the agonists that act at the NMDA receptor, are the
main instigators of increased NOS activity.  The most probable reason for not getting any
significant changes in this experiment is that brain homogenate was used.  As in
experiments 7 and 8, brain homogenate was not the ideal substrate for testing the
effects of the receptor agonists on intracellular processes.  This is because the integrity
of the neurons had been disrupted.  It is believed that the same process is taking place
here.
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9.3. CONCLUSION
These results support the findings of Pozo et al [6], who found that melatonin inhibits
NOS activity.  The results demonstrate that melatonin significantly decreases NOS
activity with as low a dose as 100 µM.  
It was not possible to show that agonists that act at the NMDA receptor increase NOS
activity, however it is well documented that [161,167] this is the case.  Brain homogenate
has been found to be an unsuitable method for investigating intracellular activities that
are regulated by membrane bound receptors.  This is probably because the cell integrity
had been disrupted by homogenisation.  Although the use of cell culture techniques may
have remedied this problem, the techniques used for brain homogenate were not
adaptable for cell culture work. 
After determining that melatonin inhibited NOS activity, Pozo et al [6] determined the
possible mechanism for this action.  As mentioned in the introduction, the binding of Ca2+
to calmodulin to form a Ca2+-calmodulin complex is the first step in initiating NOS activity. 
This is because it is the Ca2+-calmodulin complex that interacts with NOS to cause a
conformational change, that results in NOS becoming active.  In neurons then, it is the
presence of the Ca2+-calmodulin complex and not the concentration of the arginine
substrate that determines NOS activity.
Pozo et al [6] also determined that melatonin inhibited both NOS and cyclic GMP
production.  The authors further discovered that melatonin brought about this action by a
calmodulin-mediated mechanism.  Melatonin appears to bind to calmodulin, thus
preventing the Ca2+-calmodulin complex from being able to bind to NOS.  This effectively
prevents activation of NOS. 
This is a whole new mode of action for melatonin.  The Pozo et al [6] found that normal
physiological concentrations of melatonin were able to inhibit NOS activity.  The
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experiments conducted in previous chapters had demonstrated the free radical
scavenging properties of melatonin while, results in this experiment show that melatonin
is possibly acting via another mechanism as a neuroprotector. 
Melatonin could therefore be playing a very significant role in neuroprotection within the
CNS.  Not only is it able to rapidly move into neurons, but it acts as a very powerful free
radical scavenger, and now it has been shown that melatonin is even able to partially
inhibit NOS activity.  The role of melatonin as a naturally occurring neuroprotector within
the CNS, therefore needs to be considered very seriously.
CHAPTER 10
SUMMARY
10.1. CHAPTER 1
A general review of melatonin and glutamatergic neuronal transmission was presented. 
Special attention was paid to the concept of excitotoxicity and melatonin’s role in
protecting against these neurotoxic insults.  Finally there were brief discussions on
glucocorticoids, and neuronal disorders in which excitotoxicity plays a part in the
pathology of the disorder.
10.2. CHAPTER 2
The effects of stress and melatonin treatment on glutamatergic receptors were
investigated in this chapter.  Both pharmacologically administered corticosterone, and
the application of physical stresses, were used to bring about the stress response.
The results obtained demonstrate that corticosterone causes an increase in glutamate
receptor numbers, while decreasing the affinity of the receptor for its ligand.  Melatonin
caused a decrease in glutamate receptor numbers, both for animals with elevated
corticosterone levels and for unstressed animals.
10.3. CHAPTER 3
This chapter was concerned with the effect of glutamate, NMDA, QA, and KA on
neuronal cell viability.  Primary neuronal cultures were used to test the effects of the
various glutamate agonists.
The results obtained demonstrated that all of the glutamate receptor agonists tested
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were neurotoxic, as cell viability was significantly decreased in a dose dependent
manner.
10.4. CHAPTER 4
The effect of treatment of primary neuronal cultures with melatonin and the glutamate
receptor agonists was investigated.
Melatonin was found to have no neurotoxic properties when applied to primary neuronal
cultures in an ethanol vehicle.  Later, melatonin was shown to protect against  glutamate
agonist-induced neurotoxicity in a dose dependent manner.  Melatonin was only found to
be neuroprotective when administered either, during or after the agonist insult.  Pre-
treatment of neurons with melatonin had no effect on neuronal viability.  These results
demonstrated that melatonin was a potential neuroprotective agent against glutamate
agonist-induced neurotoxicity, and that the mechanism of action needed to be further
investigated.
10.5. CHAPTER 5
An investigation was conducted to determine whether melatonin was able to protect
neurons in an in vivo situation.  Intrahippocampal injections of QA were used to cause
neurodegeneration.  
Micrographs taken of the neurons in the hippocampus of rats killed five days after the QA
injection showed signs of neurodegeneration.  Melatonin administration appeared to
protect against the neurodegeneration, as the neurons appeared healthy.  QA treatment
also reduced glutamate receptor numbers.  Animals co-treated with QA and melatonin
had reduced glutamate receptor numbers, but the decrease was not as pronounced as
for animals that did not receive melatonin.  These results demonstrated that melatonin
appeared to offer neuroprotection under in vivo conditions, which further strengthened
the argument that melatonin showed potential as a neuroprotective agent.
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10.6. CHAPTER 6
A rise in intracellular Ca2+ concentrations has been proposed as one of the initial events
in the excitotoxic process.  These experiments were concerned with investigating
whether the glutamate receptor agonists had any effect on intracellular Ca2+
concentrations, and whether melatonin was able to inhibit intracellular Ca2+ accumulation.
All of the glutamate agonists caused a rapid increase in intracellular Ca2+, as measured
by atomic absorption spectroscopy.  The highest intracellular Ca2+ concentrations
occurred immediately following the agonist insult.  Eighteen hours after the initiation of
the agonist insult, all intracellular Ca2+ concentrations had returned to those of untreated
controls.  Melatonin had no effect on intracellular Ca2+ accumulation within neurons. 
These results demonstrated that the glutamate agonists cause a rapid increase in
intracellular Ca2+ concentrations, but that melatonin must act at a different level to afford
neuroprotection.
10.7. CHAPTER 7
These experiments were conducted to determine, firstly, if glutamate agonists induced
superoxide production, and secondly, to determine whether melatonin could act as a
superoxide radical scavenger.  Superoxide production is known to be induced by
elevated intracellular Ca2+ concentrations [8].  As melatonin had been unable to protect
against increasing Ca2+ concentrations, it was theorised that melatonin was offering
neuroprotection as an antioxidant.
The glutamate agonists were not able to induce O-2@ production in rat brain homogenate. 
Using primary neuronal cell cultures, all of the agonists-induced O-2@ production.  Under
both experimental conditions, melatonin was able to reduce O-2@ production.  It was
therefore concluded that melatonin was acting as an antioxidant, and that this was the
mechanism by which neuroprotection was being offered.
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10.8. CHAPTER 8
These experiments investigated the effect of the glutamate agonists and melatonin on
lipid peroxidation.  Lipid peroxidation involves the destruction of the lipid membranes by
a process initiated by ROS.  Melatonin had exhibited antioxidant properties in Chapter 7,
and these were further investigated in this experiment.
As in the previous experiment, the glutamate receptor agonists were not able to promote
lipid peroxidation using rat brain homogenate.  The exception was QA, which was very
efficient at promoting lipid peroxidation.  Using primary neuronal cultures, all of the
agonists except glutamate, induced lipid peroxidation.  Melatonin was very effective at
reducing  lipid peroxidation under all conditions.  Using rat brain homogenate, melatonin
protected against QA-induced lipid peroxidation in a dose dependent manner.  Melatonin
thus appeared to be deriving most of it’s neuroprotective effects by acting as an
antioxidant and free radical scavenger.
10.9. CHAPTER 9
It had been reported [6] that melatonin was able to inhibit NOS activity, thus preventing
the production of NO and O-2@.  The experiment in this chapter was conducted to
investigate this novel neuroprotective role for melatonin.  
Melatonin was found to decrease NOS activity in a dose dependent manner.  The
glutamate receptor agonists were not able to promote NOS activity, most probably
because disrupted neurons in the form of rat brain homogenate was used.  Melatonin
causes a decrease in NOS activity, by inhibiting the formation of the NOS enzyme.  
CHAPTER 11
GENERAL CONCLUSIONS
The experiments conducted in this study have demonstrated conclusively that melatonin
acts as a neuroprotective agent.  Initial studies were conducted to investigate whether
melatonin could offer any protection against neurotoxicity induced by elevated
glucocorticoid concentrations caused by stress.  Although direct evidence of
neuroprotection was not obtained, melatonin did decrease the number of glutamate
receptors on synaptic membranes.  When it is considered that melatonin production is
increased at times of stress [220,221,338], and that pinealectomised rats produce more
corticosterone [222], it becomes apparent that melatonin must have a role to play
following the stress response.  Melatonin appears to be modulating corticosterone
secretion and helping to decrease some of the deleterious effects of corticosterone
release, such as increased glutamate receptor numbers.  These factors together could
help to protect neurons.
The neuroprotective effects of melatonin against EAA-induced neurotoxicity were
investigated next.  The glutamate receptor agonists were shown to increase intracellular
Ca2+ concentrations, increase O-2@ production and increase lipid peroxidation in primary
neuronal cultures.  These results provided evidence that it was the excitotoxic cascade
that was giving rise to neuronal cell death, as neuronal viability was also markedly
decreased following exposure to high concentrations of the glutamate receptor agonists.
Melatonin appeared to be offering neuroprotection against excitotoxic neuronal death in
primary neuronal cultures.  This was evident by the increase in cell viability when
neurons were co-incubated with melatonin, while begin exposed to the glutamate
receptor agonists.  The method by which melatonin was offering this neuroprotection was
therefore investigated.
Melatonin did not have any effect on intracellular Ca2+ accumulation in the neurons.  It
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was however found to be effective at scavenging O-2@ and inhibiting lipid peroxidation. 
This was consistent with work done by other authors [179,340] who had also found
melatonin to be a powerful antioxidant.  It was further found that, similar to Pozo’s results
[6], melatonin was also able to inhibit NOS activity.  Melatonin therefore appeared to be a
very effective neuroprotectant against glutamate agonist-induced neurotoxicity.  The
melatonin molecule was able to obstruct the excitotoxic cascade at a number of points. 
Firstly, it was able to scavenge ROS from the neurons, while secondly, melatonin
decreased lipid peroxidation.  Finally, melatonin was able to inhibit the activity of NOS, an
enzyme responsible for the production of NO and O-2@.
These results were not just limited to in vitro primary neuronal cultures.  Melatonin also
protected hippocampal neurons against QA-induced neurotoxicity under in vivo
conditions.  Melatonin was able to decrease lipid peroxidation and superoxide anion
production in rat brain homogenate too.  These results were consistent with those of
other researchers, who had found melatonin to be a powerful antioxidant and free radical
scavenger [330,339].  Melatonin had also been shown to protect against KA-induced
neuronal death [340], safrole-induced DNA damage [183], CCl4-induced lipid
peroxidation [189], and peroxynitrite damage [173].
The results obtained thus serve to confirm that melatonin is a powerful antioxidant.  It is
particularly effective at protecting against excitotoxicity induced by agonists acting on the
ionic glutamate receptors.  Melatonin achieves this neuroprotection by interrupting many
of the steps in the excitotoxic cascade.
The neuroprotective effects outlined above offer many therapeutic opportunities. 
Diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease
are all thought to involve excitotoxicity at some stage of their pathologies.  Superoxide
anions are also know to play a role in the pathology of aging.  Melatonin production
decreases with age, while ROS production increases [233].  Chronic stress also
accelerates the aging process.  The administration of melatonin supplements to aged
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persons, or persons suffering from stress, may therefore have therapeutic benefits.  The
only side effect of melatonin administration is that it causes drowsiness in humans [46]. 
This can however be easily countered, by taking the supplements just before going to
sleep.  In the future, melatonin may therefore come to be regarded as an accepted
neuroprotective and  therapeutic agent.
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